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Abstract 
 
 
Mitochondrial dysfunction has been implicated in the early pathogenesis of 
Type 2 Diabetes.   The uncoupling proteins 2 and 3 are mitochondrial proteins 
found in man that have been implicated in protecting mammals from the effects 
of over-nutrition.  Examination of the effect of genetic variation in the UCP2-
UCP3 genetic cluster has so far been inconclusive.  The aim of this thesis was 
to examine, using a genetic strategy, the hypothesis that the role of the 
uncoupling proteins 2 and 3 in the pathogenesis of Type 2 Diabetes is via 
modification of oxidative stress.   
 
In a prospective study of nearly 3000 men the risk of type 2 diabetes at 10 
years was increased for both the UCP2-866AA (1.94 [1.18-3.19]: p=0.009) and 
the UCP3-55TT (2.06 [1.06-3.99]: p=0.03) homozygotes.  This increased risk 
was not explained by the association with any measured conventional risk 
factors. Paradoxically, in a Europe-wide cross-sectional study of 598 subjects 
the UCP2-866A variant was associated with lower waist-hip ratio (GX v AA,1.00 
[0.06] v 0.98 [0.07]; p=0.003), although also associated with lower insulin 
secretion (42.6 [24.6] v 35.6 [18.6]; p=0.03). The UCP3 variant was not 
significantly associated with any metabolic trait. 
 
The significant heritability of plasma markers of oxidative stress (TAS 0.54, 
TOAS 0.49) suggests anti-oxidant function is a plausible mechanism to 
determine Type 2 Diabetes risk.  The predictors of anti-oxidant stress in a family 
study were examined, as was the impact of UCP2-UCP3 gene cluster variation. 
Genetic variation in the UCP2-UCP3 was found to increase the risk of the Type 
2 diabetes.   While UCP2 may modify insulin secretion directly, the mechanism 
of action for UCP3 is likely to involve novel risk factors for Type 2 Diabetes such 
as modification of mitochondrial oxidative stress.   Finally, the development of a 
human model is described to examine genetic influences on oxidative stress 
burden using a meal rich in used cooking oil. 
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1.1 Type 2 Diabetes Mellitus 
 
1.1.1 Definition  
 
Diabetes Mellitus is a disorder characterised by hyperglycaemia.  Diabetes is 
diagnosed on the basis of World Health Organisation (WHO) recommendations 
(Table 1.1) which also defines the pre-diabetic states of impaired glucose 
tolerance and Impaired fasting glucose.   
 
Table 1.1  The diagnosis of diabetes mellitus and pre-diabetes states from the 
Expert Committee on the Diagnosis and classification of diabetes mellitus 
(Diabetes Care: 20: 1183-1197:1997) 
 
 
Glucose concentration in venous plasma 
(mmol/L) 
Diabetes mellitus 
Fasting ≥ 7·0 or 2-h post-glucose load ≥11·1 
 
Impaired glucose tolerance 
Fasting (if measured) <7·0 and  
2-h post-glucose load ≥ 7·8 and <11·1 
Impaired fasting glucose 
Fasting ≥ 6·1 and <7·0 and  
2 h post-glucose load (if measured) <7·8 
 
Glycaemia is regulated by a number of hormones but the key hormone is insulin.  
Failure to maintain normal glucose homeostasis is due to the inability of the 
organism to maintain normal insulin secretion from the β-cells of the pancreas 
or to maintain normal insulin action, a state defined as insulin resistance.   
Insulin resistance is present when the biological effects of insulin are less than 
expected for both glucose disposal in skeletal muscle and suppression of 
endogenous glucose production, primarily in the liver (Dineen S,1992).  The 
WHO criteria for the classification of diabetes are based on current 
understanding of the aetiology of the disease.  Type 1 diabetes results from a 
cell-mediated autoimmune attack on β cells [reviewed by Daneman D, 2006].  In 
summary, a genetic susceptibility to type 1 diabetes is inherited, mainly in the 
HLA-genotype, and the condition is triggered by an as yet unidentified, probably 
 21 
infective, environmental trigger.  The abnormal activation of the T-cell-mediated 
immune system in susceptible individuals leads to an inflammatory response 
within the islets (insulitis) as well as to a humoral (B cell) response with 
production of antibodies to β-cell antigens.  Continuing destruction of β cells 
leads to progressive loss of insulin-secretory reserve and, when insulin 
secretion falls below a critical amount to a state of absolute insulin deficiency 
(Daneman D,2006). 
 
Type 2 diabetes is by far the most common form of diabetes, it is a 
heterogeneous condition, diagnosed empirically by the absence of features of a 
secondary cause or features suggesting type 1 diabetes. 
 
Table 1.2. Classification of diabetes mellitus according to aetiology (World 
Health Organization (1998) 
 
Type 1  β-Cell destruction, usually 
leading to absolute insulin 
deficiency  
15–20% of cases in Europe and 
the United States 
Type 2  Some degree of insulin 
resistance, with relative insulin 
deficiency  
75–80% of cases in Europe and 
the United States 
Other  Other types with specific causes  5% of cases in Europe and the 
United States 
 
 
1.1.2 Demographics 
 
Diabetes Mellitus is now considered as one of the main threats to human health 
in the 21st Century (Zimmet P,2000).  Changes in the human environment, 
behaviour and lifestyle have resulted in escalating rates of both obesity and 
diabetes and the number of people with diabetes is expected to double between 
2000 and 2030 (Wild S,2004).  The diabetes epidemic relates mainly to type 2 
diabetes which accounts for over 90% of cases globally (Zimmet P,2004) which 
explains the increase in the older population (Fig1.1).  Estimates suggest that 
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5.2% of World all cause mortality is attributable to diabetes (2.9 million deaths in 
2000), which is equivalent to one in ten deaths in economically productive 
individuals aged 35-64 years in most developing countries.(Roglic G,2005). 
 
Fig. 1.1. Global diabetes prevalence by age and sex for 2000.(Wild S,2004) 
 
 
The increase in mortality is in part due to a significant increase in the risk of 
coronary artery disease, where men with type 2 diabetes have the same risk of 
myocardial infarction as men without type 2 diabetes who have already had a 
myocardial infarction (Fig.1.2).  This is equivalent to the increased risk of 
myocardial infarction associated with an increase in age of 15 years (Booth 
GL,2006).  
 
The link between type 2 diabetes and cardiovascular disease is partly explained 
by a cluster of adverse changes to lipid profiles and blood pressure.  This 
cluster has been termed the metabolic syndrome. An attempt to define this 
syndrome was first made by the WHO in 1998, of which abnormal glucose 
tolerance was a key factor.  A clinical definition of metabolic syndrome was 
produced by the National Cholesterol Education Program- Adult treatment 
program III in 2001, which includes abdominal obesity, dyslipidaemia, 
hypertension, insulin resistance and prothrombotic and inflammatory states 
(Expert Panel on Detection EaToHBCiA,2001).  There is, however, much 
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debate as to whether current definitions identify an entity that adds any 
cardiovascular disease risk above the individual components in the definition or 
other primary risk factors not included in the definition, such as smoking and 
LDL cholesterol, which also tends to cluster with hypertension etc. (Alberti 
KGMM,2005; Kahn R,2005). 
 
Fig. 1.2.  Relation between age and rates of AMI by diabetes status and sex [All 
lines fitted according to a polynomial equation, R >0·99 for each fitted line 
(Booth GL,2006)] 
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1.2 Pathogenesis of type 2 diabetes 
 
 
The core elements involved in the pathogenesis of type 2 diabetes are  
impaired insulin action, known as insulin resistance, and impaired insulin 
secretion leading to a relative insulin deficiency. The core elements can be 
influenced both genetically and environmentally.  Longitudinal studies suggest 
that a defect in insulin action precedes the development of type 2 diabetes, and 
the pre diabetic states, with the disease only becoming evident when β-cell 
failure  means that insulin secretion is unable to compensate for the increased 
requirements (Weyer C,1999).  Adiposity, especially central adiposity leads to 
increased release and circulating levels of non-esterified fatty acids [NEFA] 
which aggravates insulin resistance in liver and muscle (Boden G,1997).  The 
excess lipid is also stored in ectopic sites, such as skeletal muscle, where it 
further impairs insulin action (Pan DA,1997).   
 
Fig. 1.3.  A summary of the pathogenesis of type 2 diabetes 
Over 
delivery of 
nutrients
Obesity
Genetic  predisposition
NEFA
Inflammation
Ectopic storage
Insulin 
resistance
Β-cell 
failure
Hyperglycaemia
Type 2 diabetes
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1.2.1 Genetic predisposition to Type 2 Diabetes 
 
1.2.1a  Evidence for a genetic basis for type 2 diabetes 
 
The recent epidemic of type 2 diabetes is a clear indication of the importance of 
environmental factors in type 2 diabetes onset.   However, there is also an 
abundance of evidence concerning the presence of a genetic component. 
 
Ethnic Differences 
 
There is wide variation in the prevalence of type 2 diabetes by ethnic group, 
with very low levels in some, such as rural Chinese, to extremely high rates 
found in the Pima Indians in Arizona (WHO Ad Hoc Diabetes Reporting 
Group,1993).  However, this could be due to non-genetic cultural and 
environmental factors, but as the prevalence of type 2 diabetes reduces with the 
extent of Pima/European American interbreeding (Williams RC,2000) this is less 
likely.  The prevalence of type 2 diabetes also differs between ethnic groups 
that share similar environments, such as the United Kingdom where the 
prevalence of type 2 diabetes in Caucasians is 2.4% but prevalence is 3-6 fold 
higher in individuals of South Asian descent (Simmons D,1991). 
 
Family Studies 
 
A higher prevalence in family members is thought to be because of an 
increased number of shared genes, including those that play a role in disease 
predisposition shared between family members.  Such a relationship has been 
described a number of times, most recently in the Framingham Offspring study 
where risk of type 2 diabetes increased by 3.5 times with one affected parent 
and to 6.1 with both parents affected (Meigs J,2000).  However, there is still the 
possibility of these results being confounded by shared culture, environment 
and habits.   This can be addressed by twin studies.  Several twin studies have 
been carried out and although concordance rates vary they are higher in 
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monozygotic twins than dizygotic twins (Barroso I,2005).  The fact that 
concordance in monozygotic twins may be as high as 80% (Ghosh S,1996), 
together with the other studies, suggest that type 2 diabetes has a substantial 
genetic component. 
 
1.2.1b  The role of insulin resistance 
 
The requirement for over fifty essential nutrients in modern man to achieve 
maximum health and longevity means that a diverse diet has been linked to 
health and that this relationship developed early in hominid pre-history (Hockett 
B,2003).   The survival of the genes predisposing to type 2 diabetes, not only in 
man but in other species, such as Free-Ranging Baboons (Kemnitz JW,2002) 
would imply that they may have been selected for in the past.   Pre-human 
ancestors (2-4 million years) consumed a significant proportion of carbohydrate 
in their diet (Colagiuri S,2002), as a result the brain developed a specific 
requirement of glucose  as a source of fuel.    Brain stores of glycogen are 
sufficient for only a few minutes survival without blood flow, so systems had to 
develop to ensure a robust supply of glucose (Kitano H,2004).  These systems 
evolved in past environments far different to those found today and our genome 
remains largely adapted to our Palaeolithic existence (Johanson D,1998).  This 
pre-agricultural age diet overlaps little with current foods and was based mainly 
on meat protein (Hunter) and protein from nuts and shellfish, with little 
carbohydrate from fruits and vegetables (Gatherer)(Colagiuri S,2002).   To 
maintain blood glucose for the brain the organism would develop reduced 
peripheral blood glucose utilisation and increased hepatic glucose production 
i.e., insulin resistance (Rossetti L,1989), a state that is also a feature of periodic 
starvation (Newman WP,1983).  At the end of the last Ice Age the population 
was insulin resistant.  The advent of agriculture increased the amount of 
carbohydrate in the human diet (Eaton SB,1985), although it was not until the 
industrial revolution that highly processed carbohydrate was widely available, 
which, coupled with the lack of energy (activity) spent in food procurement 
(Eaton SB,2002), and high calorie diet, produced an environment where this 
adaptation started to become deleterious.  This then confers higher 
susceptibility to a number of chronic degenerative diseases.   
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1.2.1c   Using Genetics in the study of type 2 Diabetes 
 
Epidemiology is “the study of distribution determinants [and control] of health 
related states and events in populations”.  The concept of “genetic 
epidemiology” is less well defined but regarded as the study of the genetic 
determinants of disease, and also the joint effect of genes and non-genetic 
determinants (Burton PR,2005).  The disease-exposure association of 
traditional epidemiology is essentially replaced with the genetic variation-
exposure association.  There are a number of methods available to locate and 
identify causative genes.     
 
Learning from Monogenic Disorders 
 
A small proportion of diabetes cases are due to mutation in a single gene.  
There are three main groups of disorders, MODY [maturity onset diabetes of the 
young], neonatal diabetes and Mitochondrial diabetes.  The understanding of 
the genetic basis for these conditions has improved understanding of the 
physiology of metabolism and energy balance and the pathophysiology of 
polygenic diabetes (McCarthy MI, 2008).      
 
Although 10% of cases MODY do not have a cause identified the remaining 
cases fall into two types  (Vaxillaire M, 2006).  Glucokinase mutations account 
for 14% and give rise to a non-progressive mild impairment of glucose sensing 
in the pancreatic β-cell (Hattersley AT, 1993).  The remaining cases are due to 
mutations in the genes for a number of transcription factors that are thought to 
play key roles in pancreatic development and function, including TCF-1,TCF-2, 
IDF-1, Nuerod 1 and CEL (McCarthy MI, 2008).      
 
Neonatal diabetes presents in the first six months of life.  The genes identified 
all code for proteins that form an ATP dependant potassium channel 
[KCNJII/ABCC8].  Identification of the underlying genetic aetiology has enabled 
an effective and tailored treatment strategy to be developed for these` patients 
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using the sulponylurea group.  Mitochondrial diabetes is discussed in a 
following section on insulin resistance. 
 
Unravelling the genetic variation –exposure in polygenic disease 
 
One option is to move straight to the obvious candidate genes, however, in 
complex diseases such as type 2 diabetes there are a very large number of 
plausible candidate genes.  Linkage analysis can be used to identify broad 
genomic regions that might contain a disease gene, even without a plausible 
candidate being present in that area (Teare MD,2005).   Two genetic loci are 
linked if they are transmitted together from parent to offspring more often than 
expected under independent inheritance (c.f. Linkage disequilibrium, which 
refers to loci found together on haplotypes in the population at a frequency 
greater than expected).  Linkage analysis identifies markers that are passed 
down through a family, that consistently accompany the disease of interest. 
They have been more successfully used for monogenic conditions than 
complex polygenic conditions (Botstein D,2003).  To date, over 50 type 2 
diabetes linkage studies  have been conducted in a variety of populations, in 
which some chromosomal regions have now been replicated in multiple studies 
(Barroso I,2005).   This is in part due to the intrinsic limitations of linkage 
analysis studies due to low statistical power, which can also be reduced by 
missing pedigree information, genetic differences between populations and 
genotype errors, such that the sample size to detect genetic linkage of the 
modest size expected in complex traits may be unobtainable (Risch N,2000).    
The power of linkage analysis in type 2 diabetes is also reduced by difficulty 
defining the phenotype, with the possibility that early onset type 2 diabetes may 
have different genetic determinants, and the difficulty in identifying subjects who 
may have latent autoimmune diabetes.  The power of the study will be diluted 
further by the possibility of genetic heterogeneity within families, where a 
different combination of genes may determine a complex trait within a family 
(Teare MD,2005). However, despite these difficulties, a number of regions have 
now been replicated (reviewed by (Florez JC,2003), and at least two important 
genes have been identified by this approach namely, calpain 10 (Horikawa 
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Y,2000) and TCF7L2 (Grant SFA,2006), neither of which were plausible 
candidate genes. 
 
Association studies have more in common with traditional epidemiology, where 
the risk is a particular allele, genotype or haplotype of a genetic marker.  Most 
performed so far employ a case-control design, and have been of the candidate 
gene type.  They have also not been well replicated, because of poor matching 
of cases and controls, use of convenient samples, small study size, limited 
number of markers per gene and failure to take into account environmental 
interaction (Barroso I,2005) although, these can somewhat be overcome if a 
prospective sample is used (Humphries SE,2003).  The presence of an 
association does not always imply causation, but may reflect an association 
with a nearby causal variant (i.e. in strong linkage disequilibrium with the variant 
studied) or be due to some underlying stratification or admixture of the 
population (Cordell HJ,2005).  Genetic association studies have identified a 
number of polymorphisms reproducibly associated with type 2 diabetes, 
including Pro12Ala in PPAR-gamma (Altshuler D,2000).  A review of the 
published candidate gene polymorphism association studies can be found in 
Barroso I(2005). 
 
New techniques in genetic epidemiology 
 
The Genome Wide Association study 
 
The development of high performance genotyping (Fan JB, 2006) coupled with 
the identification of most known patterns of common variation by the HapMap 
consortium (The International HapMap Conssortium, 2003)  have enabled 
researchers who have either through collaboration or design amassed more 
suitable sample sizes to perform  genome wide association studies (McCarthy 
MI, 2008).  This approach is not based on any plausible biological basis but 
aims to capture most of the common variation in the whole genome in one study.   
This approach .has led to a recent increase in the number of replicated gene-
type 2 diabetes association studies.  The following have been identified as 
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important genes by genome wide association studies, HHEX/IDE, SLC30A8, 
FTO, CDKAL1, CDKN2A and IGF2BP2 (McCarthy MI, 2008).      
 
Mendelian Randomisation 
 
When a robust finding from observational studies [vitamin C and CHD (Khaw 
KT, 2001)] is not backed up by interventional studies (Heart Protection Study 
Collaborative group, 2002) one of the likely causes is the presence of 
confounding variables.   Mendelian randomisation overcomes some of problems 
as the association can be tested on the basis of random genetic variation.  A 
genetic variant that alters a biological exposure eg CRP should increase the 
prevalence of the related disease as predicted by its effect on the risk factor 
(Smith GD, 2007).  If this is not the case then the disease-risk factor relationship 
observed is likely to be due to confounding factors.   
 
  
1.2.2 Molecular Mechanisms in type 2 diabetes- gene-lifestyle interaction 
 
 
The cardinal features of type 2 diabetes are the development of insulin 
resistance and the failure of insulin secretion.  Both of these develop from a 
combination of genetic predisposition and environmental influences.  There is 
continued debate about which is the initial abnormality.  Early studies suggested 
that insulin resistance was the strongest predictor of type 2 diabetes in Pima 
Indians (Lillioja S,1993) and that insulin resistance was present at least ten 
years before development of the disease, whilst reduction in insulin secretion 
occurred only a few years prior to development of type 2 diabetes (Warram 
JH,1990).  However, recently this data has been questioned, with evidence that 
β-cell dysfunction is present in normal glucose tolerant individuals predisposed 
to type 2 diabetes (van Haeften TW,1998), and that people with type 2 diabetes 
may not be more insulin resistant than appropriate obese controls (Weyer 
C,1999).  Certainly both are present at time of hyperglycaemia (Chiasson 
JL,2004), and it may be the relationship between them that is more important 
than each individually (see 1.2.2b).   
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1.2.2a The development of insulin resistance 
 
 
Insulin is a peptide hormone secreted from the β-cells of the islets of 
Langerhans, in the pancreas.   The actions of insulin include increased glucose 
uptake into muscle and fat, decreased hepatic glucose production, and 
increased protein, glycogen and lipid synthesis with concurrent reductions in 
breakdown and cell growth and differentiation (Saltiel AR,2001).  Sensitivity to 
insulin action is influenced by age, genetics, exercise and fitness, diet, 
medication and obesity (Kahn SE.,2003).  Insulin resistance is strongly 
associated with “over-nutrition” driving obesity, although, the over-nutrition may 
not be all dietary, as defects in mitochondrial fat oxidation have also been 
described in type 2 diabetes.   The consequences of obesity and insulin 
resistance include impaired glucose tolerance, hypertension and dyslipidemia 
(low High Density Lipoprotein [HDL], high Very Low Density Lipoprotein [VLDL] 
and a preponderance of small dense Low Density Lipoprotein [LDL]) and can 
even be detected in obese children (Weiss R,2004).  The metabolic changes all 
promote vascular damage, and cardiovascular disease and mortality and 
morbidity is increased in the presence of insulin resistance (Laasko M,1996). 
 
 
Normal Insulin Action (Fig.1.4) 
 
The insulin receptor consists of two α and two β subunits. The α units make up 
the extracellular ligand binding domain and normally inhibit the action of the 
intracellular tyrosine kinases domain (β subunits).  When insulin binds to the 
receptor this inhibition of tyrosine kinase activity is reduced, and conformational 
changes occur in the β subunits which enhance tyrosine kinase activity (Patti 
MR,1998).   The β-subunits activate, by phosphorylation, a cascade of insulin-
receptor substrate proteins (IRS), which act as docking proteins for and activate 
phosphatidylinositol-3 kinase [PI(3)K] (Kahn BB,1996).  The IRS cascade also 
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activates Mitogen-Activated Kinase [MAP-Kinase], which is responsible for 
some of the cell growth and proliferation effects and is not down-regulated in 
insulin resistance (Cusi K,2000).  PI(3)K activates a number of pathways related 
to glucose metabolism, through activation of protein kinase B/Akt and protein 
kinase C (Schinner S,2005).  These include transposition of GLUT-4 glucose 
uptake proteins to the cell membrane, and the reduction of glycogen synthase 
kinase 3 activity which allows glycogen synthesis to occur (Shulman GI,2000).  
The activation of a number of forkhead transcription factors (FkHR/FOXO) 
inhibits the key enzymes of glycogenolysis, phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (Schmoll D,2000), whilst 
activation of the mTOR pathway can control the translation of a number of 
proteins with metabolic actions, either directly or through P70rsk activation 
(Saltiel AR,2001).  There is also a second pathway of GLUT-4 activation, the 
Cbl/CAP pathway.  On binding of insulin to the insulin receptor Casitas B-
lineage lymphoma protein (Cbl) is activated, which then forms a complex with 
Cbl associated protein (CAP).  This complex locates the G-protein TC10 in 
membrane rafts and  activates it, which then provides a signal for GLUT-4 
activation (Chiang SH,2001) . 
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Fig 1.4. Signal transduction in insulin action (Saltiel AR,2001). 
 
Insulin receptor pathways are terminated by protein tyrosine-phosphatase 1B which 
dephosphorylates the signal pathways.  The insulin signal can also be inhibited by 
serine/threonine phosphorylation (Zick Y,2001) by atypical Protein Kinase C isoforms 
or the C-Jun Pathway (White MF,2002) or by enhanced degradation of the IRS proteins 
as occurs in SOCS signalling (Rui L,2002). 
 
Consequences of Obesity 
 
Adipose tissue is an important determinant of whole body insulin sensitivity.  
The distribution of the excess body fat is also important, with central fat being 
more important in driving insulin resistance than peripheral fat (Fujimoto 
WY,1994).  Central fat is intra-abdominal visceral fat which tends to collect 
around the waist, which is itself a strong predictor of type 2 diabetes 
(Wahrenberg H,2005).   Visceral fat has a different phenotype, with increased 
lipolysis compared to subcutaneous fat (Abate N,1995).   The important role of 
adipose tissue in whole body insulin sensitivity is indicated by animal models.  
The GLUT-4 adipose tissue specific mouse is severely insulin resistant (Abel 
ED,2001) while the skeletal muscle tissue specific GLUT-4 knockout has mild 
diabetes only (Zisman A,2000).   This may be because Insulin Growth factor 
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signalling can compensate in skeletal muscle (Shefi-Friedman L,2001) but the 
adipose tissue GLUT-4 over-expression model is also more insulin sensitive 
despite being more obese (Shepherd PR,1993).  Adipose tissue specific GLUT-
4 over-expression also corrects the mild insulin resistance seen in the muscle 
specific knockout, without any direct effect on skeletal muscle but by increasing 
the number of small adipocytes (Carvalho E,2005).  In man, GLUT-4 expression 
is reduced in adipose tissue and not skeletal muscle in those with obesity or 
type 2 diabetes (Carvalho E,2001). 
 
Expanded adipose tissue can promote the development of type 2 diabetes by a 
number of mechanisms.  These are triggered by a change in adipocyte size. 
Large adipocytes, that occur in obesity, undergo changes in gene expression 
such as reduced adiponectin, and tend to promote insulin resistance (Yang 
X,2004) with increased intracellular lipid in non adipose tissue.  The presence of 
large adipocytes is also a predictor of type 2 diabetes and numbers inversely 
correlate with insulin sensitivity (Weyer C,2000), whilst in patients with type 2 
diabetes adipogenesis is impaired, decreasing the availability of new adipose 
cells and increasing average cell size (Yang X,2004). Large adipocytes have 
diverse functional abnormalities (Le Lay S,2001) with impairment of proliferation 
pathways (β-catenin), insulin signalling pathways (GSK-3) and reduced 
adiponectin secretion (Yang X,2004). 
 
There are a number of candidates for the signal from adipose tissue that 
induces insulin resistance in liver and muscle.  Non-Esterified Fatty Acids 
[NEFA] are released in larger quantities by expanded adipose tissue (Ravussin 
E,2002) and are increased in the offspring of patients with type 2 diabetes even 
if glucose tolerance is normal (Perseghin G,1997).  Circulating levels of NEFA 
are inversely correlated with net glucose disposal (Baldeweg SE,2000).  The 
infusion of NEFA inhibits glucose uptake after 3-4 hours (Fig 1.4), (Boden 
G,1997) which with decreased glycogen synthesis (Krebs M,2001) means that 
there is a reduction in the effectiveness of insulin-driven pathways.  NEFAs 
reduce PI(3)K activity (Dresner A,1999) possibly through activation of atypical 
PKC isoforms and Serine/Threonine phosphorylation of IRS proteins (Shulman 
GI,2000).   Increased delivery of NEFA alters membrane composition (Borkman 
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M,1993) and has a direct effect on glucose transporters (Long SD,1996), which 
also contributes to other mechanisms driving insulin resistance, including 
intracellular lipid stores and inflammation. 
 
Adipose tissue forms over 10% of total body weight, but it is now clear that 
adipocytes have functions other than simple storage cells (Shimada K,2004).  
The most significant of these appears to be the secretory capacity of the 
adipocyte.  The adipocyte secretes a number of peptides that have been 
labelled adipocytokines or adipokines (Kadowaki T,2005).  Adipokines identified 
to date seem to function as modulators of metabolism, such as Leptin and 
Resistin, or of inflammation, such as Tumour Necrosis Factor-α (TNF-α), 
Interleukin 6 [IL-6], adipsin (also known as complement factor D), acetylation-
stimulating protein, visfatin (also known as B-cell colony-enhancing factor), 
plasminogen-activator inhibitor type 1, as well as other complement 
components and interleukins (Hug C,2005; Rajala MW,2003).   
 
The most abundantly secreted adipokine is adiponectin, making up 0.01% of 
circulating protein, with serum concentration a thousand times greater than 
other hormones and 106 times greater than other inflammatory cytokines 
(Shimada K,2004). Studies from animal models and human subjects confirm 
that adiponectin is an insulin-sensitising hormone, that is negatively regulated 
by obesity [Reviewed in Gable D, 2006a].    A significant number of the 
metabolic actions of adiponectin are dependent on the activation of AMP-
dependent kinase (AMPK) (Tomas E,2002; Wong GW,2004; Yamauchi T,2002; 
Yamauchi T,2003), a fuel-sensing enzyme (Wong GW,2004).  AMPK 
dependent fuel-sensing systems have been identified in myocytes, hepatocytes, 
skeletal muscle and parts of the central nervous system (Wong GW,2004).  
AMPK is activated when ATP is required, and one of its main stimulators is the 
AMP/ATP ratio.  Activation increases glucose transport, glycogen accumulation 
and fatty acid oxidation, with the aim of increasing ATP production.  Adiponectin 
also has anti-inflammatory actions.  The increase in insulin sensitivity 
associated with Leptin secretion is also through AMPK activation, although the 
secretion of anorexigenic peptides also contributes to reduced over-nutrition 
(Minokoshi Y,2002).   
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Leptin is described as a “starvation signal” as its levels decline during fasting, 
but in obese individuals levels are often higher.  The mechanism of this Leptin 
resistance has yet to be elucidated (Ahima RS,1999).  TNF-α is also produced 
by adipose tissue and acts in an autocrine and paracrine way, increasing NEFA 
release (Itani SI,2002), reducing adiponectin release (Ruan H,2002) and 
reducing insulin signalling efficiency in adipocytes (Saltiel AR,2001).   
 
The possibility that inflammation was important in the development of insulin 
resistance was first suggested when it was noted that the lipid abnormalities in 
type 2 diabetes were similar to those seen in the acute phase response 
(Blackman JD,1993).  Further evidence of the link between inflammation and 
insulin resistance is suggested by an increase in levels of pro-inflammatory 
cytokines in the post prandial period (Carroll MF,2003), and the relationship of 
type 2 diabetes and obesity with low grade inflammation.  Low grade 
inflammation precedes and predicts the development of insulin resistance.   
Insulin resistance is associated with higher levels of C-Reactive Protein (CRP), 
and levels of this acute phase protein, as well as others such as IL-6, 
orosmuoid and sialic acid are associated with risk of type 2 diabetes  (Duncan 
BB,2003).    Obesity is also associated with non-specific markers of activation of 
the immune system including temperature, white cell count and total γ-globulin 
(Tataranni PA,2005). The acute phase response is part of the innate immune 
system and IL-6, of which up to 30% of the circulating levels are produced by 
adipose tissue (Mohamed-Ali V,1997), is one of the prime stimulators of acute 
phase proteins (Gabay C,1999).  IL-6 levels correlate with obesity and insulin 
resistance and predict the onset of type 2 diabetes (Bastard JP,2000).   Infusion 
of IL-6 induces insulin resistance (Tsigos C,1997), with IL-6 having a direct 
effect on inactivating IRS function  via SOCS (Rui L,2002).  One of the key 
transcription factors involved in the innate immune system activation is NF-κβ, 
which is maintained in its inactive state by binding with Iκβ.  NF-κβ is activated 
after Iκβ is released by the action of the kinase IKK.   Lipid infusion, which is 
associated with increased insulin resistance activates NF-κβ (Tripathy D,2003), 
while  blockade of IKK activity lowers blood glucose in rodents (Kim JK,2001) 
and in man (Hundal RS,2002).   The inflammatory response in obesity may be 
driven by changes in adipose tissue (Fig. 1.5), as a response to being unable to 
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store all the energy delivered (Wellen KE,2003).  Adipose tissue and the 
immune system are similar, with both functions performed by the fat body in 
Drosophila (Xu H,2003).  There are many shared pathways between T-cells, 
macrophages and adipocytes, with the peroxisome proliferator-activated 
receptors [PPAR] transcription factors, now known to regulate a large repertoire 
of inflammatory genes as well as their well known metabolic function (Way 
JM,2001).  A number of macrophage and inflammatory genes are also 
upregulated in obesity (Xu H,2003). 
 
Skeletal muscle is responsible for 75% of post-prandial glucose disposal (Klip 
A,1990), and a defect in removal of glucose and glycogen by skeletal muscle is 
found in all insulin-resistant subjects (Shulman GI,1990).  Early investigations 
demonstrated increased lipid in the skeletal muscle of subjects with type 2 
diabetes (Dagenais GR,1976) and although the early studies required prior 
removal of all extracellular lipid and were prone to error, they suggested that 
intramyocellular lipid (IMCL) was a good predictor of insulin resistance 
(Machann J,2004).  Advanced imaging techniques (Simoneau JA,1995), and 
more recently the use of magnetic resonance spectroscopy, has confirmed this 
association  (Thamer C,2003).   However, endurance athletes also have 
elevated levels of IMCL but are very insulin sensitive (Goodpasture BH,2001).  
Fatty acid metabolites, such as long chain acyl-CoA (Ellis BA,2000), are 
correlated with level of insulin resistance and diacylglycerol, and can increase 
serine/threonine phosphorylation of the insulin signaling cascade, possibly by 
activating atypical PKC isoforms or through pro-inflammatory pathways (Itani 
SI,2002).  However this relationship can be modified by the oxidative capacity of 
skeletal muscle (Thamer C,2003). 
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Fig 1.5. Inflammation in obese adipose issue 
 
Obese adipose tissue is characterized by inflammation and progressive infiltration by 
macrophages as obesity develops. Changes in adipocyte and fat pad size lead to physical 
changes in the surrounding area and modifications of the paracrine function of the adipocyte.  
For example, in obesity, adipocytes begin to secrete TNF- , which can stimulate preadipocytes 
to produce monocyte chemoattractant protein-1 (MCP-1). Increased secretion of leptin (and/or 
decreased production of adiponectin) by adipocytes may also contribute to macrophage 
accumulation by stimulating transport of macrophages to adipose tissue and promoting 
adhesion of macrophages to endothelial cells, respectively. Whatever the initial stimulus to 
recruit macrophages into adipose tissue, once these cells are present and active, they, along 
with adipocytes and other cell types, can perpetuate a vicious cycle of macrophage recruitment, 
production of inflammatory cytokines, and impairment of adipocyte function. (Wellen KE,2003). 
   
 
Mitochondria and insulin resistance 
 
Oxidative capacity is determined by mitochondrial function and there is 
evidence of mitochondrial dysfunction in insulin resistance and type 2 diabetes.  
Mitochondria are also an important source of oxidative stress [see 1.3.4]. 
 
Mitochondria have their own genome, and mutations in the mitochondrial 
genome are associated with diabetes.  The mitochondrial genome is maternally 
inherited, consists of 16.6kB and codes for 13 proteins that form part of the 
electron transport chain.  Mutations have been associated with neurological   
disease and diabetes, and for the tRNA and rRNA involved in ribosomal protein 
synthesis within mitochondria (Wallace DC, 1999).  The most common causes 
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of mitochondrial diabetes are the 3243A>G variant in the Leu,URR gene, a DNA 
encoded tRNA that is associated with low BMI, lipomas and hepatic fat 
infiltration suggesting the underlying problem is aberrant fat storage.  The 
diabetes tends to occur around age 40 and is associated with significant β-cell 
damage.  A second gene [LARS2] has also been implicated in mitochondrial 
diabetes (Maassen JA, 2007). 
 
In mouse models there is reduced biogenesis of mitochondria (Choo HJ,2006) 
disease, while mitochondria in subjects with type 2 diabetes are smaller and 
have reduced activity of the electron transport chain (Kelley DE,2002).   In 
subjects with type 2 diabetes or insulin resistance, gene expression profiling 
shows reduced electron transport chain genes, especially in visceral fat 
(Dahlman I,2006), and also reduced copies of oxidative phosphorylation protein 
encoded in mitochondrial DNA (Bogacka I,2005a).  PPAR-γ co-activator 1 
(PGC-1α) is a transcription factor that drives mitochondrial biogenesis (Wu 
Z,1999) and has a role in gluconeogenesis and fatty acid oxidation (Bogacka 
I,2005b).  PGC-1α expression is reduced in type 2 diabetes (Mootha VK,2003) 
and also in insulin resistant offspring of subjects with type 2 diabetes (Patti 
ME,2003).  The deterioration in mitochondria function that occurs with age leads 
to reduced oxidative phosphorylation in the elderly which correlates with the 
increase in insulin resistance seen with age (Petersen KF,2003) and the 
reduced utilization of fatty acids in those with insulin resistance (Kelley 
DE,2000).  Total fasting fat oxidation is correlated with insulin sensitivity 
(Wahrenberg H,2005).  Insulin sensitivity is also correlated with post-prandial 
thermogenesis (Robinson S,1992).  Women predisposed to obesity have lower 
24hr fat oxidation compared to controls (Raben A,1994), whilst in obese women 
relative post prandial fat oxidation is reduced (Blaak EE,2006).  The mechanism 
linking fat oxidation and insulin resistance is unclear.   ICML is important, as 
blocking fatty acid uptake molecules, such as CD36 (Hajri T,2002) and Fatty 
acid transporter-1, (Kim JK,2004) protects from insulin resistance.  In insulin-
sensitive individuals, insulin increases ATP synthesis and Respiratory Quotient, 
which does not occur in insulin-resistant states (Brehm A,2006).  Fat oxidation 
only adapts slowly to intake (Raben A,1994) and, combined with a diminished 
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capacity to use fat as a fuel, it may be that mitochondrial dysfunction potentiates 
the problems of over-nutrition and abnormal adipose tissue biology. 
 
 
1.2.2b The development of pancreatic failure  
 
Although insulin secretion in type 2 diabetes is abnormal in response to a 
number of stimuli, including intravenous and oral glucose, arginine, β-agonists 
(isoproteronol), and sulphonylureas (Kahn SE,2003), it was not thought that 
poor insulin secretion contributed to the early aetiology of type 2 diabetes.  
Initial investigations demonstrating that subjects with type 2 diabetes continue 
to secrete insulin (Yalow RS,1960), and this taken with the evidence that insulin 
resistance appeared to be the first factor to appear, suggested that abnormal 
insulin secretion was a late event in the pathogenesis of type 2 diabetes.   
However, these studies did not take into account that  insulin secretion is 
modified by insulin resistance (Kahn SE,1993) and recent data suggests that β-
cell dysfunction occurs early, and is important in the pathogenesis of type 2 
diabetes as does data from the understanding of MODY [discussed below].    
Recently, genome wide association studies have also suggested an important 
role for insulin secretion as, to date, most of the replicated identified associated 
genetic variants seem to have more of a role in modulating pancreatic function 
rather than insulin resistance. 
 
 
Normal Insulin secretion (Fig 1.6) 
 
Insulin secretion occurs as the result of uptake of glucose into the β-cell by 
GLUT-2, a low affinity, high capacity glucose transporter. Glucose is 
“trapped“ in the cell by the action of glucokinase converting the glucose to 
glucose-6-phosphate.   Further transformation to pyruvate via the tricarboxylic 
acid cycle and the mitochondrial electron transport chain to ATP follows.   
Alteration of the intracellular ADP:ATP ratio leads to closure of ATP-sensitive 
potassium channels.  These channels include in their structure the 
sulphonylurea receptors (SUR1/SUR2) and the subunits Kir6.1, Kir6.2 which 
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have been implicated in the aetiology of neonatal diabetes and are closed in the 
presence of glucose.  This leads to a change in membrane electrical energy 
potential and opening of voltage-gated calcium channels (MacDonald PE,2005).  
 
Fig 1.6.  Normal Insulin secretion 
 
IAPP=islet amyloid polypeptide. G-6-P=glucose-6-phosphate. CoA=coenzyme A. 
GLUT2=glucose transporter 2.(MacDonald PE,2005). 
 
Initially, there is release of docked and readily available vesicles and then 
vesicle mobilization is stimulated.  Therefore, insulin release is biphasic (Del 
Prato S,2002) with an early peak (acute phase) followed by a more sustained 
plateau or second phase (Fig 1.7). 
 
Fig. 1.7.  Representation of the Biphasic insulin secretion 
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β-cell function in subjects at high risk of diabetes  
 
As described earlier, the presence of insulin resistance in those at risk of type 2 
diabetes will modify insulin secretion, which is often used as a marker of β-cell 
function.  This relationship is shown in Fig 1.8.   
 
Fig 1.8. Relationship between insulin sensitivity and β-cell function in 93 healthy 
individuals  (Kahn SE,1993). 
 
 
 
 
 
 
 
 
 
 
 
 
AIRglucose = acute insulin response to glucose.  Insulin sensitivity Index is derived from minimal 
model analysis of frequently sampled intravenous glucose tolerance testing.  5
th
,25
th
,50
th
,75
th 
percentiles shown.
 
  
 
The development of insulin resistance must be associated with an increase in 
insulin secretion for normal glucose homeostasis to be maintained, a move to 
the right along the same centile.   When groups at increased risk of type 2 
diabetes are examined (Fig.1.9) they are indeed found to be insulin resistant but 
in addition β-cell dysfunction is also present as indicated by insulin secretion 
falling into the lower centiles (Kahn SE,1996). 
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Fig. 1.9.  Relationship between insulin sensitivity and β-cell function in groups 
at high risk of type 2 diabetes 
 
  
PCO= women with polycystic ovary syndrome 
GDM= Gestational Diabetes Mellitus   (Kahn SE,1996) 
 
The first defect in β-cell function that occurs, even in those with normal glucose 
tolerance, is the loss of the acute phase response (Del Prato S,2002), even 
though the relationship between second phase and insulin sensitivity is 
maintained.  During the development of worsening glucose tolerance the acute 
phase insulin release progressively worsens (Weiss R,2005).   There is also 
evidence of abnormal insulin processing with increased release of pro-insulin, 
again even in those at high risk of type 2 diabetes but with normal glucose 
tolerance (Saad MF,1990).  The proportion of pro-insulin released is a predictor 
of future development of type 2 diabetes (Kahn SE,1995).  Insulin is co-
secreted with a 37 amino acid polypeptide, islet amyloid polypeptide (Cooper 
GJS,1987) which is also found to be secreted in lower amounts in type 2 
diabetes (Kahn SE,2003). 
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Mechanisms of β-cell dysfunction 
 
 
The investigation of monogenic Maturity Onset Diabetes Mellitus of the Young 
[MODY] identified the causal genes as a number of transcription factors 
(Barroso I,2005).  Mutations in transcription factors have a different clinical 
phenotype of progressive beta-cell failure resulting in increasing 
hyperglycaemia and requirement for treatment 
(www.projects.ex.ac.uk/diabetesgenes/index). Knockout mouse models 
generally have a reduced β-cell mass which can be compensated for in early 
life, but normal glucose levels cannot be maintained (Hattersley AT,2004).  In 
autopsy series, β-cell mass is reduced by 20-50%, however, this occurs many 
years after diagnosis and is consistent with the finding of increased apoptotic 
events in subjects with type 2 diabetes (Butler AE,2003).  The study of the 
pancreas in individuals at high risk of diabetes is difficult, but differences in 
insulin secretion suggest the problem is not simply reduced β-cell mass.  In 
dogs with 65% of their pancreas removed, acute phase insulin secretion is 
maintained, in part, by increasing the sensitivity of the existing β-cell mass to 
glucose (Ward WK,1988).  A similar compensation occurs early in Type1 
diabetes as β-cells are destroyed by the autoimmune process (Johnston 
C,1987), but this compensation is not seen in type 2 diabetes suggesting other 
processes are also underway. 
 
There is a possibility that the increased circulating NEFA can also directly affect 
β-cell function.  NEFA increase insulin secretion for the first 24 hours but after 
this inhibit β-cell function, and long term exposure is associated with β-cell 
dysfunction, as indicated by reduced insulin release as well as reduced pro-
insulin processing (Zhou YP,1996).  NEFA are converted to long chain acyl-
CoA in the cell, which can counteract ATP-induced closure of potassium 
channels (Bränström R,2004).  They can also modulate intracellullar calcium 
through the orphan G-protein coupled receptor GPR40 (Itoh Y,2003) and induce 
β-cell apoptosis through increased nitric oxide production (McLean N,1955).  
However, circulating fatty acids are essential for glucose-stimulated insulin 
secretion after prolonged fasting (Dobbins RL,1998), and long chain acyl CoA 
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facilitates the fusion of secretory granules to the cell membrane (Deeney 
JT,2000).  The factors modulating the complex relationship between circulating 
fatty acids and insulin secretion are not fully understood.  The composition of 
free fatty acids can have different effects, with polyunsaturated fatty acids 
stimulating insulin secretion and short chain and saturated fatty acids inhibiting 
secretion (Haber EP,2002).  Glucose-stimulated insulin secretion depends on 
glucose oxidation, and there is a reciprocal relationship between glucose and 
fatty acid oxidation (Zhou YP,1996).  NEFA reduce glucose uptake and 
oxidation, which is more pronounced in insulin resistant states (Zhou YP,1995), 
and feeding rats with a high fat diet reduces the rate of glucose oxidation 
(Carpinelli AR,1992).   Complex changes in the ratio of fat to glucose oxidation 
may explain the effects of NEFA on insulin secretion. 
 
The β-cell dysfunction progresses as glucose tolerance worsens, and the most 
severe insulin deficiency is seen after 10 years of type 2 diabetes (Wallace 
TM,2002).  Glucose toxicity contributes to this failure, probably through a 
mechanism involving oxidative stress (see 1.3), increasing cytokine production  
(Maechler P,1999) and accelerating apoptosis (Butler AE,2003). 
 
Autopsy of subjects with type 2 diabetes reveals another potential mechanism 
of β-cell dysfunction.  Up to 90%, of subjects with type 2 diabetes have deposits 
of amyloid in the pancreas (Knowles NG,2002).  The protein is based on the 
islet amyloid polypeptide, which is co-secreted with insulin and could 
accumulate with increased insulin demand.  These aggregates are toxic to islets 
in culture and increase β-cell apoptosis (Lorenzo A,1994).  The degree of 
amyloid replacement predicts the need for insulin therapy (Kahn SE,1998).  
Overexpression of islet amyloid protein in animal models fed a high fat diet 
leads to higher glucose levels,  (Verchere CB,1996) which suggests that islet 
amyloid has a role in type 2 diabetes.  However, the fact there is no  increase in 
amyloid in impaired glucose tolerance states (Butler AE,2003) and that it is not 
present in all subjects with type 2 diabetes, means that its role has yet to be 
defined.  It may be a response to the underlying processes of β-cell dysfunction 
rather than driving it. 
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1.3 Type 2 Diabetes and Oxidative Stress 
 
Redox reactions include all chemical processes in which atoms have their 
oxidation number (the charge that it would bear if all the ligands were removed 
along with the electron pairs that were shared with the central atom) changed. 
Oxidation is defined as an increase in oxidation number, and reduction as a 
decrease in oxidation number.  In most cases oxidation occurs when a molecule 
transfers electrons to another molecule, but dehydrogenation is also an 
alternative method of oxidation.  Substances that have the ability to oxidize 
(remove electrons from) other substances are known as oxidizing agents, 
oxidants or oxidizers, and are themselves reduced in the reaction. In biological 
systems normal metabolism results in the generation of a number of oxidants 
known as reactive oxygen species [ROS] if based on oxygen, or reactive 
nitrogen species [RNS] if nitrogen based, although they are often described 
together as ROS.  These are generally very small molecules and are highly 
reactive due to the presence of unpaired valence shell electrons. To protect the 
structure of the organism from oxidation a number of cellular defences have 
developed.  Oxidative stress occurs when cellular anti-oxidant defences are 
inadequate to inactivate generated ROS, and they are free to react with other 
cellular components (Stocker R,2004). 
 
 
1.3.1 Sources and effects of oxidative stress 
 
Oxidative stress can result from exogenous processes such as radiation, 
pollution, smoking (Ghiselli A,2000) and toxins.  ROS generation is thought to 
be responsible for the cardiac side effects of anthracylines (Keizer HG,1990) 
and the hepatic toxicity of some antibiotics (Orrenius S,1985) or from 
endogenous metabolism.  ROS are continuously generated by the organism as 
a by-product of oxidative metabolism (Gate L,1999) described in more detail 
later (1.3.3c).  The six main ROS are superoxide [O2-], hydrogen peroxide 
[H2O2], peroxyl radical ROO
-, Hydoxyl radical [OH-], singlet oxygen [O2] and 
peroxynitrite [NO-] (Huang D,2005).  Cellular damage from ROS has been 
implicated in a number of pathological conditions including atheroma (Heinecke 
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JW,2003), Alzhiemer’s disease (Pratico D,2004), Parkinson’s disease (Giasson 
BI,2000), Rheumatoid arthritis (Baskol G,2005), inflammatory bowel disease 
(Kruidenier L,2002), cancer (Brown NS,2001) and may even be responsible for 
the deterioration in function associated with ageing (Finkel T,2000).   ROS could 
be involved in pathology either through direct oxidative damage to biomolecules 
or through the cellular response such as apoptosis (Harrison DG,1997).    
 
Lipids are oxidised by ROS to aldehydes, of which the two most studied are 
malondialdehyde (MDA) and 4-hydroxyl-2-nonenal (HNE).  Oxidised lipid 
changes the biological properties of cell membranes, inactivating membrane-
bound receptors and enzymes, and reducing cell junction communication 
(Dalle-Donne I,2006).  In endothelial cells, oxidation of lipid increases 
expression of cell adhesion molecules, activates matrix metallproteinases and 
induces proliferation of underlying vascular smooth muscle (Suzuki YJ,1997).  
These  induce thrombosis and endothelial dysfunction (Calingasan NY,1998), 
all changes associated with atheroma. A key part in the pathological process of 
atheroma involves oxidation of circulating LDL particles (Ceconi C,2003).  
These changes in function can lead to cell death, with evidence that MDA is 
cytotoxic (Uchida K,2003) and HNE can induce apoptosis (Esterbauer H,1991). 
 
Oxidation of protein can alter its structure and function, and for example 
cataract is a consequence of photo-oxidation of the lens proteins (Taylor 
A,1993).  Modification of proteins  can generate new antigens and an immune 
response (Rosen A,1997), and inhibit enzyme function (Dalle-Donne I,2006) 
which can cause secondary damage if repair mechanisms are affected 
(Wiseman H,1996).  The oxidised protein is often poorly degraded, and can 
form aggregates within the cell that can cause metabolic dysfunction and initiate 
apoptotic processes (Dean RT,1997).   
 
DNA modification will have a broad range of effects on cellular function.  
Modified DNA contributes to risk of cancer (Block G,2006) and may contribute 
to ageing and reduced lifespan (Hart RW,1974) as urinary excretion of 
damaged DNA correlates with lifespan across a broad range of mammals 
(Foksinski M,2004). 
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1.3.2 Anti-oxidant systems 
 
Anti-oxidants are substances that oppose oxidation or inhibit reactions 
promoted by oxygen or peroxides.  Living organisms have developed a complex 
anti-oxidant network to protect themselves from the damaging effects of ROS 
(Prior RL,1999).  There are essentially two main groups, the enzymatic anti-
oxidants and the non-enzymatic scavengers that break down radical chain 
reactions and are in the process sacrificed and need to be regenerated (see 
Fig.1.10) (Huang D,2005).  The most significant circulating anti-oxidant is 
probably uric acid which is metabolised to allantoin (Grootveld M,1987). Anti-
oxidants can also be classified by their lipid solubility, with the lipophilic 
carotenoids important in the protection of lipoproteins, while vitamin C is much 
more hydrophilic (Gate L,1999) and may have different roles. 
 
 
Fig 1.10.  Biological anti-oxidant systems 
•Enzymatic
Superoxide Dismutase
Catalase
Glutathione 
Peroxidase
•Non Enzymatic
Autooxidation factors [Se, Coenzyme 
Q10]
Oxidative enzyme inhibitors [Aspirin]
Transition Metal chelators [EDTA]
Radical Scavengers [Vitamin C & E]
 
(Huang D,2005) 
 
The function of intra-cellular anti-oxidants is supported by the enzymatic anti-
oxidants superoxide dismutase, which detoxifies superoxide, and catalase,  
which breaks down hydrogen peroxide.   Anti-oxidant defences also depend on 
the action of glutathione, a low molecular weight thiol made from glutamate, 
cysteine, and glycine.  Glutathione acts as a scavenger of ROS, and is oxidised 
to glutathione disulfide which protects the rest of the cell.  The glutathione is 
replenished by the action of glutathione reductase on glutathione disulfide (Wu 
G,2004).  Anti-oxidants that can be obtained from the diet include vitamin C and 
E (Ames BN,1995) and the carotenoids eg lycopene in tomatoes (Stahl 
W,1992).  Long-term anti-oxidant supplementation intervention trials have so far 
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been disappointing in the prevention of cancer or heart disease (2002; Beta 
Carotene Cancer Prevention Study Group The Alpha-Tocopherol,1994; 
Hennekens CH,1996; Omenn GS,1996) despite epidemiological evidence that 
high vitamin C and E intake protects against degenerative disease (Enstrom 
JE,1992; Rimm EB,1993).  This may in part be due to the fact that life long 
exposure or genetic influences are more important and overwhelm the effect of 
short time (relative to total lifespan) supplementation.  Single nucleotide 
polymorphisms in catalase and superoxide dismutase genes have been 
associated with differences in oxidative stress pathophysiology (Kohno S,1999; 
Liao F,1994; Sandstrom J,1992).  When a measure of total anti-oxidant status 
(see 1.3 for explanation) was examined in a family study, 37.8% of the variance 
was thought to be genetic.  The proportion increased when other factors such 
as smoking were taken into consideration so that in smokers 42% of the 
variation was genetic in nature whilst in non-smokers it was only 26%.  This 
study also found that diet had little effect on total anti-oxidant status (Wang 
XL,2001). 
 
 
1.3.3 Measuring the Oxidative Stress Burden 
 
The measurement of ROS is possible, but requires electron spin resonance or 
chemi-luminescence.  The first method is non-invasive but is expensive and as 
ROS are unstable, do not accumulate and are unsuitable for routine use (Dalle-
Donne I,2006).  Hydrogen peroxide is stable in body fluids and can be 
measured in urine (Varma SD,1990) and breath (Jobsis RQ,2001), but there are 
insufficient data at present to support its widespread use.  The accuracy of the 
electron spin resonance  method can be improved with the use of ROS “traps” 
such as 1,1,3-trimethylisinordole-N-oxide (Bottle SE,2003), but their safety in 
man has yet to be proved and they may also only “trap” a small proportion of 
ROS produced so their validity is also not yet certain (Halliwell B,2004).  The 
“trap” concept can also be applied to molecules for which an assay already 
exists, this includes using salicylate which is non-enzymatically modified to 2-3 
dihydroxybenzoate (Ingelman-Sundberg M,1991) or endogenous uric acid 
excreted as allantoin (Grootveld M,1987).  These will suffer from the same 
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problems as the other “trap” methods, in so far as it is not possible to determine 
the percentage of generated ROS that is “trapped”. 
 
Due to the difficulties of measuring ROS directly, oxidative stress burden is 
most commonly assessed through biomarkers.   A biomarker is used to assess 
the generation of ROS indirectly.  To reflect ROS generation accurately a  
biomarker of oxidative stress must be 
 
 stable, as further oxidation products are often generated during sample 
handling  (Firuzi O,2006).   
 must accumulate to detectable concentrations.  
 be non-invasive and represent specific oxidative pathways [ROS 
generation].    
 must correlate with disease severity (Dalle-Donne I,2006).   
 
The biomarkers of oxidative stress fall into three groups.   These are either the 
measurement of the oxidation of macromolecules, anti-oxidant concentration or 
the capacity of body fluids or tissue to interfere with in vitro redox reactions. 
 
1.3.3a Oxidation of Macromolecules 
 
Malondialdehyde [MDA] is one of the most stable of the lipid peroxidation 
products. It can be detected in plasma by the Thiobarbituric acid reactive 
substances assay [TBARS] (Buege JA,1978).  This is relatively non-specific and 
has now been replaced with a method using high performance liquid 
chromatography [HPLC] (Wong SH,1987).   However, MDA is only one of a 
number of products, and can be absorbed through the gut (Nelson GJ,1993).  
The oxidative modification of fatty acids to pentane and ethane gives products 
which can be detected in breath, but this method is problematic because of the 
difficulty in preventing contamination by airbourne sources (Knutson MD,2000).  
The most accurate method of measuring lipid peroxidation products is the assay 
of F2-isoprostanes.  These are derived from the non-enzymatic oxidation of 
arachidonic acid (Morrow JD,1990).  They can be measured in plasma using 
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gas chromatography-mass spectroscopy [GCMS].  This method has high 
sensitivity and specificity and is not affected by passage across the gut (Blaak 
EE,2006).  However, F2 isoprostanes are only a minor end product (Lawson 
JA,1999) and this method is very labour intensive and requires expensive 
equipment (Milne GL,2005).  An immunoassay is now available (Morrow 
JD,2005) but there is limited information available regarding accuracy (Dalle-
Donne I,2006), and GCMS remains the most common method used. 
 
The most useful assay of modified proteins is also a mass spectroscopy assay 
of nitro-chloro-orthtyrosine, however, this can be generated in sample handling 
(Halliwell B,2004).  An attempt to design simpler methods has not so far led to 
the development of an improved technique.  Antibodies to tyrosine derivatives 
have not been specific enough (Duncan MW,2003) and also suffer from the 
same problems of generation during sample handling.  A calorimetric assay 
using dinitrophenylhydrazine has been developed to detect the more stable 
carbonylated proteins that result from oxidation of side chains (Levine RL,1990).  
These are stable, even when stored frozen (Stadtman ER,2003) but the assay 
is not specific and is confounded by glycated proteins and protein oxidation that 
occurs during cooking (Halliwell B,2004). 
 
A huge range of base and sugar modification products are generated during 
DNA oxidation (Dizdaroglu M,2002).  The most widely measured is 8-oxo,7,8-
dihydro-2-deoxyguanasine [8-OHdG] which can be measured by HPLC or 
Enzyme Linked Immunosorbent Assay [ELISA] (Cooke MS,2000).  The assay is 
limited by low availability of tissue, as DNA is intracellular, and leucocytes are 
often used as a surrogate.  When 8-OHdG is measured in the urine as a marker 
it can be confounded by variation in the efficiency of the DNA repair 
mechanisms (Halliwell B,2002).   
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1.3.3b Anti-oxidant concentrations 
 
The concentration of a number of anti-oxidants is decreased by ROS attack, 
and therefore, may function as a marker of oxidative stress (Rossi R,2006).  
Vitamin C, carotenoids and glutathione/glutathione disulfide [GSH/GSSG] can 
all be measured by HPLC (Craft NE,1992; Margolis SA,1996; Paolisso G,1992).  
These methods are time consuming, expensive, yield little information about 
combined effectiveness, and do not account for those that are undiscovered or 
difficult to measure (Maxwell SR,2006).  The measurement of lipid-soluble anti-
oxidants in plasma could also be misleading, and it has been reported that the 
risk of myocardial infarction correlates with adipose tissue levels of carotenoids 
but not plasma levels (Kohlmeier L,1997; Su LC,1998).  The measurement of 
anti-oxidants is further confounded by degradation during sample handling 
(Rossi R,2002). GSH/GSSG can be stabilised by the addition of Methyl-2-vinyl-
pyridium trifluoromethane sulfonate [M2VP] to the sample when it is taken.  The 
development of a colorimetric assay which is as accurate as the HPLC method 
(Floreani M,1997) has helped to allow the simple measurement of the 
GSH:GSSG ratio as a marker of intracellular redox status (Schafer FQ,2001).    
 
 
1.3.3c  Total anti-oxidant capacity assays 
 
 
The anti-oxidant function of plasma is a result of the interaction  between many 
different compounds, and often co-operation provides greater protection than 
each one alone,  as they regenerate and recycle each other (Packer JE,1979). 
Total anti-oxidant capacity assays [TAC] test all the multifunctional anti-oxidants 
present in the sample (Frankel EN,2000).  Although, this concept is attractive 
there are a number of disadvantages to the methods developed.  The redox 
reactions do not occur in a biological system, and the chain propagation that 
follows lipid peroxidation in vivo does not occur (Antunes F,1999).  The assays 
will all detect the anti-oxidant effect of uric acid, but this can be increased as a 
consequence of conditions where oxidative stress is higher, such as renal 
failure (MacKinnon KL,1999). These assays are also only able to detect 
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scavenger anti-oxidants (Huang D,2005), and can only look at either the 
hydrophilic or hydrophobic phase at one time.  In vitro TAC depends on the 
distribution and interaction of anti-oxidants in the two phases (Huang SW,1996).  
The results also need to be interpreted with caution, as increased anti-oxidant 
levels may reflect an adaptive response to increased ROS generation, and low 
levels may just reflect low background ROS generation eg in low calorie feeding 
(Prior RL,1999). There are many versions of this assay but they can be divided 
into two main groups.  Firstly, where plasma is used to interfere with an 
oxidation reaction, this requires an oxidant and a marker that undergoes 
oxidation.  Secondly, to drive a reducing reaction, which requires an oxidized 
marker that undergoes a reduction.   
 
Total Radical Trapping Anti-oxidant Parameter [TRAP] 
 
Method:  Inhibition of oxidation 
Oxidant:  2,2’-azobis(2-amidinopropane) [AAPH]  
Marker: O2 production (oxygen electrode) (Wayner DD,1985) 
  Luminol (Alho H,1999) 
  Fluoroscein (Valkonen M,1997) 
Result:  Lag phase 
 
The result is calculated on the basis of the delay in the reaction seen as the 
anti-oxidants in the serum are consumed, and this is compared to the lag phase 
seen with the addition of a standard amount of the anti-oxidant Trolox (Fig 1.11).  
The initial method was modified because of difficulties in maintaining the 
oxygen electrode (Ghiselli A,2000).   
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Fig. 1.11  The use of lag phase to calculate TRAP result 
 
The kinetics of oxidation reaction in the presence of plasma after the addition of AAPH 
and trolox.  The result is calculated by comparing the two lag phases obtained. 
 
The method is more time-consuming than others because of the method of 
calculating the result, and the method is also susceptible to error if the plasma 
is diluted, as this leads to significantly different values (DeLange RJ,1989). 
 
Oxygen Radical Absorbance Capacity [ORAC] 
 
Method:  Inhibition of oxidation 
Oxidant:  AAPH  
Marker: Phycoerythin (Cao G,1998) 
  Fluoroscein (Naguib YM,2000) 
Result: Area under the curve method 
 
This method is similar to the TRAP method but the result is calculated 
differently.  The oxidation reaction is allowed to proceed to completion and the 
result is calculated from the area under the curve in comparison to trolox 
standards (Prior RL,1999).  This method will not be able to detect slowly-
reacting anti-oxidants such as plasma proteins, which may react with ROS 
generated at a rate slower than the marker (DeLange RJ,1989).  This will 
change the slope of the oxidation curve and can alter the area under the curve 
(Cao G,1993). 
 
 55 
Trolox Equivalent Anti-oxidant Capacity [TEAC] 
 
Method:  Inhibition of oxidation   Reduction 
Oxidant: Ferrylmyoglobin*    persulphate used to generate  
  Hydrogen peroxide/   preformed ABTS+ 
  Horseradish peroxidase^ 
Marker: ABTS+ Generation (Green) ABTS Generation (Clear) 
Result: Endpoint    Endpoint (Re R,1999) 
 
* Commercialised by Randox Laboratories and known as Total anti-oxidant 
status  [TAS] (Miller NJ,1993). 
^ Known as Total anti-oxidant status [TAOS] (Sampson MJ,2002).  This 
combination has also been used in a chemilumenescence assay with luminol as 
the marker (Maxwell SR,2006) 
ABTS= 2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) 
 
ABTS forms a clear solution, that when oxidised to ABTS+ , undergoes a colour 
change which can be detected in a plate reader.  The assay is quick because of 
the use of an endpoint method to calculate the results.  The assay has also 
undergone significant commercial development, which enables it to be run at 
high speed on multiple samples on a number of automatic multi-channel 
analysis machines. 
 
Ferric ion Reducing Anti-oxidant Parameter [FRAP] 
 
Method: Reduction 
Oxidant: Fe3+ 
Marker: Fe2+ generation 
Result: Endpoint (Benzie IF,1996) 
 
The main disadvantage of this assay is that it is confounded by elevations in 
serum bilirubin (Huang D,2005), and, as with other reduction methods the anti-
oxidants present may not be able to reduce Fe3+  with the same efficiency that 
they would achieve with ROS, especially as in vivo transition metal pro-oxidant 
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states tend to be limited by chelators not scavenging anti-oxidants (Prior 
RL,1999).  A similar assay has been developed using copper instead of iron, 
total anti-oxidant potential (Zaporozhets OA,2004) or using the Folin-Ciocalteu 
regent which is misleading known as total phenol assay (Singleton VL,1999). 
 
Crocin Bleaching Assay 
 
Method: Inhibition of oxidation 
Oxidant: AAPH 
Marker: Bleaching of crocin 
Result: rate of bleaching 
 
Crocin is a natural pigment extracted from saffron and is subject to significant 
lot-to-lot variability.  The reaction rate of some anti-oxidants is very similar to 
blank controls, so the assay is prone to inaccuracy, and as the colour of crocin 
is very similar to some of the samples in which it is used to measure, this assay 
has found only limited applications (Huang D,2005).   
 
1.3.3d  Which Biomarker of oxidative stress? 
 
No biomarker has yet fulfilled all the criteria set out in 1.3.3 (Dalle-Donne 
I,2006).  This explains why the evidence for oxidative stress being involved in 
disease in humans in vivo is not definitive (Halliwell B,2004).   The poor 
correlation between the different methods is an indication of the high level of 
confounding that occurs when attempts are made to estimate oxidative stress 
burden.  Prior to assay, different biomarkers will appear under different time 
courses, so that at any one time, after an oxidative stress insult, products of 
lipid oxidation and DNA oxidation will correlate poorly (England T,2000).  
Variation in sample handling is also a source of error, as anti-oxidants are 
unstable and degrade when exposed to air and light (Ghiselli A,2000), while any 
clotting that occurs during sampling will lead to the release of ROS from 
platelets (Leo R,1997).  DNA oxidation assays are more variable if performed 
on isolated DNA than on urine, suggesting that the additional handling 
introduces error, to the extent that there is currently no agreement on basal 
 57 
levels (Collins AR,2004).  When considering the TAC assays, they measure the 
chemical activity of the plasma anti-oxidants under very specific conditions.  
The affinity of different anti-oxidants with the radicals generated will differ 
between assays, so that the anti-oxidant activity of vitamin C is low in TRAP 
[AAPH] but high in TAS [Ferrylmyoglobin] (Schlesier K,2002).  When different 
methods have been compared the correlation has been poor.  When FRAP was 
compared to markers of lipid and protein oxidation, although correlation was 
described, it was found to be weak (r<0.5) (Firuzi O,2006).   
 
Three studies have compared TAC methods, no correlation was found between 
ORAC and TEAC, or FRAP and TEAC in one, with a weak correlation between 
ORAC and FRAP(r=0.35,p=0.019) only.  When the proportion of the TAC due to 
individual anti-oxidants was calculated the proportions were significantly 
different, indicating that the assays have different affinities for the variety of anti-
oxidants found in plasma (Fig1.12) (Cao G,1998). A similar weak correlation 
was found when a luminol method was used comparing ABTS and AAPH 
(r=0.37,p=0.03) (Waring WS,2003).   
 
Fig 1.12  The difference in the proportion of TAC due to individual anti-oxidants 
in different TAC methods (Cao G,1998) 
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When the anti-oxidant capacity of ten drinks was compared using five different 
methods the absolute values were different, although the drinks that ranked 
higher tended to be the same regardless of the method used (table 1.3) 
(Schlesier K,2002).  This has led to the suggestion that investigators should 
report two replicate biomarkers when reporting associations with oxidative 
stress burden (Block G,2006; Schlesier K,2002).  This would overcome the two 
main confounding issues, firstly, the variability of the baseline between studies 
reflecting sampling artefact, and secondly, the variability in the substrate/ROS 
interaction, where different ROS have different affinity for different substrates 
(Mayne ST,2003). 
 
 
Table 1.3  The ranking by anti-oxidant capacity of different drinks using five 
different TAC methods.  See paper for details of methods used. (Schlesier 
K,2002) 
 
  TEAC DPPH DMPD FRAP PCL 
Blackcurrant juice 1 1 1 2 1 
Blackcurrant Nectar 2 2 2 1 6 
Green Assam Tea 3 6 6 4 5 
Black Assam Tea 4 4 4 7 3 
Green Darjeeling Tea 5 3 3 6 4 
Black Darjeeling Tea 6 5 5 5 2 
Apple Juice 1 7 8 8 3 7 
Apple Juice 2 8 7 7 8 10 
Tomato Juice 1 9 10 10 10 9 
Tomato Juice 2 10 9 9 9 8 
 
 
1.3.4 Role of oxidative stress in type 2 diabetes 
 
There are a number of steps in the natural history of type 2 diabetes where 
oxidative stress may play a role.  These include the development of insulin 
resistance, β-cell failure and end organ damage secondary to hyperglycaemia.   
States that predispose to the development of type 2 diabetes appear to be 
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associated with increased oxidative stress.  ROS production increases with fat 
accumulation in humans, with higher levels of both TBARS (Furukawa S,2004) 
and isoprostanes (Keaney JF,2003) in obese subjects compared to controls.   
Reduced anti-oxidant expression has also been demonstrated in obese mice 
compared to controls (Furukawa S,2004).  Oxidative stress is also increased in 
the metabolic syndrome, with 3.7 times greater levels of isoprostanes and a 
41% reduction in the anti-oxidant activity of HDL in a AAPH system compared 
to controls (Hansel B,2004).  Diabetogenic cytokines such as TNFα are also 
associated with higher levels of oxidative stress (Qi C,2000).  If ROS are 
important in the development of type 2 diabetes then they should be associated 
with over-nutrition.  Post-prandial increases in lipid and carbohydrate levels 
increase oxidative stress (Tsai WC,2004), in part, driven by increased rates of 
non-enzymatic glycation (Dandona P,1996) and glucose auto-oxidation 
(Mullarkey CJ,1990) seen after a meal, but also by the presence, in the 
circulation, of oxidized lipids, from a processed diet (Blaak EE,2006).  This may 
be more important in western societies where a significant part of the day is 
spent in the post-prandial state (Sies H,2005).    
 
This increase in ROS may act as a sensor of the nutrient environment (Nemoto 
S,2000).  This is because increased nutrient delivery will increase mitochondrial 
activity, and ROS generation is an obligatory consequence of aerobic 
metabolism (Bloch-Damti A,2005).  Mitochondria are the principle source of 
ROS in cells (Zhou YP,1995), and the primary factor determining the rate of 
production is the redox state of the electron transport chain (Skulachev 
VP,1996).   Glycolysis and the citric acid cycle generate NADPH and FADH, 
which donate electrons to the electron transport chain.  As electrons are moved 
along the four complexes, hydrogen ions are pumped out of the mitochondria 
and an electrochemical gradient is established (Nishikawa T,2000a).  This 
gradient is dissipated through the ATP synthase complex, converting ADP to 
ATP  for use as an energy source in the cell (Fig 1.13).   
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Fig.1.13 A representation of the electron transport chain for the production of 
energy in the form of ATP from NADPH and FADH generated during oxidation 
 
(http://www.biologycorner.com/resources/electrontransport.jpg) 
The amplitude of this gradient regulates chain activity and increased nutrient 
delivery will increase this gradient (Maddux BA,2001), which reduces activity 
and leads to the partial reduction of oxygen and the generation of ROS, whilst 
electrons are “held up” in the chain (Nishikawa T,2000b).   Reducing the 
membrane potential, such as for ATP production, reduces ROS generation 
(Fridlyand LE,2006). 
 
Mitochondrial DNA is in close proximity to the electron transport chain, and it is 
possible that mitochondrial DNA damage is the cause of the small dysfunctional 
mitochondria found in type 2 diabetes (Maassen JA,2004).  Significant oxidative 
stress leads to programmed death of mitochondria, reducing oxidative capacity 
further (Watson RT,2004).  Reducing the delivery of electrons to the electron 
transport chain would reduce oxidative stress.  The best way to achieve this is 
to prevent nutrient entrance into cells i.e. insulin resistance.  It may be that 
insulin resistance is a protective mechanism when large amounts of ROS are 
being generated by the electron transport chain (Fridlyand LE,2006). 
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The generation of ROS has a number of deleterious effects on insulin secretion 
and sensitivity.   A transient increase in ROS enhances insulin signalling 
(Keaney JF,2003), possibly because insulin signalling itself may require ROS as 
a second messenger (Kaneto H,1999).  A burst of ROS is triggered with a 
variety of ligands including Platelet Derived Growth Factor (Sundaresan 
M,1995), Epidermal Growth Factor (Bae YS,1997) and Angiotensin II 
(Griendling KK,2000) and ROS is becoming increasingly recognised as an  
important intracellular signal (Goldstein BJ,2005).  However, chronic oxidative 
stress is damaging to insulin action (Furukawa S,2004) and may precede the 
development of type 2 diabetes (Salonen JT,1995).  Hydrogen peroxide impairs 
insulin signalling in 3T3-L1 adipocytes, increases serine/threonine 
phosphorylation of IRS (Potashnik R,2003), reduces PI3 kinase and Akt 
activation (Furukawa S,2004; Tirosh A,1999) and GLUT 4 translocation (Pessler 
D,2001; Rudich A,1998).  Hydrogen peroxide can also alter gene expression, 
reducing the expression of the insulin sensitisers adiponectin and leptin 
(Kamigaki M,2006) 
 
ROS also stimulates intracellular processes that will lead to secondary 
increases in insulin resistance.  These stimulate a number of transcription 
factors such as Mitogen Activated Protein Kinase, p38 kinase, protein kinase C 
isoforms and c-Jun kinases (Kaneto H,2005) and, hence, activate inflammatory 
pathways which regulate gene expression, promoting insulin resistance as 
described earlier.  Exposure to oxidative stress therefore promotes insulin 
resistance by, firstly, impairment of insulin signalling and secondly, activation of 
cellular stress kinases (Pessler D,2001).   
 
The important role of oxidative stress is further supported by the effect of anti-
oxidants on insulin sensitivity.  In either cell (Benhamou PY,1998) or animal 
(Kubisch HM,1997)  models of diabetes, genetic modifications of the oxidative 
stress load maintain insulin sensitivity, and the anti-oxidant α-lipoic acid 
improves glucose utilisation in cell culture (Maddux BA,2001) and when given 
orally (Konrad T,1999).   Insulin sensitivity is also improved by the 
administration of the anti-oxidants vitamin C, E, N-Actylcysteine and Glutathione 
(Fridlyand LE,2006; Hildebrandt W,2004). 
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Β-cell function and insulin secretion are also similarly affected by ROS.  ROS 
lowers glucose-induced insulin secretion as early as 30 minutes after exposure 
(Maechler P,1999), and in keeping with the functional abnormalities described 
in type 2 diabetes, hydrogen peroxide can suppress first phase insulin secretion 
(Sakai K,2003), while glucokinase, a crucial part of the glucose sensor, can be 
inactivated by ROS (Lenzen S,1988).  The pancreas is particularly vulnerable to 
oxidative stress as it has the lowest intrinsic anti-oxidant capacity (Grankvist 
K,1981), and does not activate anti-oxidant enzymes during times of cellular 
stress (Maechler P,1999). Β-cells are also susceptible to overfeeding as they 
are not dependant on insulin for glucose uptake (Ceriello A,2004).  Activation of 
stress signalling pathways is associated with reduced insulin gene expression 
and cell apoptosis (Kaneto H,2005), which may explain why the pancreas is 
unable to compensate for increased insulin resistance and type 2 diabetes 
develops (Pick A,1998).   These defects in β-cell function can also be reversed 
by anti-oxidant strategies, such as over-expression models of glutathione (Tran 
PO,2004) or C-Jun inhibitors (Duval A,2000) or by the administration of N-
acetylcysteine (Tanaka Y,2002). 
 
Oxidative stress may also play a role in the progression of β-cell dysfunction, 
glucose intolerance and development of the complications of type 2 diabetes 
(Maritim AC,2003).  Development of hyperglycaemia in rats is associated with 
more severe defects in insulin secretion and sensitivity (Tanaka Y,1999).  The 
effect on β-cells is known as glucose toxicity (Robertson RP,2006).  In cultured 
human islet cells high levels of glucose switch on expression of apoptosis 
genes Bad, Bid and Bik, while reducing expression of the anti-apoptosis gene 
Bcl-x1 (Federici M,2001).  This may explain the failure of β-cell mass to expand 
in order to counteract the effect of early glucose intolerance (Pick A,1998). 
 
Hyperglycaemia also appears to increase the oxidative stress burden.  TRAP is 
lower (higher oxidative stress) in both type 1 (Tsai EC,1994) and type 2 
diabetes (Ceriello A,1997).  Markers of oxidative stress, including salicylate 
hydroxylation (Ghiselli A,1992), F2-isprostanes (Gopaul NK,1995) and oxidised 
DNA (Rehman A,1999), are consistently elevated in type 2 diabetes, and this 
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seems to be related to blood glucose levels as  F2-isprostane levels fall with 
improvements in diabetes control (Davi G,1999).  Acute rises  in plasma 
glucose (after a glucose tolerance test) have been demonstrated to be 
associated with increased F2-isoprostanes (Sampson MJ,2002), reduced anti-
oxidant vitamins, uric acid and TRAP in subjects with type 2 diabetes (Ceriello 
A,1998), although similar findings in healthy volunteers were not replicated in a 
separate study measuring anti-oxidant vitamins, FRAP and allantoin (Ma 
SW,2005).  This may be because a higher blood glucose is needed as during a 
clamp study a serum glucose of 15mmol/l increased nitrotyrosine levels in 
healthy volunteers (Marfella R,2001).  The role of oxidative stress in glucose 
toxicity is further supported by the reduction of severity of insulin resistance and 
β-cell dysfunction by the use of anti-oxidants in animal models, using the zucker 
diabetic rat (Tanaka Y,1999)and db/db mouse (Kaneto H,1999).    
 
The potential mechanisms by which high glucose levels could increase ROS 
generation are shown in Fig 1.14.  Glucose can generate ROS through non-
enzymatic pathways, including the generation of ketoaldehydes (Maritim 
AC,2003) and the formation of Advanced Glycation End products [AGE].  
Glycation of proteins produces a Schiff base, which undergoes rearrangement 
to form amadori products, which after further auto-oxidation of glucose form 
AGE.  AGE can bind to specific receptors, triggering stress signalling through 
NF-κβ activation, as well as generating ROS (Yan SD,1994).  The upregulation 
of alternative metabolic pathways also increases ROS generation and stress 
signalling, and is responsible for the development of a number of complications 
of type 2 diabetes (Brownlee M,2001).   
 
The sorbitol pathway leads to the accumulation of fructose, which consumes 
intracellular anti-oxidants and promotes stress signalling (Brownlee M,2001; 
Evans JL,2002).  The hexosamine pathway is also upregulated, and the end 
product of this pathway, UDP-N-acetylglucosamine, is the substrate for the 
glycosylation of important intracellular factors including transcription factors, 
particularily those involved in stress signalling  (Rolo AP,2006).   
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Fig1.14 The pathways leading to the generation of ROS during hyperglycemia.   
 
 
 
 
Six biochemical pathways along which glucose metabolism can form reactive oxygen 
species (ROS). Under physiological conditions, glucose primarily undergoes glycolysis 
and oxidative phosphorylation (6). Under pathological conditions of hyperglycemia, 
excessive glucose levels can overwhelm the glycolytic process and inhibit 
glyceraldehyde catabolism, which causes glucose, fructose 1:6-bis-P, and 
glyceraldehyde 3-P to be shunted to other pathways: (1) enolization and α-
ketoaldehyde formation, (2) PKC activation, (3) dicarbonyl formation and glycation, (4) 
sorbitol metabolism, and (5) hexosamine metabolism (Robertson RP,2006). 
 
 
In hyperglycaemia, increased synthesis of diacylglycerol [DAG] activates up to 9 
isoforms of PKC, which can also activate stress signalling and lead to the 
generation of ROS (Brownlee M,2001).  The deleterious effects of these 
pathways are not all dependent on ROS, but oxidative stress from 
hyperglycemia-induced overproduction of superoxide by mitochondria is the 
trigger that drives each of these pathways (Rolo AP,2006) (Fig1.15).   
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Fig 1.15.  The stimulation of pathological pathways by hyperglycemia-induced 
ROS generation 
 
 
(___, direct role; -----, indirect role). GlcNac, O-linked N-acetylglucosamine; PAI, 
plasminogen activator inhibitor; TGF-β, transforming growth factor-β. (Rolo AP,2006) 
 
 
 
The effect of NEFA on the induction of insulin resistance and β-cell function 
may also in part be modified by generation of ROS.  In healthy volunteers 
infusion of NEFA increases levels of MDA, reduces intracellular GSH (Paolisso 
G,1996) and activates NF-κβ (Evans JL,2003).  The long chain fatty acid 
sodium palmitate increases ROS generation in isolated rat β-cells, in parallel 
with decreases in glucose-stimulated insulin secretion, indicating ROS may also 
play a part in NEFA-induced β-cell dysfunction. 
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Therefore, despite significant difficulties in the assessment of oxidative stress 
there is considerable evidence that the development of insulin resistance and β-
cell dysfunction are driven by oxidative stress-dependent mechanisms and that 
once established, glucose tolerance is perpetuated by increased generation of 
ROS.  The mitochondria, and more specifically the rate of mitochondrial 
oxidation and the mitochondrial membrane, appear to be key components of 
this process. 
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1.4   Mitochondrial Uncoupling Proteins 
 
The uncoupling proteins 2 and 3 (UCP2/UCP3) are part of a mitochondrial 
carrier superfamily that are membrane proteins of around 300 amino acids with 
six transmembrane domains (Bross O,2000).   Their description as uncoupling 
proteins is based on their homology to uncoupling protein 1 (UCP1), the first of 
the family to be described.   
 
The generation of a proton gradient across the mitochondrial membrane during 
fuel substrate oxidation is described earlier in this chapter.  However, isolated 
mitochondria can continue to respire in the absence of ATP (Brand MD,1994).  
This is due to leak of the protons back across the membrane rather than 
through ATP synthase.  The stored energy is released as heat, and fuel 
substrate metabolism is said to be “uncoupled” from ATP production (Fig. 1.16).  
Proton leaks are a feature of all living cells (Schrauwen P,2002a) but the 
mechanism of these leaks was not previously understood.   
 
Fig 1.16 The dissipation of the mitochondrial proton gradient to provide ATP 
synthesis (coupled) or with energy wasting (uncoupled) (Schrauwen P,2002a) 
 
 
 
 
In rodents, body temperature is maintained by uncoupling (Nicholls DG,1999), 
and is mediated primarily by brown adipose tissue (BAT) (Rothwell NJ,1979).  
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This led to the identification of a uniquely expressed protein, UCP 1 (Lin 
CS,1980) which was responsible for the thermogenic proton leak.  UCP 1 
expression increases with cold stress (Silva JE,1997), and the UCP1 knockout 
mice were more likely to develop hypothermia in cold conditions than wild-type  
mice (Enerback S,1997). 
 
However, uncoupling was not unique to BAT (Rolfe DF,1996) with proton leaks  
responsible for 26-50% of resting energy expenditure (Rolfe DF,1996).  This led 
to the identification of UCP2 and UCP3,  which show 55% and 57% homology 
with UCP1 respectively and 71% homology with each other (Vidal-Puig A,1997).  
These two UCPs are both located in a gene cluster on chromosome 11q13, 
within 8kb of each other, and share similar genomic structures (Pecqueur 
C,1999).  Two central nervous system UCPs have also been identified, known 
as UCP4 (Mao W,1999) and UCP5 or Brain Mitochondrial carrier protein-1 
(Sanchis D,1998), although the homology of these two proteins with UCP1 is 
low (<40%) (Dalgaard LT,2001a).  UCP-like proteins have also been identified 
in plants and birds, indicating that they are an ancient, well-conserved family 
likely to be important physiologically (Rousset S,2004). 
 
 
1.4.1. Physiology of Uncoupling Protein 2 
 
UCP 2 was discovered in 1997 (Fleury C,1997; Gimeno RE,1997).  The protein 
is expressed widely in spleen, lung, stomach, skeletal muscle, pancreas, heart, 
liver, kidney and macrophages (Fleury C,1997; Gimeno RE,1997; Millet L,1997; 
Pecqueur C,2001),with high homology among species e.g. 95% between rat 
and human (Matsuda J,1997).   The ability of UCP1 to dissipate the proton 
gradient without the generation of ATP (Nicholls DG,1984) identifies its function 
as an uncoupler of metabolism, although the exact mechanism of proton 
transfer is still unclear (Esteves TC,2005).  The similarity in structure suggests 
that UCP2 should also function as an uncoupling protein.  A number of 
experimental systems suggest UCP2 does possess uncoupling properties, 
including E. coli inclusion bodies (Jaburek M,1999) or liposomes (Echtay 
KS,2001), overexpression in yeast systems (Fleury C,1997; Gimeno RE,1997; 
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Rial E,1999), and cell culture systems [Hela cells (Mills EH,2002), INSE-1 cells 
(Hong Y,2001), Human thymus (Krauss S,2002), Ob/Ob mice hepatocytes 
(Chavin KD,1999)and Zucker diabetic rat islet cells (Cortez-Pinto H,1999)].  
However, there is not a close link between tissue proton leak and UCP2 levels 
(Dalgaard LT,2001a), and some of these systems such as liver cells and yeast 
mitochondria can exhibit a proton leak in the absence of UCPs (Porter RK,1995; 
Stuart JA,1999a).  The yeast system also has other potential confounding 
features that may apply to the other systems.  When UCP2 is expressed in 
yeast it is misfolded and only poorly incorporated into the membrane.  
Replication at low levels of expression did not demonstrate a proton leak, and it 
is thought that the earlier results could be due to an over-expression artefact 
(Stuart JA,2001). The structure of UCP2 also lacks a histidine pair thought to be 
essential for UCP1 function (Masaki T,1997).  Therefore, the evidence that 
UCP2 functions as an uncoupler of mitochondrial metabolism is not conclusive.  
There is no change in proton conductance in the UCP2 mouse under basal 
conditions, although this does change under certain conditions such as 
activation by ROS or free fatty acids (Esteves TC,2005).   These results 
suggest that UCP2 has a novel function that may be dependent on conventional 
uncoupling, or may act through a non-uncoupling mechanism. 
 
1.4.1a UCP2 and Metabolism 
 
Despite there being little BAT in adult humans (Garruti G,1992) there is no 
evidence to suggest that UCP2 has a role in thermogenesis.  The UCP1 
knockout mouse remains cold-sensitive despite increased expression of UCP2 
(Enerback S,1997), while the UCP2 knockout mouse is not cold sensitive 
(Arsenijevic D,2003).  The expression of UCP2 in ectothermic fish, which 
remain the temperature of the surrounding water, also suggests that UCP2 has 
no role in the regulation of body temperature (Stuart JA,1999b).   
 
The ability to waste energy derived from substrate utilisation would make UCP2 
an attractive molecule for a role in the adaptive response to over-nutrition.   
Resting metabolic rate is dependent on thyroid and steroid hormone levels, 
sympathetic nervous system activity and ratio of fat to fat-free mass (Toubro 
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S,1996).   Energy expenditure over 24hrs is in part genetic, with a heritability of 
between 0.26-0.70 (Dalgaard LT,2001a), and lower expenditure is more 
predictive of future weight gain than increased nutrient intake (Roberts SB,1988) 
with only very small differences increasing the risk of obesity significantly 
(Leibel RL,1997).  UCP2 expression is increased in obese mouse models, the 
Ob/Ob  and db/db mouse (Chavin KD,1999; Gimeno RE,1997), and the obesity 
prone C57b/6 mouse fails to upregulate UCP2 when fed a high fat diet (Fleury 
C,1997).  In man, abdominal muscle tissue mRNA was 28% lower in obese 
subjects compared to those without obesity (Nordfors L,1998) and muscle 
mRNA levels correlated with percentage body fat and BMI (Bao S,1998).  Low 
expression was also found in intraperitoneal fat tissue taken at surgery, which 
persisted even when the subjects lost weight (Oberkofler H,1998).   However, 
most of this evidence is circumstantial, and UCP2 expression could be following 
other obesity-induced metabolic changes.  The UCP2 knockout mouse does not 
gain weight on a high fat diet (Arsenijevic D,2003), UCP2 levels do not change 
after weight loss in man (Vidal-Puig A,1999) and groups with lower UCP2 
expression, such as first degree relatives of those with type 2 diabetes, do not 
have lower energy expenditure.  This suggests either that UCP2 does not have 
a major role in energy balance, or that there is significant overlap in energy 
control mechanisms (Erlanson-Albertsson C,2003).  The data, so far, does not 
support a critical role for UCP2 in energy balance.  This is confirmed by the 
upregulation of UCP2 by fasting, a state of reduced energy expenditure and 
reduction in body temperature.   
 
The upregulation of UCP2 by fasting has been consistently demonstrated in rats 
(Boss O,1997a; Cadenas S,1999; Memon RA,2000; Samec S,1998a; Samec 
S,1998b; Teshima Y,2003; Xiao H,2004), mice (Kersten S,1999; Samec 
S,1999a) and humans (Millet L,1997).  Interestingly, these studies 
demonstrated a reduction in mRNA expression with re-feeding, although not if 
re-fed with a high fat diet (Samec S,1999a; Teshima Y,2003; Xiao H,2004).   
The fasting state and the re-fed high fat diet state are both associated with 
elevations in free fatty acids, and abolishing this increase with intervention 
prevents the induction of UCP2 expression (Dulloo AG,2001).  The observation 
that free fatty acids uncouple mitochondrial metabolism (Challoner DR,1966) 
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raises the possibility that this is due to UCP2, which has a function in fuel 
substrate switching or protection of the high rate of oxidation associated with 
fatty acid delivery.  The changes seen with fasting were more pronounced in 
muscle that is usually glucose dependent (fast twitch-gastrocnemius) than 
muscle groups with high rates of basal fat oxidation (slow twitch-soleus) (Samec 
S,1998a).  Free fatty acids appear to be key regulators of UCP2 mRNA 
expression.  The higher fatty acid levels associated with a high fat diet (Aubert 
J,1997; Chan CB,2001; Fleury C,1997; Gong DW,1999; Joseph JW,2002; 
Matsuda J,1997; Surwit RS,1998; Tsuboyama-Kasaoka N,1999), chemically 
induced diabetes (Hidaka S,2000; Kageyama H,1998) and acute exercise 
(Thompson MP,2004)  all increase UCP2 mRNA levels in a number of rodent 
models and tissues, including in hepatocytes which do not normally express 
UCP2 (Cortez-Pinto H,1999).  The transition from glucose to free fatty acid 
metabolism in cardiomyocytes at birth is associated with a five times increase in 
levels of UCP2 mRNA in rats (Van Dere Lee KAJM,2000).  Interventions such 
as fibrates (Tsuboyama-Kasaoka N,1999) and nicotinic acid (Samec S,1998a), 
which lower free fatty acid levels, also lower UCP2 mRNA in rodents.  In 
humans, lipid infusion increased mRNA expression in subcutaneous fat (Nisoli 
E,2000) although no change was found in skeletal muscle in another study 
(Khalfallah Y,2000).  Cell culture experiments confirm these studies with 
palmitate, α-bromopalmitate, oleic acid and linoleic acid all increasing UCP2 
mRNA in a variety of cell lines, including rat cardiomyocytes and hepatocytes, 
3T3-L1, INS-1, H9c2 and L6-myotubules (Armstrong MB,2001; Aubert J,1997; 
Camirand A,1998; Lameloise N,2001; Medvedev AV,2002; Reilly JM,2000; Van 
Dere Lee KAJM,2000; Viguerie-Bascands N,1999).   In rat islet cells the 
increase in mRNA expression paralleled the increase in fat oxidation and was 
inhibited by high glucose levels, which lowers fat oxidation (Medvedev AV,2002).   
 
A role in fatty acid metabolism is also suggested by the regulation of the gene 
by the key metabolic transcription factors of the PPAR group (Masaki T,1997), 
as well as other regulators that modify fatty acid metabolism, including thyroid 
hormones (Nagase I,2001), catecholamines (Masaki T,1997) and the sterol 
regulatory element binding protein-1 (Medvedev AV,2002).  The result of this is 
that changes in UCP2 mRNA parallel changes in other genes in fat oxidation 
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such as carnitine palmitoyltransferase, acylcoA dehydrogenase and long chain 
CoA dehydrogenase (Samec S,2001). 
 
Overexpression of uncoupling proteins in mice induced resistance to weight 
gain, even on a high fat diet with higher oxygen metabolism (Li B,2000).  The 
widespread expression would make UCP2 an attractive candidate for energy 
balance control.  The expression of UCP2 suggests an important role in fatty 
acid metabolism but does not support the hypothesis that this role is in energy 
balance.  The ability of fatty acids to uncouple is probably not dependent on 
UCP2 (Hirabara SM,2006), and may just be a reflection of the fatty acid content 
of cell membranes (Porter RK,2001).  Therefore, despite a large body of 
evidence that UCP2 is an important component of fatty acid metabolism its 
physiological role is unclear.  From an evolutionary standpoint the development 
of a mechanism to waste energy, when food seeking and energy conservation 
is given high priority, is surprising (Erlanson-Albertsson C,2003).  The earlier 
sections of this chapter describe an important difference between glucose and 
fat oxidation, documenting the higher levels of ROS production by the electron 
transport chain during fat metabolism.   Non-thermogenic uncoupling does, 
however, reduce ROS generation (Vidal-Puig AJ,2000).  The possibility that 
UCP2 is a modulator of ROS production is examined in more detail in 1.4.1c, 
but if this is the case then the involvement in fatty acid metabolism may be 
purely a feature of the higher levels of ROS generated therein.  
 
 
1.4.1b UCP2 and Islet Cell Function 
 
The dependence of insulin secretion on ATP production makes it likely that 
expression of UCP2 in the pancreas will have a modifying effect on β-cell 
function.  A small study described 80% higher skeletal muscle UCP2 mRNA 
levels in type 2 diabetes, although the small number of subjects in the study 
meant that this difference was not statistically significant (p=0.09)(Bao S,1998).  
However,  UCP2 mRNA levels in skeletal muscle correlate with fasting blood 
glucose in subjects with obesity/type 2 diabetes (Bao S,1998).  The UCP2 
knockout mouse has increased β-cell ATP levels, and higher glucose-stimulated 
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insulin secretion, leading to 18% lower blood glucose levels (Zhang C-Y,2001), 
as well as higher β-cell mass and insulin content even on a high fat diet (Joseph 
JW,2002).  If UCP2 is knocked out in the Ob/Ob mouse, then first phase insulin 
secretion is restored and higher insulin levels and lower blood glucose levels 
are observed, with no changes to insulin sensitivity (Zhang C-Y,2001) Although 
one early dissenting report suggested the opposite (Wang MY,1999), UCP2 
over-expression models have now shown consistently lower insulin secretion in 
rat islet cells (Chan CB,1999), human insulinoma cells (Hong Y,2001) and 
mouse and human islet cells.  The defect in insulin secretion is isolated to 
glucose, with no difference in response to direct stimulators of ATP-dependent 
K channels (Chan CB,2001) .  
 
Studies on the UCP2 knockout mouse have suggested UCP2 may be an 
important modulator of insulin secretion.   The reduction of β-cell function, and 
increase in UCP2 mRNA, seen with free fatty acids, may in part explain their 
diabetogenic effect.  The exposure of the UCP2 knockout mouse to palmitate 
does not cause the lower glucose-stimulated insulin secretion that is normally 
seen in response to free fatty acids.  Isolated islet cells have higher ATP levels, 
and the mitochondrial membrane is hyperpolarized faster and to a greater 
extent (Joseph JW,2004).  Superoxide can also have a negative effect on β-cell 
function, which is absent in the UCP2 knockout mouse (Krauss S,2003).   
 
Thus UCP2 appears to be a critical modulator of insulin secretion, but once 
again it is not clear if that is the primary function of the protein, or if it is simply a 
side effect of UCP2 being activated by fatty acid-derived ROS.  This means that 
potentially enhanced UCP2 function would be associated with protection from 
obesity but increased risk of type 2 diabetes, an “Adiposity Angel and Diabetes 
Devil” (O'Rahilly S,2001).  This effect also raises the possibility that UCP2 could 
be a therapeutic target for the treatment of type 2 diabetes.  In mice, a 
pharmacological inhibitor of UCP2-determined proton leak did reverse obesity-
induced β-cell dysfunction through higher levels of ATP production, although it 
is not clear how long this effect persists (Zhang CY,2006). 
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1.4.1c  UCP2 and oxidative stress. 
 
In most cells the majority of ROS is generated by the electron transport chain, 
so that a protein that can modulate mitochondrial function would be a good 
candidate for being part of the cellular defense against ROS (Skulachev 
VP,1996).   Mitochondrial production of superoxide is inversely correlated with 
the amount of uncoupling (Gimeno RE,1997), and mitochondrial ROS 
generation can be modulated by UCP2 activation (Negre-Salvayre A,1997), 
whilst inactivation using an antisense RNA method increases ROS generation 
in a mouse endothelial cell line (Duval C,2002).  The immune system is also a 
high producer of ROS, and oxidative stress. The regulation of UCP2 with 
immune function further suggests that it may have a role in the modulation of 
oxidative stress.  UCP2 mRNA expression is activated by superoxide (Echtay 
KS,2001; Echtay KS,2002a), hydroxynonenal (Echtay KS,2003), AAPH (Murphy 
MP,2003), lipopolysaccharide [LPS] (Faggioni R,1998; Viguerie-Bascands 
N,1999) and TNF α (Cortez-Pinto H,1998; Viguerie-Bascands N,1999) and 
levels become high in macrophages as they differentiate into functioning 
phagocytes (Nishio K,2005).   The induction of UCP2 expression by LPS can be 
blocked by the administration of the anti-oxidant n-acetylcysteine, indicating the 
role of ROS generation in UCP2 expression regulation (Alves-Guerra MC,2003).  
UCP2 expression is also increased in pathological situations where ROS is 
thought to be important, such as ischaemia (de Bilbao F,2004), ischaemic pre-
conditioning (McLeod CJ,2005), irradiation (Voehringer DW,2000), left 
ventricular dilatation and failure (Guo P,2005) and inflammatory conditions 
(Rousset S,2004).  The findings of increased ROS in UCP2 knockout models 
(Bai Y,2005; Joseph JW,2004), and decreased ROS in over-expression models 
(Kizaki T,2003), confirms the finding that ROS is a modulator of UCP2 function, 
and that changes to UCP2 function can modulate ROS production. 
 
The first study to demonstrate that this may be of physiological importance was 
a study on the immune function of the UCP2 knockout mouse.  Pathogen killing 
is dependent on the generation of superoxide by  macrophages (Babior 
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BM,2000).  The UCP2 knockout mouse had a higher bactericidal activity against 
Salmonella typhimurium, and was able to clear Toxoplasma gondii infection, 
which remains a chronic infection in wildtype mice (Arsenijevic D,2003).   The 
activation of the immune system by LPS is also higher with higher levels of 
inflammatory cytokines, NF-κβ activation and hydrogen peroxide generation 
during bacterial killing compared to wildtype mice (Bai Y,2005).  The role of 
UCP2 modulation of ROS has also been studied in a number of models of 
neuroprotection.  UCP2 over-expression reduces the toxicity of 1,2,3,6-methyl-
phenyl-tetrahydropyridine [a toxin used to induce an animal model of 
Parkinsons disease] on isolated neurones (Conti B,2005), and injury size in 
stroke and traumatic brain injury models (Mattiasson G,2003).   In a mouse 
model of Multiple Sclerosis the knock out of UCP2 led to higher disease scores 
and increased T-cell activity and cytokine production (Vogler S,2006).  The 
response to toxins that induce ROS-dependent disease is also higher in UCP2 
knockout mice, including tumour development to azooxymethane (Derdak 
Z,2006) and cell damage to mendione in hepatocytes (Collins P,2005), while 
hepatic regeneration after injury is also delayed as ROS interferes with the cell 
cycle (Horimoto M,2004) . 
 
ROS are thought to play an important part in the generation of cardiovascular 
disease.   LDL oxidation is one of the first steps of atheroma.  The LDL-receptor 
knockout mouse is a model of cardiovascular disease, and when the UCP2 
gene was also knocked out in this mouse the plaque area was increased by 
42% compared to the LDL-receptor knock out “wildtype” (Blanc J,2003).  The 
plaques in the UCP2/LDL receptor knockout mouse were strongly positive for 
nitrotyrosine staining [a marker of peroxynitrite generation form superoxide and, 
thus, oxidative damage] while the UCP2 wildtype/LDL receptor knockout mouse 
nitrotyrosine staining was barely detectable (Blanc J,2003). In  human vascular 
smooth muscle cells overexpression of UCP2 lowered the toxic effects of 
glucose and angiotensin II (Park JY,2005) .   
 
Cell death pathways including apoptosis can be stimulated by ROS or 
mitochondrial dysfunction.  The early steps often include changes to 
mitochondrial membrane potential, mitochondrial calcium entry and ROS 
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generation.    UCP2 can protect mitochondrial function by modulating 
membrane potential.  Cell survival after exposure to hydrogen peroxide is 
higher with UCP2 over-expression in β-cell (Li LX,2001), cardiomyocytes 
(Teshima Y,2003; Zackova M,2003) and endocrine cell models (Diano S,2003).  
In human aortic endothelial cells UCP2 over expression inhibited all the steps of 
mitochondrial dysfunction and cell death that occurred with administration of 
lysophophatidylcholine [LPC].  This effect appears to be physiologically relevant 
as LPC induces impaired endothelial function, an effect not seen in isolated rat 
aorta infected with an UCP2 over-expression vector (Lee KU,2005). 
 
Summary 
 
The function of UCP2 is still not fully understood.  The protein may be a 
conventional uncoupler, but there is no evidence of a role in thermogenesis or 
obesity/energy balance.  Expression studies indicate a potential role in fatty acid 
metabolism, or protection from the redox pressure on the electron transport 
chain from the higher ATP production associated with fatty acid metabolism.  
The modulation of ATP production means that UCP2 clearly modulates insulin 
secretion, although it is not clear if this is a primary function.  The immune 
system is a large generator of ROS and patterns of expression, such as in the 
liver where it is located in the phagocytic Kuppfer cells only (Larrouy D,1997), 
suggests that protection from immune system ROS is a potential function, while 
a modulator of immune function or even inflammation-induced pyrexia (Faggioni 
R,1998) are potential functions.   The possibility that the mRNA expression 
observed in other tissues is due to the presence of entrapped circulating or 
tissue immune cells has yet to be examined.  However, expression studies 
need to be interpreted with caution, as UCP2 mRNA undergoes significant 
translational modification and regulation, and a number of tissues may have 
mRNA identified in them but not UCP2 protein (Pecqueur C,2001).  The 
absence of a specific antibody further impedes the understanding of the role of 
UCP2. 
 
 
 
 77 
1.4.2 Physiology of Uncoupling Protein 3 
 
UCP3 was also identified by cDNA library screening (Boss O,1997b; Vidal-Puig 
A,1997) and mapped to chromosome 11q13 in man, adjacent to UCP2 
(Solanes G,1997).  UCP3 mRNA was identified in two forms, UCP3L and 
UCP3S, the second form lacking the sixth transmembrane domain and the 
nucleotide binding site (Boss O,1997b).  However, levels of the two forms are 
highly correlated, indicating regulation by a common mechanism (Bao S,1998).   
UCP3 also shows high homology between species, mouse UCP3 is 88% 
identical and rat 86% to humans, and both also express a UCP3S mRNA also 
lacking a transmembrane domain (Solanes G,1997) and a purine binding site 
(Bouillaud F,1994).   The tissue distribution of UCP2 and UCP3 are very 
different, with UCP3 being located predominantly in skeletal muscle, with weak 
signals seen in the heart, thyroid and bone marrow, and in rodents, in brown 
adipose tissue (Boss O,1997b; Vidal-Puig A,1997). 
 
1.4.2a UCP3 thermogenesis and uncoupling 
 
The tissue-specific distribution in skeletal muscle makes UCP3 an attractive 
candidate for a role in energy balance in man.  Skeletal muscle is responsible 
for roughly 80% of resting energy expenditure (Ravussin E,1992) and 40% of 
adrenaline-induced thermogenesis (Simonsen L,1993). Skeletal muscle 
metabolism is also uncoupled, with up to 50% of resting metabolic rate due to 
proton leaks (Rolfe DF,1996).   UCP3 uncouples metabolism in yeast over-
expression systems (Gong DW,1997; Hagen T,1999; Hinz W,1999; Zhang 
CY,1999), insulinoma cells (Hong Y,2001), MCF7 cells (Stock MJ,1999), 293T 
cells (Mao W,1999), E. Coli (Echtay KS,2001; Jaburek M,1999), C2C12 
myoblasts (Boss O,1998a) and L6 myocytes (Guerini D,2002).  However, most 
of these systems are susceptible to overexpression artefact, and the proton leak 
is not regulated by purine nucleotides in a physiological manner (Schrauwen 
P,2006a).  Like UCP2, UCP3 lacks the histidine pair thought to be required for 
conventional uncoupling activity (Masaki T,1997).   
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Evidence from whole organisms is also unclear.  Mice UCP-3 over-expression 
models have smaller adipose tissue depots, are resistant to obesity and do 
demonstrate increased energy expenditure, fat oxidation, oxygen consumption 
and a decline in mitochondrial membrane potential (Clapham JC,2000), but the 
proton leak is again not regulated in a physiological manner, indicating that this 
may be an artefact (Cadenas S,2002).  The UCP3 knockout mouse is not obese 
and has normal energy expenditure even though the mitochondria are more 
coupled.   There appears to be no effect on bodyweight or temperature 
regulation phenotype (Cline GW,2001; Gong DW,2000; Vidal-Puig AJ,2000).   
Temperature maintenance in hibernating squirrels is not dependent on UCP3 
even at temperatures as low as -10C (Barger JL,2006). In Pima Indians mRNA 
levels are associated with 24hr energy expenditure and adjusted metabolic 
rates and inversely correlated with BMI and percentage body fat (Schrauwen 
P,1999).  Women who successfully lost weight were more uncoupled and had 
higher UCP3 mRNA levels than women who were unable to lose weight in a 
simple trial of dietary advice (Harper ME,2002).   When UCP3 protein is 
measured directly no such relationship with BMI (Schrauwen P,2001a), sleeping 
metabolic rate or 24 hour energy expenditure (Schrauwen P,2002a) could be 
detected.  In rodents, although free fatty acids uncouple mitochondrial 
metabolism, this does not occur in conjunction with changes in UCP3 mRNA 
levels (Hirabara SM,2006).  Acute exposure to cold does upregulate UCP3, 
mRNA which later falls on chronic exposure (Lin B,1998), but again this does 
not correspond to the time course of non-shivering heat production (Schrauwen 
P,2002a), while in humans mild cold exposure has no effect on UCP3 mRNA or 
protein levels (Schrauwen P,2002b).   Although UCP3 expression is regulated 
by thyroid hormone, and in pathological thyroid states changes in energy 
metabolism may be in part due to altered UCP3 levels (Hesselink MK,2005), 
there is no evidence that the primary role of UCP3 is mitochondrial uncoupling 
and regulation of energy expenditure. This data, combined with similar evidence 
reviewed later, shows that UCP3 is regulated by skeletal muscle fatty acid 
tissue delivery regardless of body temperature or energy balance, which makes 
it unlikely that the primary function of UCP3 is the regulation of either of these 
parameters. 
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1.4.2b UCP3 and fatty acid metabolism 
 
The paradoxical increase in UCP3 mRNA with fasting again led to a number of 
studies that suggest that UCP3 has an important role in fatty acid metabolism.   
UCP3 mRNA levels correlate with free fatty acids (Boss O,1998a; Vidal H,1999) 
and in most cases, physiological or pharmacological increases in free fatty 
acids and their metabolism increase UCP3 mRNA levels or protein.  This 
includes in the rat, fasting (Boss O,1998c; Cadenas S,1999; Gong DW,1997; 
Samec S,1999b; Samec S,1998b; Weigle DS,1998), sepsis (Sun X,2003), 
acute exercise (Cortright RN,1999), high fat feeding and lipid infusion (Weigle 
DS,1998) in skeletal muscle; fasting (Gong DW,1997; Samec S,1998b; Sivitz 
WI,1999), high fat feeding  (Matsuda J,1997) in brown and white adipose tissue 
and fasting in the heart (Hidaka S,1999).  In mice, fasting, high fat feeding , and 
acute exercise have similar effects in both adipose tissue and skeletal muscle  
(Gong DW,1999; Hwang CS,1999; Schrauwen P,2003; Tsuboyama-Kasaoka 
N,1998; Tsuboyama-Kasaoka N,1999).  At the beginning of suckling, levels of 
free fatty acids rise over a couple of weeks in mice, and this is accompanied by 
a rise in UCP3 mRNA over the exact same time course (Brun S,1999).  In 
humans, UCP3 is upregulated by fasting (Millet L,1997; Vidal H,1999), lipid 
infusion (Khalfallah Y,2000; Nisoli E,2000), acute exercise (Noland RC,2003; 
Schrauwen P,2002a) and by a high fat diet (Hesselink MKC,2003).  The switch 
to fat metabolism in the failing heart is also associated with higher UCP3 mRNA 
levels (Murray AJ,2004).  The effect of fatty acids persists at thermoneutrality 
(Boss O,1998a) and is more pronounced in glycolytic muscle fibres (Samec 
S,1998a).  It does not occur if levels of free fatty acids are suppressed (Samec 
S,1998a) or if fatty acid oxidation is suppressed (Schrauwen P,2002a).  The 
reversal of these changes, such as by refeeding, also reverses the effect on 
UCP3.   Cell systems also demonstrate increased UCP3 mRNA levels, with free 
fatty acids in C2C12 cells (Cabrero A,2000; Hwang CS,1999), human myocytes 
(Sbraccia P,2002), L6 myocytes (Costello A,2003; Nagase I,1999; Son C,2001) 
and rat myocytes (Hoeks J,2003). 
 
Fasting is not accompanied by a change in proton conductance (Cadenas 
S,1999), and changes in proton gradient with any of these stimuli follow a 
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different time course to the changes in UCP3 (Bevilacqua L,2005), so it is likely 
that the role of UCP3 is related to fatty acid oxidation rather than energy 
balance or conventional uncoupling.   A number of studies support this 
hypothesis;  during lipid infusion in humans the lipid oxidation rates correlate 
with UCP3 mRNA and free fatty acid levels (Khalfallah Y,2000), and the 
regulation of UCP3 expression occurs in parallel to other fatty acid oxidation 
genes (Samec S,2001).  The PPAR family are also important regulators of 
UCP3 expression  (Cabrero A,2000; Nagase I,1999; Son C,2001) and both 
PPAR α (Silvestri E,2006) and γ (Brunmair B,2004; Hwang CS,1999) agonists 
increase UCP3 mRNA, while levels are lower in the PPARγ knockout mouse 
(Murray AJ,2005).  However there are a number of situations when fatty acid 
metabolism is not associated with an increase in UCP3 mRNA or protein levels.   
UCP3 mRNA levels are higher in muscle groups with a higher proportion of fast 
twitch glycolytic fibres and lower fat oxidation (Schrauwen P,2001b).  Exercise 
training (Boss O,1998b; Russell AP,2003; Schrauwen P,2005; Tsuboyama-
Kasaoka N,1998) and weight reduction (Esterbauer H,1999; Schrauwen 
P.,2000; Vidal-Puig A,1999), which increase fat oxidation capacity, are also 
associated with lower levels of UCP3 mRNA or protein.  The pharmacological 
inhibition of fatty acid oxidation is also associated with an increase in UCP3 
mRNA (Cabrero A,2001; Samec S,1999b).  In all these conditions UCP3 levels 
do not appear to correlate with the rate of fat oxidation, however, the muscles 
with low oxidative capacity tend to accumulate excess free fatty acids 
(Schrauwen P,2004), and it appears that UCP3 expression may be regulated by 
intracellular  fatty acid surplus, which has led to the hypothesis that UCP3 
functions in mitochondrial fatty acid transport.  
 
1.4.2c UCP3 and fatty acid transport 
 
Although thought to be the classical uncoupling protein the actual mechanism of 
mitochondrial uncoupling by UCP1 is unclear and it is possible that rather than 
directly transporting protons the protein transports fatty acid anions (Schrauwen 
P,2002a).  The function of UCP3 is dependent on the availability of free fatty 
acids, and the mRNA is specifically upregulated by the oversupply of long chain 
but not medium chain fatty acids (Schrauwen P,2003).  There is an important 
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difference in the handling of these two types of fatty acid by mitochondria.  Fatty 
acids are taken up into the mitochondrial matrix by CPT1, with carnitine as a co-
factor, where they are converted to fatty acylCoA.  The inner mitochondrial 
membrane is impermeable to fatty acylCoA, so fatty acids are transported by 
conversion to fatty acyl carnitine by CPT1 and then back to fatty acylCoA in the 
inner mitochondrial matrix by CPT2.  This is then available for oxidation 
(Schrauwen P,2006a).  Fatty acids can accumulate within the matrix by either 
removal of the acylCoA by thioesterases, releasing the CoA for immediate 
oxidation in the citric acid cycle, or by passive transport of neutral fatty acids, 
when fatty acid supply overwhelms the ability to incorporate them into fatty acid 
acylCoA.  Within the inner mitochondrial matrix medium chain fatty acids can be 
readily oxidised without modification, whilst this is not the case for long chain 
fatty acids.  These are deprotonated into fatty acid anions (Hamilton JA,1999), 
which become trapped within the mitochondria, as the membrane is 
impermeable to fatty acid anions (Ho JK,2002).   The accumulation of fatty acid 
anions near the respiratory chain are prone to oxidation by lipid peroxides, 
which are highly reactive (Yagi K,1987), and will have the capacity to further 
damage important metabolic enzymes as well as mitochondrial DNA (Goglia 
F,2003).   The impairment of mitochondrial function has been linked to insulin 
resistance and ageing as described earlier.   
 
Thus there are a number of potential mechanisms by which UCP3 may protect 
the mitochondria from fatty acid anion and lipid peroxide accumulation (see Fig 
1.18) and there are a number of studies supporting this as the primary function 
of UCP3.  Medium chain fatty acids are less susceptible to oxidative damage, 
and, as discussed above, are not linked to regulation of UCP3 expression.  In 
mouse models UCP3 mRNA is regulated in parallel with mRNA levels of 
thioesterases (Moore GBT,2001).  UCP3 over-expression increases fatty acid 
oxidation, CPT1 levels, and reduces lipid accumulation in skeletal muscle 
(Bezaire V,2005), without any effect on glucose oxidation or convention 
uncoupling (MacLellan JD,2005). Fat oxidation is reduced in the UCP3 
knockout mouse (Bezaire V,2001), which also demonstrates higher levels of 
ROS production (Vidal-Puig AJ,2000), intramuscular lipid peroxides (Hoeks 
J,2006) and oxidative damage to protein lipids and DNA (Brand MD,2002; 
 82 
Echtay KS,2003).  Aconitase function, inactivated by superoxide, is reduced 
both by purine inhibition of UCP3 function and in the UCP3 knockout mouse 
(Talbot DA,2005).  The effects in the knockout mouse are influenced by diet, 
with a decrease in lipid peroxide formation on a high fat diet, because of a 
decrease in intracellular fat storage by a mechanism as yet unknown (Echtay 
KS,2003).  Therefore, these results must be interpreted with caution, in case 
they are confounded by a compensatory mechanism. 
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Fig 1.17 Hypothesized mechanisms by which UCP3 may protect from fatty acid accumulation and peroxidation (MacLellan JD,2005) 
 
1)UCP3 removes long-chain fatty acids (LCFA) 
produced by MTE1; the latter liberates mitochondrial 
matrix CoASH, a rate-limiting coenzyme for ß-oxidation 
and the Krebs cycle. Long-chain fatty acids are exported 
from the matrix by UCP3 for reactivation by acyl-CoA 
synthase in the intermembrane space. Thus, MTE1 and 
UCP3 are proposed to function in tandem to facilitate 
fatty acid oxidation (Himms-Hagen J,1990).  
2) UCP3 removes excess long-chain fatty acids that 
have entered the mitochondrial matrix independently of 
the CPT system. This would serve to remove potentially 
damaging fatty acid anions from the matrix (Schrauwen 
P,2003). 
 3) UCP3 translocates lipid peroxide anions, generated 
from the interaction of matrix ROS with unsaturated fatty 
acids of the inner leaflet, from the inner to the outer 
leaflets of the mitochondrial inner membrane (Goglia 
FERN,2003). This would remove fatty acid peroxides 
and prevent damage of mitochondrial DNA, aconitase, 
and other matrix components.  
4) 4-hydroxynonenal (HNE), a lipid by-product of 
mitochondrial superoxide (SOD) production, is proposed 
to activate a UCP3-mediated proton leak (Echtay 
KS,2003). It is proposed that this   decreases 
mitochondrial membrane potential and hence decreases 
ROS production.  
 84 
If the function of UCP3 is to control lipid accumulation and peroxidation then 
UCP3 expression should be induced by ROS or oxidative damage.  Muscle 
contraction releases ROS and increases UCP3 mRNA, which is blocked by the 
administration of anti-oxidants (Silveira LR,2006), as does ROS induced by 
hypoxia in C2C12 cells (Flandin P,2005) and in peri-infarct cardiomyocytes 
(Almsherqi ZA,2006).   The increase in mitochondrial proton conductance seen 
with the administration of hydrogen peroxide is dependent on free fatty acids 
and is not seen in the UCP3 knockout mouse, indicating the role of UCP3 in 
protection from ROS (Echtay KS,2002b).  Interestingly, superoxide does not 
appear to regulate UCP3 expression  directly (Mozo J,2006) but 4-hydroxy-2-
nonenol one of the major products of lipid peroxidation does have this function 
(Echtay KS,2003).  Where higher UCP3 mRNA levels have been attributed to 
higher ROS generation, such as the models above, it may be the higher 
generation of mitochondrial peroxides by the generated ROS that increases 
UCP3 mRNA levels.   However, ROS generation per se does not seem to be 
the main stimulus of UCP3  expression.  Metabolic changes in ischaemic pre-
conditioning are only partly dependent on UCP3 (McLeod CJ,2005) and 
although UCP3 levels increase after administration of LPS this is thought to be 
due to fatty acid changes rather than higher levels of ROS (Yu XX,2000).  
UCP3 function will, as an added feature of its suggested function, lower the 
mitochondrial membrane potential and reduce metabolic ROS generation, so 
protecting the cells where it is found (Vincent AM,2004). 
 
In summary, the putative function of UCP3 is, firstly, the protection of 
mitochondria from fatty acid anion accumulation and peroxidation.  Secondly, it 
also has a role in the protection of mitochondrial function against further 
oxidative damage from these lipid oxidation products. 
 
1.4.2d UCP3 and type 2 diabetes 
 
The possibility that insulin resistance is a disorder of fat oxidation or 
mitochondrial function, as discussed earlier, suggests that UCP3 may have an 
important role in protection from the development of insulin resistance, and that 
aberrant UCP3 function might be associated with type 2 diabetes.  UCP3 
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mRNA  levels are correlated with glucose tolerance (Samec S,1999b).  Studies 
of UCP3 mRNA in subjects with type 2 diabetes have had differing results, with 
studies showing higher (Bao S,1998; Vidal H,1999) and lower levels (Krook 
A,1998) associated with disease.  Lower levels were also reported in rats with 
diabetes (Vincent AM,2004).  The level in subjects at risk of type 2 diabetes is 
also variable, with no difference reported in those with first degree relatives 
(Pedersen SB,2005), but lower levels seen in subjects with impaired glucose 
tolerance which were corrected by treatment with the insulin sensitizer 
rosiglitazone  (Schrauwen P,2006b).   UCP3 protein was 50% lower in subjects 
with type 2 diabetes (Schrauwen P,2001a), and UCP3 gene expression is not 
upregulated in fasting subjects with type 2 diabetes (Vidal H,1999).  
Experimental models also support a role for aberrant UCP3 function in insulin 
resistance.  UCP3 over-expression in mice is associated with improved glucose 
tolerance (Clapham JC,2000; Vincent AM,2004; Wang S,2003), while over 
expression in L6 myocytes increases GLUT4 levels, glucose uptake and insulin 
signalling (Huppertz C,2001; Hwang CS,1999).  The increase in UCP3 mRNA 
levels after acute exercise is mirrored by an increase in GLUT4 mRNA 
(Tsuboyama-Kasaoka N,1998) leading to increased glucose uptake.  The UCP3 
knockout mouse is not diabetic (Brand MD,2002), but this may be because 
other compensatory mechanisms are limiting the delivery of free fatty acids to 
mitochondria (Schrauwen P,2006a).   Lipid peroxidation and mitochondrial 
dysfunction are features of type 2 diabetes, and, through its effects on lipid 
oxidation, UCP3 appears to play a protective role against insulin resistance.   
 
1.5 Variation in the uncoupling Protein Genes 2 and 3 
 
The genes for UCP2 and UCP3 are, as described earlier, located on 
chromosome 11q13 within 8Kb of each other (Pecqueur C,1999).   UCP2 
consists of eight exons while UCP3 consists of seven.  The gene structures are 
represented in Fig 1.17. The region including these two genes or their 
equivalent has been associated, by linkage analysis, with obesity and diabetes 
in the mouse (Seldin MF,1994; Taylor BA,1996; Warden CH,1995).  In man 
11q13 has been linked to resting metabolic rate and percentage fat mass 
(Bouchard C,1997), type 1 (Hashimoto L,1994) and type 2 diabetes (Ghosh 
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S,1996; Watanabe RM,2000), all in caucasian samples.  However, replication 
has been poor, with a number of studies failing to find linkage with obesity or 
type 2 diabetes in Caucasians or Mexican Americans (Comuzzie AG,2000; 
Elbein SC,1997; Hager J,1998; Lee JH,1999).  However, this does suggest that 
this area of the genome may be important in determining risk of obesity and 
diabetes.  
 
Fig 1.18. The structure of the UCP2 and UCP3 gene on chromosome 11 
 
 
 
1.5.1 Uncoupling Protein 2 
 
The human UCP2 gene consists of 8 exons, of which exons 1 and 2 are non-
coding (Pecqueur et al. 2001).  Exon 2 contains a short open reading fragment 
that is, like the protein amino acid sequence, highly conserved among species 
(Jastroch M,2004), and seems to act as an inhibitor of translation although the 
functional significance of this is unclear at present (Pecqueur C,2001).  The 
transcription site is preceded by a region that contains a strong cis-acting 
positive regulatory element (-141 to -65) which may underlie the ubiquitous 
expression of UCP2.  In keeping with the changes in expression described, 
several consensus sequences exist for transcription control elements, such as 
C/EBP- , CREB-1 (cAMP response binding protein 1), two PPAR  responsive 
elements, two TREs (thyroid hormone response elements), and NF -B. 
 
The first UCP2 variants to be identified were in exon 4, a +164C>T variant 
which results in an amino acid change of alanine to valine (A55V) and a 45bp 
 
1 kb 
Exons 
I III IV II V VI VII I II III 
IV 
V 
VI 
VII 
VIII 
TGA ATG TGA TGA ATG ATG 
UCP3  UCP2 
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insertion/ deletion in exon 8 (3‟UTR).  Although the +164C>T variant was not 
associated with obesity or diabetes markers in a Danish population (Urhammer 
SA,1997), in Pima Indians these two variants were associated with either 
sleeping metabolic rate (+164C>T) or 24 hour energy expenditure (45bp I/D).  
The 3‟UTR variant had no effect on mRNA levels in this study (Walder K,1998).   
The 3‟UTR was associated with BMI in South Indian women living in the UK but 
not in a Caucasian sample, and was not associated with type 2 diabetes in 
either a family study or a case control study (Cassell PC,1999).  Thus early 
studies suggested that UCP2 was not important in the susceptibility to either 
obesity or type 2 diabetes. 
 
Interest in UCP2 as a candidate gene for type 2 diabetes and obesity was 
renewed by the discovery of five new variants, -2723T>A, -1957G>A,-866G>A, 
-371G>C and a 13bp insertion deletion in exon 1.  Esterbauer et al showed two 
of these were associated with mRNA levels in intraperitoneal fat tissue, the        
-2723T>A and -866G>A.  The UCP2 promoter consists of two main blocks, with 
most of the activity in the first 1200bp with a second inhibitory block from -1200 
to -1600bp (Dalgaard LT,2003). The -866G>A variant is at a junction between a 
negative and positive cis-acting DNA region, and within a region that contains 
binding sites for hypoxia, aromatic hydrocarbons, inflammatory cytokines and 
the important β-cell transcription factor PAX-6.  This variant is in 100% LD with 
the -2723T>A promoter variant, strong LD (97%) with the A55V and moderate 
(75%) LD with the 3‟UTR.  The -866G>A variant has been reported to account 
for 71% of the variation in mRNA transcript ratio of the 3‟UTR variant, 
regardless of the nucleotide at -2723 indicating that the -866G>A may be more 
important in the LD block.  The higher activity of the variant promoter, confirmed 
in expression studies in Paz-6 cells (derived from brown fat cells), was 
associated with a lower risk of obesity in two separate case-control studies in 
Caucasians from the Salzburg area of Austria.  In the second cohort the 
population attributable fraction associated with this variant for obesity was 
14.7% (Esterbauer H,2001).  In a similar case-control study from Austria the -
866A was associated with risk of type 2 diabetes.  The over activity of the -866A 
promoter was confirmed in INSE-1 cells (a β-cell line) when stimulated with 
PAX-6.  Interestingly, the same stimulus was associated with lower activity from 
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the -866A promoter in COS-7, cells suggesting that regulation of UCP2 is tissue 
specific (Krempler F,2002).  This was confirmed using electromobility shift 
assays which showed that different complex patterns formed with THP-1 
(macrophages)  and HUVEC (endothelium) cells compared to INSE-1 and Paz-
6 cells, indicating differences in transcription factor binding.  Baseline mRNA 
levels in THP-1 and HUVECS are higher for the wildtype promoter and these 
differences in activity appeared to be in response to an aryl hydrocarbon 
receptor/ nuclear translocator [AhR/ARNT], and Hypoxia inducible factor-
1α/ARNT complex binding (Oberkofler H,2005).   These transcription factors are 
involved in cell stress responses to either environmental pollution (Park H,1999) 
or hypoxia (Semenza GL,2001), and could explain why the -866A variant is 
associated with higher F2-isoprostanes, lower TOAS, higher prospective risk of 
coronary artery disease in Caucasian men (Dhamrait SS,2004) and more 
extensive carotid atheroma in women (Oberkofler H,2005), all of which are 
associated with increased oxidative stress,  and would be expected if UCP2 
function (i.e. mRNA and protein levels) were lower in carriers of -866A. 
 
Overall, cross-sectional studies have been consistent in demonstrating 
associations between UCP2-866G>A and markers of obesity, oxidative stress-
related disease and type 2 diabetes.  In other ethnic groups the relationship has 
been less consistent, with the -866G associated with type 2 diabetes in a mixed 
race sample from the USA (Wang H,2004), and the -866AA genotype 
associated with higher waist hip ratio and risk of metabolic syndrome in Chinese 
and South Asians (Shen H,2006).  This indicates that the effect may be race-
specific or that UCP2 variation has only a modest effect, confounded by 
environmental differences, such as diet, between ethnic groups.  The gene 
association studies for UCP2 are summarized in table 1.4.   
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Table 1.4a The associations of the A55V variant in the UCP2 gene and obesity 
and diabetes markers. 
 
Phenotype Population Assoc^n Risk 
Allele 
Reference 
 
 
Obesity 
 
    
Sleeping MR Pima Indians Y AV↑ (Walder K,1998) 
Exercise Eff↑ Denmark Y V (Buemann B,2001) 
24hrEE ↓ Denmark Y V (Astrup A,1999) 
↓Fat Oxid Denmark Y V (Astrup A,1999) 
Weight loss ↓ USA –overfed* Y V (Ukkola O,2001) 
Morbid Obesity Taiwan Y V (Chen HH, 2007) 
Weight Loss post 
Surgery 
Taiwan Y V (Chen HH, 2007) 
Obesity Taiwan Y V (Wang TN, 2007) 
Weight Loss Korea Y A (Yoon, Y,2007) 
24hr EE Pima Indians N  (Walder K,1998) 
Juvenile cc Denmark N  (Urhammer SA,1997) 
BMI Utah N  (Wang H,2004) 
Obesity cc Italy N  (Mancini FP,2003) 
Obesity cc Japan N  (Kubota T,1998) 
Juvenile cc USA-mixed N  (Yanovski JA,2000) 
Resting MR USA- 
baseline/overfed* 
N  (Ukkola O,2001) 
Weight gain USA-
baseline/overfed* 
N  (Ukkola O,2001) 
BMI,%Fat Korea N  (Yoon, Y,2007) 
 
Diabetes 
 
    
Type 2 Pima Indians Y V (Walder K,1998) 
Type 2 Utah Y V (Wang H,2004) 
Type 2 USA-Mixed 
[obese] 
Y V (Yu X,2005) 
Type 2 Pima Indians N  (Walder K,1998) 
Type 2 Denmark N  (Urhammer SA,1997) 
Glucose/Insulin Italy N  (Mancini FP,2003) 
Type 2 Pima Indians N  (Kovacs P,2005) 
Type 2 Japan N  (Kubota T,1998) 
 
Other 
 
    
Multiple Sclerosis Basque Y A (Otaegui D,2007) 
HDL Cholesterol Korea Y V (Cha MH, 2007) 
Plasma Leptin Scotland Y V (Rance KA,2007) 
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Key for Table 1.4a-c 
*Volunteers partook in an controlled overfeeding protocol 
[ ] indicated in this sub group only (F= female), EE= energy expenditure, MR= 
metabolic rate, cc=case control study. 
 
Table 1.4b The associations of the 45bp 3UTR insertion/deletion [I/D] in the 
UCP2 gene with mRNA levels and obesity and diabetes markers. 
 
Phenotype Population Associ^n Risk 
Allele 
Reference 
 
 
mRNA 
 
    
Half life Paz-6 cells Y D (Esterbauer H,2001) 
Levels Muscle biopsy N  (Walder K,1998) 
 
Obesity 
 
    
Sleeping MR Pima Indians Y I/D ↑ (Walder K,1998) 
24hr EE Pima Indians Y D (Walder K,1998) 
BMI South Indian [F] Y D (Cassell PC,1999) 
BMI Utah Y D (Wang H,2004) 
24hr EE Pima Indians Y D↓ (Kovacs P,2005) 
Obesity Germany Y D (Evans D,2001) 
Juvenile Obesity USA-Mixed Y D (Yanovski JA,2000) 
Fat Mass [Dialysis] Sweden Y D (Wang X, 2006) 
Obesity Spain Y D (Ochoa MC,2007) 
Weight gain USA-
baseline/overfed* 
N  (Ukkola O,2001) 
Obesity cc Denmark N  (Dalgaard LT,1999) 
BMI England N  (Cassell PC,1999) 
24hr EE Pima Indians N  (Kovacs P,2005) 
10 yr wt gain Denmark N  (Berentzen T,2005) 
Adiposity [Dexa] Scotland N  (Rance KA,2007) 
Plasma Leptin Scotland N  (Rance KA,2007) 
Weight Loss Korea N  (Yoon, Y,2007) 
BMI,%Fat Korea N  (Yoon, Y,2007) 
 
Diabetes 
 
    
Type 2 Pima Indians Y D (Walder K,1998) 
Type 2 Utah Y D (Wang H,2004) 
Insulin Resistance Spain Y D (Ochoa MC,2007) 
Type 2 Pima Indians N  (Walder K,1998) 
Type 2 South Indians N  (Cassell PC,1999) 
Type 2 Pima Indians N  (Kovacs P,2005) 
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Table 1.4c The association the -866 variant in the UCP2 gene with mRNA 
levels and obesity and diabetes markers. 
Phenotype Population Assoc^n Ris
k  
Reference 
 
mRNA 
(Low activity) 
    
Promoter activity Paz-6 cells Y G (Esterbauer H,2001) 
Promoter activity INSE-1 cells Y G (Krempler F,2002) 
Promoter activity COS-7 cells Y A (Krempler F,2002) 
Promoter activity THP/HUVEC cells  Y A (Oberkofler H,2005) 
Levels SC Fat (mixed) Y A (Wang H,2004) 
Promoter Activity INSE-1 cells Y G (Sasahara M,2004) 
Levels Blood (cauc) Y G (Vogler S,2005) 
Promoter activity Jukhat (T-cell) 
U9377 (Mphage) 
Y G (Vogler S,2005) 
Obesity     
BMI Austria Y G (Esterbauer H,2001) 
Fat:Glc OX Europe Y G (Le Fur S,2004) 
24hr EE Pima Indians Y G (Kovacs P,2005) 
WHR Indian/Chinese Y A (Shen H,2006) 
Weight Loss Korea Y A (Yoon, Y,2007) 
Obesity Spain Y G (Ochoa MC,2007) 
BMI,%Fat Korea N  (Yoon, Y,2007) 
BMI,%FAT Denmark N  (Dalgaard LT,2003) 
Juvenile onset Europe N  (Le Fur S,2004) 
Obesity cc Japan T2 N  (Sasahara M,2004) 
BMI France T2 N  (Reis AF,2004) 
BMI Japan N  (Ji Q,2004) 
Morbid Obesity Taiwan N  (Chen HH, 2007) 
Weight Loss post 
Surgery 
Taiwan N  (Chen HH, 2007) 
Obesity Taiwan N  (Wang TN, 2007) 
Body Adiposity 
[Dexa] 
Scotland N  (Rance KA,2007) 
Diabetes     
Type 2 Austria Y A (Krempler F,2002) 
GSIS Italy Y A (Sesti G,2003) 
Type 2 Utah Y G (Wang H,2004) 
Type 2  Italy [F] Y A (D'Adamo M,2004) 
Insulin therapy Japan Y A (Sasahara M,2004) 
Type 2  Italy Y G (Bulotta A,2005) 
Glucose/Insulin Italy N  (Mancini FP,2003) 
NEFA/Insulin 
Relationship 
Hungary Y Lost 
in A 
(Bokor S, 2007) 
Type 2 Diabetes North India Y G (Rai E, 2007) 
Insulin Resistance Spain Y G (Ochoa MC,2007) 
Glucose/Insulin Denmark N  (Dalgaard LT,2003) 
Glucose/Insulin France N  (Reis AF,2004) 
HOMA-R Japan N  (Ji Q,2004) 
Type 2 Pima Indians N  (Kovacs P,2005) 
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Oxidative Stress 
 
    
Multiple Sclerosis Germany Y G (Vogler S,2005) 
TOAS England Y A (Dhamrait SS,2004) 
CAD England Y A (Dhamrait SS,2004) 
Carotid Atheroma Austria [F] Y A (Oberkofler H,2005) 
Neuropathy Japan Type 2 Y A (Yamasaki H,2006) 
Neuropathy USA- Europe/Type  Y G (Rudofsky G,2006) 
TOAS [Smokers] England Y A (Stephens J, 2007) 
Other 
 
    
Triglycerides France T2 Y A (Reis AF,2004) 
Hypertension Japan Y A (Ji Q,2004) 
Triglycerides Indian/Chinese Y A (Shen H,2006) 
Long Chain FA Hungary Y A (Bokor S, 2007) 
HDL Cholesterol Iran Y A (Akrami SM, 2007) 
HDL Cholesterol Korea Y A (Cha MH, 2007) 
Plasma Leptin Scotland N  (Rance KA,2007) 
 
1.5.2 Uncoupling Protein 3   
 
The UCP3 gene has 7 exons and the presence of binding sites for muscle 
dependent transcription factors CCAC and E box, Mefz and MyoD explains how 
UCP3 expression is targeted to skeletal muscle cells (Acin A,1999).  The 
promoter has several other binding sites, and is regulated by other important 
metabolic signals including retinoic acid (Solanes G,2000), PPAR, thyroid 
hormone (Acin A,1999), leptin, steroids and β3 (Gong DW,1997) and β2 
receptors (Masaki T,1997).  The activity of the metabolic response elements in 
most cases is also dependent on activation of muscle-dependent transcription 
factors ensuring metabolic response is  also targeted to skeletal muscle cells 
(Solanes G,2000) 
 
Sequencing and gene association studies involving UCP3 have been less 
successful in identifying important variants with consistent effects.  The 
discovery of significant mutations in obese African Americans with type 2 
diabetes suggested that UCP3 may be important.  One of these sites, a 
mutation at the splice site of exon 6, was associated with a significant 50% 
reduction in fat oxidation (Argyropoulos G,1998).    
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A number of variants have been identified throughout the gene (see table 1.5) 
but only one of these has been associated with differences in mRNA levels.  
The -55C>T was originally located near a TATA box (6bp) although a recent 
report (Acin A,1999) places the variant in the „5UTR near (4bp) a PPAR 
responsive element, which also suggests it could modify regulation of UCP3 
expression.  The variant allele was associated with higher levels of mRNA but 
not with obesity (Schrauwen P,1999). This variant is also near a DR1 retinoic 
acid response element (6bp) and an area responsible for MyoD activity (61bp) 
(Solanes G,2000), so may affect the action of other important factors as well. 
 
Phenotype association studies have been very inconsistent, and often in conflict 
with the association with mRNA levels.  The T allele was associated with higher 
BMI or WHR, consistent with decreased function, in French and German 
Caucasians, South Asian Indian parent-offspring trios, South Asian Indians and 
the British Diabetic Association Warren 2 trios collection (Cassell PG,2000; 
Halsall DJ,2001; Herrmann SM,2003; Otabe S,2000).  However, one study 
showed a lower BMI in TT subjects in a United Kingdom sample (Halsall 
DJ,2001), and increased function is also suggested with the association of 
protection from diabetic neuropathy (Rudofsky G,2006).  In these studies 
association with T2DM was examined only once and a relationship not found.  
The variant allele was found to be protective against T2DM in two French 
cohorts, suggesting increased function, although also associated with an 
atherogenic lipid profile (Meirhaeghe A,2000).  These studies are summarized 
in table 1.6.  The results in both tables are not well replicated.  The frequency of 
a number of the variants is different across ethnic groups (Kimm SY,2002; Liu 
YJ,2005), so differences could be seen depending on the origin of the sample.  
The effect of variation in UCP3 on obesity is likely to be small, estimated at 2-
3% of total variation in one study (Liu YJ,2005), which means that not all the 
studies will be adequately powered to detect a difference.  There is strong LD 
between the variants in both genes (Walder K,1998) and some signal from a 
functional variant is likely to be detected in studies of several “non-functional” 
variants across the cluster. 
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Table 1.5  A summary of association studies for variants within  UCP3 
excluding the -55C>T polymorphism. [The variants are described as the appear 
most commonly in the literature.] 
Variant Phenotype population Risk  Reference 
Promoter     
-155C>T Obesity France No (Otabe S,2000) 
-439Del A Obesity France No “ 
Exon 1     
+5 G>A Obesity France No (Otabe S,2000) 
Exon 2     
Val9Met Obesity France No (Otabe S,1999) 
 Growth/O2 use Yeast No (Hagen T,1999) 
Intron 2     
+521G>C BMI/Weight loss Korea No (Cha MH,2006) 
Exon 3      
Arg70Trp Growth/O2 use Yeast Variant 
↓  
(Brown AM,1999) 
Ala83Ala Obesity/DM France No (Otabe S,1999) 
Gly84Ser Juvenile Obesity Denmark No (Urhammer 
SA,1998) 
Tyr99Tyr Obesity/DM France CC ↑BMI (Otabe S,1999) 
 Juvenile Obesity Denmark No (Urhammer 
SA,1998) 
 Weight Loss Canada [F] No (Harper ME,2002) 
 Resting EE USA-mixed No (Kimm SY,2002) 
 BMI USA- Cauc No (Liu YJ,2005) 
 Met R./Obesity Pima No (Walder K,1998) 
 TSH r TRH USA ↓ CC (Ukkola O,2001) 
 Weight loss after 
overfeeding 
USA  ↓ CC (Ukkola O,2001) 
 RQ Baseline + 
after overfeeding 
USA ↓ CC (Ukkola O,2001) 
 BMI/Weight loss Korea No (Cha MH,2006) 
 BMI/Weight loss Korea No (Yoon Y, 2007) 
Val109Ile Resting EE USA-mixed No (Cha MH,2006) 
 Growth/O2 use Yeast No (Brown AM,1999; 
Hagen T,1999) 
 Obesity Tiawan No (Wang TN, 2007) 
Intron 3     
-46A>T Juvenile Obesity Denmark No (Urhammer 
SA,1998) 
-47A>G Juvenile  Obesity Denmark No “ 
 BMI/Weight loss Korea No (Cha MH,2006) 
-96C>T Juvenile Obesity Denmark No “ 
-143A>G Juvenile Obesity Denmark No “ 
Intron 4     
+36C>T Obesity/DM France TT↑DM (Otabe S,1999) 
+1811C>T BMI/Weight loss Korea No (Cha MH,2006) 
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EE = Energy Expenditure, RQ = Respiratory Quotient, DM = Diabetes Mellitus, Met R 
=Metabolic rate, [ ] = in this subgroup only, F= females.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Variant Phenotype population Risk  Reference 
Exon 5      
Tyr210Tyr Obesity/DM France TT↑DM (Otabe S,1999) 
 Juvenile Obesity Denmark No (Urhammer SA,1998) 
 Fat/Lean mass USA women TT↑  
(↓intake) 
(Damcott CM,2004) 
 BMI/fat mass Canada-
mixed 
↑ T (Lanouette CM,2002) 
 BMI USA No (Liu YJ,2005) 
 Weight loss Canada [F] No (Harper ME,2002) 
 Resting EE USA- mixed ↑ T 
[Black] 
(Kimm SY,2002) 
 BMI/Weight loss Korea No (Cha MH,2006) 
 HDL Cholesterol Korea Y (Cha MH, 2007) 
 BMI/Weight loss Korea No (Yoon Y, 2007) 
Exon 6     
Splice site 
Mutation 
Fat oxidation Black USA Yes (Argyropoulos 
G,1998) 
 Growth/ O2 use YEAST No (Brown AM,1999) 
 BMI/Fat mass USA Black No (Chung WK,1999) 
 UCP3mRNA USA Black UCP3S 
only 
(Chung WK,1999) 
Intron 6     
GAIVS6 
(microsatellite) 
BMI/skin fold Canada 
[Cauc] 
↑
wildtype 
(Lanouette CM,2002) 
Exon 7     
Arg308Trp Obesity DM France No (Otabe S,1999) 
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Table 1.6  The association of the -55C>T variant in UCP3 with Obesity and 
Diabetes phenotypes.  
 
EE= Energy Expenditure, DM = Subjects with diabetes mellitus, [ ] = in this subgroup 
only, F= females 
 
Phenotype  Population Association Risk  Reference 
mRNA     
Decreased PIMA Y C (Schrauwen P,1999) 
Obesity     
WHR Germany Y TT↑ (Herrmann SM,2003) 
Obesity Spain Y T (Ochoa MC,2007) 
WHR South 
Indian[F] 
Y T↑ (Cassell PG,2000) 
WHR UK White[F] Y T↑ “ 
Obesity France  Y TT ↑BMI (Otabe S,2000) 
BMI USA 
Caucasians 
Y C ↑ (Liu YJ,2005) 
Juvenile 
Obesity 
UK Y C ↑ BMI (Halsall DJ,2001) 
% Fat/VO max UK N  “ 
Obesity/ 
weight gain 
Denmark N  (Dalgaard LT,2001b) 
Weight loss Canada [F] N  (Harper ME,2002) 
Resting EE USA mixed N  (Kimm SY,2002) 
BMI France DM N  (Meirhaeghe A,2000) 
Weight Gain Denmark  N  (Berentzen T,2005) 
Obesity Korea N  (Cha MH,2006) 
Obesity Taiwan N  (Wang TN, 2007) 
Obesity PIMA N  (Schrauwen P,1999) 
T2DM     
Family study South Indian N  (Cassell PG,2000) 
Case-control South Indian N  “ 
Family study UK N  “ 
Case-control France Y C↑DM (Meirhaeghe A,2000) 
Insulin 
resistance 
Spain Y T (Ochoa MC,2007) 
Misc     
Cholesterol France DM Y ↑TT (Meirhaeghe A,2000) 
Neuropathy Germany DM Y ↑ CC (Rudofsky G,2006) 
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1.6 Study Aims 
 
The aim of this study was to use a genetic approach to determine the role of the 
Uncoupling Proteins 2 and 3 in the development of type 2 diabetes mellitus.    
 
 
Hypothesis: 
 
Uncoupling Proteins 2 and 3 influence the risk of development of type 2 
diabetes through the modulation of oxidative stress. 
 
 
Specific Aims 
 
1) Confirmation that identified genetic variants in the UCP2-UCP3 gene 
cluster are associated with type 2 diabetes using a prospective study 
design. 
 
 
2) Examining the association of common variants in the UCP2-UCP3 gene 
cluster traits with markers of oxidative stress. 
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2.1 Study Samples 
 
2.1a Japanese American Family Study (JAM) 
The JAM Study was organised by the Department of Epidemiology, University of 
Washington.  The study was designed to investigate risk factors for coronary heart 
disease, diabetes, and the insulin resistance syndrome in Japanese American 
families (Austin MA,2004a).  The study had full Institutional Review Board approval 
from The University of Washington.  
Probands were Nisei (2nd generation) participants in the Japanese American 
Community Diabetes Study (JACDS) who had a spouse of Japanese descent and 
children, and who were non-diabetic at the time of the first community-wide survey 
conducted in 1983. Members of the Nisei generation now range in age from 
approximately 65 to 75 years. Because most Nisei married other Japanese 
Americans, the Sansei (3rd generation) is predominately of Japanese descent, with 
ages now ranging from about 30 to 55 years.  Probands were contacted by letter 
and those interested were asked to give permission to contact family members. 
Eligible family members included parents, spouses and offspring of the proband, 
siblings, spouses of siblings, and nieces and nephews of the proband, age 18 
years and over, residing anywhere in the United States, who were not pregnant 
and not too ill to participate.   Thus, the study sample consists primarily of two-
generation extended Nisei and Sansei kindreds. Each proband and relative was 
contacted individually by letter and phone, and asked to participate by providing a 
fasting blood sample and medical history questionnaire. For relatives living outside 
of the Seattle metropolitan area, blood samples were shipped by overnight mail to 
the University of Washington.   Type 2 diabetes was defined as fasting glucose 
>125 mg/dl, taking known medication for diabetes, self-reported diabetes, and self-
report of taking insulin or oral antidiabetic pills by questionnaire (Austin MA,2004a) 
The study participants all provided written, informed consent.  I would like to thank 
Mellissa Austin, principal Investigator, for the use of JAM samples. 
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2.1b The Second Northwick Park Heart Study Cohort (NPHSII) 
 
The Second Northwick Park Heart Study (NPHSII) was recruited by the Medical 
Research Council Cardiovascular group at The Wolfson centre for Preventative 
Medicine.  In brief, 3012 unrelated healthy Caucasian middle-aged male subjects 
(mean age 56.1+3.5 years) recruited from nine UK general practices, detailed 
elsewhere were prospectively followed for up to 15 years (Gable DR,2006b).  The 
study was approved by the institutional ethics committees and performed in 
accordance with the declaration of Helsinki.  All subjects gave written informed 
consent. 
 
Baseline characteristics were ascertained by means of a questionnaire at entry into 
the study.  Exclusion criteria at baseline were a history of myocardial infarction, 
cerebrovascular disease, life-threatening malignancy or regular medication with 
aspirin or anticoagulants.  At entry, a 5ml EDTA blood sample was obtained, from 
which genomic leukocyte DNA was extracted. Time to first CHD event (defined as 
sudden cardiac death, symptomatic/silent MI (the appearance of a new major Q 
wave on the follow up ECG, using Minnesota codes 11,12.1 to 12.7, 12.8 plus 51 or 52, 
or coronary revascularisation) was recorded, yielding only one event/subject.  
Cases of Type 2 Diabetes at baseline were identified by self report.  Exclusion 
criteria precluded subjects requiring insulin or oral hypoglycaemics from entry into 
NPHS II.  New cases were identified by practice note search for physician 
diagnosed and treated T2DM according to current national guidelines.  To date, 
288 coronary heart disease events have occurred in 2775 of the subjects with DNA 
available for analysis.  There were 76 cases of Type 2 Diabetes at baseline and by 
15 years a further 169 cases had been identified.  
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2.1c Hypercoagulability and Impaired Fibrinolytic Function Mechanisms Study 
(HIFMECH) 
 
The HIFMECH study was designed to study genetic and environmental 
mechanisms contributing to the higher cardiovascular risk in Northern compared to 
southern Europe (Juhan-Vague I,2002).  The study samples of Caucasian male 
first myocardial infarction survivors below 60 years of age were recruited from four 
European centres (Northern European-Stockholm, London; Southern European-
Marseille, San Giovani Rotondo) (n=598). Subjects with familial 
hypercholesterolemia and insulin-dependent diabetes mellitus were excluded.  A 
selection of randomly-selected age-matched healthy controls were also recruited 
from each catchment area (n=653).  The study was performed in accordance with 
the guidelines in The Declaration of Helsinki and approved by local ethics 
committees. Written informed consent was obtained from all subjects.  The patients 
and control subjects were examined in parallel in the early morning after an 
overnight fast, and a blood sample was also obtained.  Post-infarction patients 
were investigated 3 to 6 months after the acute event.  
 
2.1d UCL Diabetes and Cardiovascular Disease Study (UDACS) 
 
The UDACS is a cross-sectional sample of subjects designed to study the 
association between common variants in inflammatory/metabolic genes and 
biochemical risk factors implicated in CHD in patients with diabetes.  The subjects 
were recruited by Dr Jeffrey Stephens (Cardiovascular Genetics, UCL and 
Diabetes and Endocrinology, University College London Hospitals NHS Foundation 
Trust) between December 2001 and January 2003 from the diabetes clinic at 
University College London Hospitals NHS Trust (UCLH).  Clinical information was 
gathered from the computerised clinic database, which was first established in 
1983. The database contains demographic and clinical information on patients 
attending the diabetes clinic and clinic measurements of blood pressure (supine 
and lying), weight and height were measured on all subjects and routine clinic 
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biochemistry was also recorded.  All patients had diabetes according to WHO 
criteria current at the time of diagnosis.  Patients were categorised by the 
presence/absence of clinically manifest CHD.  The presence of CHD was recorded 
if any patient had positive coronary angiography/angioplasty, coronary artery 
bypass, cardiac thallium scan, exercise tolerance test, myocardial infarction or 
symptomatic/treated angina. Any individual who was asymptomatic or had negative 
investigations was categorised as „no CHD‟.   Ethical approval was obtained from 
UCL/UCLH Ethics Committee and the project was registered with the Department 
of Research and Development at UCLH.  All subjects completed a self-assessment 
questionnaire and gave written consent before being recruited in the study.  All 
subjects were free from acute illnesses at the time of recruitment. 
 
2.2 Genotype Determination  
 
 
Leukocyte DNA for genotyping had previously been extracted for all studies from 
whole blood using the “salting out” method (Miller SA,1988). Briefly, the cell lysis  is 
achieved with a sugar lysis buffer followed by nuclear lysis using the defined 
nuclear lysis buffer.  De-proteinisation is performed with sodium perchlorate.  The 
DNA was extracted using chloroform and then precipitated from the aqueous 
phase using ethanol.  The extracted DNA was dissolved and stored in TE Buffer.    
All samples were carefully logged and entered into a database with a unique 
identifier in order to preserve the anonymity of individuals in the study. This stock 
DNA is used to prepare working 96 well arrays for genotyping. 
 
Working DNA was standardized to a concentration of 15ng/ l.  This was achieved 
by calculating the volume of DNA required to be added to 750 l of dH2O to achieve 
this concentration on the basis of the absorbance of a 10 l sample of stock DNA.  
Stock arrays were created in labelled 96-well Beckman‟s array.  These were stored 
at -20oC. To create working arrays, 100 l of each sample was removed from the 
stock array, and transferred to another labelled 96-well array. 
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2.2a Polymerase chain reaction & Restriction Digest (RFLP) 
 
The technique of Polymerase chain reaction (PCR) relies on double stranded DNA 
being denatured into single strands by heat, consequently annealing with 
oligonucleotides, and with the addition of DNA polymerase and nucleotide bases, 
the synthesis of a double strand on cooling. This process leads to binary 
replication, generating large quantities of DNA in a short period of time. The first 
step is therefore a short period of high temperature to denature or „melt‟ the DNA. 
This is followed by cooling in the presence of oligonucleotides that are 
complementary to the DNA either side of the sequence to be studied. These 
oligonucleotides anneal, and a DNA polymerase adds nucleotides base by base, 
thus replicating the DNA (Fig. 2.2). The polymerase used is derived from the 
bacterium Thermus aquaticus (Taq) and is heat stable. Therefore, it does not need 
to be replenished after each cycle of heating and cooling.  
 
Fig. 2.1: Schematic representation of the polymerase chain reaction (PCR). Denaturation 
of double stranded DNA occurs at 95°c (melting). Annealing of oligonucleotides varies 
according to the relative amounts of the four bases present. Polymerisation with Taq 
usually occurs at 72°c (polymerisation). 
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Sample Preparation for Polymerase Chain Reaction  
 
The DNA samples were prepared for PCR by centrifuging the DNA working-array 
at 200g for one minute to ensure that all the DNA dilutions were at the bottom of 
their respective wells, reducing the possibility of cross-well contamination when the 
array lid was removed. The appropriate amount of DNA (see 2.2c) was then 
removed from each array and transferred into a standard 96-well PCR plate from 
Corning Inc. (Hemel Hempstead, UK) using a multichannel dispenser.  Life Positive 
and negative controls were utilised to ensure accuracy. Extreme care was taken to 
ensure that samples were placed in the identical orientation as in the original 
arrays.  
 
A bulk mix of reagents was made up for each PCR, allowing adequate volume for 
the planned number of reactions, with an additional 10% added to ensure that the 
mix would not run short. PCR oligonucleotides and Taq polymerase were kept on 
ice and added just before the commencement of the reaction. PCRs were 
performed in a total volume of 20 l made up with distilled water. Each reaction 
contained 1x concentration of appropriate polmix, MgCl2, 8pmol of each 
oligonucleotide and 0.4U of Taq polymerase. 
 
The PCR mix was added to each well of the PCR plate using an automatic 
repeating dispenser. Each sample was overlaid with 20 l of mineral oil to prevent 
evaporation. The microtitre plate was then sealed with a clear sticky plastic lid and 
carefully labelled. Plates were centrifuged at 200g for thirty seconds to ensure 
good mixing of the reaction components in each well. PCR amplification was 
performed on an MJ Tetrad DNA Engine Thermocycler.   A description of the 
individual primers and conditions for each variant can be found in section 2.2c. 
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Detection of DNA (Agarose gels) 
 
In order to check the successful amplification and size of PCR products, agarose 
gels were utilised.  For a 2% gel, 2 grams of agarose  was mixed with 100ml of 
1×TBE solution containing 10µL of Ethidium bromide (10µg/µL). A microwave oven 
was used to heat the mixture and dissolve the agarose. The melted agarose was 
poured into a plastic gel tray (10 × 14cm) and a comb inserted. Solid gels were 
placed into an electrophoresis tank containing 750ml of 1xTBE buffer solution. 2 l 
of MADGE loading dye was added to 5µL PCR product and the entire volume was 
mixed thoroughly and placed in the separate, submerged wells of the gel. 2µl of a 
1Kb ladder (Invitrogen, Paisley UK) was pipetted into the central well in order to 
size relevant products. All agarose gels were run at 100 volts (v) for a minimum of 
30 minutes. 
 
Restriction digestion 
 
Restriction enzymes are derived from bacteria, and cleave double stranded DNA at 
a particular sequence. The enzyme translocates along the DNA until a particular 
recognition site is reached, where the DNA is cut. The restriction enzyme is 
sensitive even to a single base change in the recognition sequence, and thus can 
be used to detect point mutations and single base polymorphisms. A single base 
change can either eliminate or create a cutting site for a particular enzyme. 
 
A restriction enzyme digest mix with the recommended buffer system was made up 
in a 1ml Eppendorf tube on each occasion, containing sufficient enzyme to digest 
the PCR products in each well of the PCR plate.  5 l of digestion mix was then 
added to 8 l of each reaction product using a repeater pipette as for the PCR mix. 
Each omniplate was then centrifuged at 200g for thirty seconds to ensure that the 
PCR product and restriction enzyme were mixed well. The PCR/digestion mix was 
then incubated overnight at the recommended temperature. The specific conditions 
and possible product sizes for each genotyping assay are detailed in section 2.2c. 
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Microtitre Array Diagonal Gel Electrophoresis (MADGE) 
 
The DNA fragments produced by restriction enzyme digest were separated by 
electrophoresis on a non-denaturing polyacrylamide gel, using Microtitre Array 
Diagonal Gel Electrophoresis (MADGE)(Day IN,1995). This technique makes it 
possible to electrophorese all the 96 wells of a standard PCR plate on a single gel, 
by allowing the samples to run diagonally. Use of MADGE allowed the 96 well DNA 
array format to be retained throughout the screening process.  
 
MADGE consists of an open arrangement of 8x12 wells each 2mm deep. The wells 
are arranged at an angle of 71.2o to the short axis of the array, but perpendicular to 
the long-axis of the Perspex formers used (Fig. 2.2A).   Before making the mix, 
glass plates of appropriate size (160 x 100 x 2mm) were rigorously cleaned and 
hand dried. 5 drops of -methacryloxypropyltrimethoxysilane („sticky‟ silane) were 
spread across the plates and left to air-dry. Polymerisation of the MADGE mix was 
initiated by the addition of ammonium persulphate and the solution was mixed and 
quickly poured into the three-dimensional former. A glass plate was then gently 
placed over the mould (silane side facing downwards) taking care not to trap any 
air bubbles. This was then left for fifteen minutes to set, using a small weight to 
ensure that the glass did not slip whilst the gel was setting. Excess gel was 
trimmed from the edges of the MADGE former before the glass plate and attached 
gel were then prised away from the plastic former.  
 
Gel staining and loading 
 
Prior to loading a gel with digested PCR product, each gel was stained with 
Ethidium Bromide (EtBr). This was achieved by placing them individually in a 
Stuart box, shielded from direct light, containing 100ml of 1x TBE and 10 l EtBr for 
20 minutes.   MADGE loading dye (2 l) was added to each well of a new, round-
bottomed, loading tray, followed by 5 l of each digested sample, using a multi-
channel pipette to pick up the samples from under the oil in the plates. The 
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digested samples were gently mixed, by aspirating the formamide dye–digest 
mixture up and down several times into the pipette, before dispensing them on the 
digest plate.  
 
After placing the stained MADGE gel into an electrophoresis tank containing 750ml 
of 1xTBE buffer solution, a multi-channel pipette was used to transfer 5 l of this 
digest/dye mixture to the wells of the gel. At all times the samples were kept in the 
same layout as on the PCR tray, allowing each sample to be easily identified 
without being re-labelled. The gel was electrophoresed at 150v for a minimum of 
30 minutes. 
 
Following electrophoresis, the gel was viewed and photographed under ultraviolet 
light using the UVP Gel Documentation System. Care was once more taken to 
ensure the correct orientation of the MADGE under UV.  Figure 2.2B illustrates a  
typical pattern obtained for the polymorphisms genotyped. 
 
All genotyping was performed in a double blind fashion using both positive and 
negative controls. The results were rechecked by two individuals at the time of 
MADGE imaging and during data entry into the computer database. Any apparent 
genotype differences were resolved by repeat PCR. Overall there was excellent 
reproducibility with >95% consistency between observers. 
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Fig. 2.2: Perspex former (A) and visualised MADGE gel (B) for the UCP2-866G>A and 
UCP3 -55C>T gene variants.  
 
   
 
Perspex former is used to create angled Indentations in 
the gel.  
 
 
 
 
 
 
 
 
 
 
B 
 
Both wild type 
genotypes were cut by 
their respective 
enzymes. Arrow at the 
bottom of the gel 
represents the direction 
of electrophoresis. 
 
 
 
 
 
 
 
A 
A1 
H1 
Direction of electrophoresis 
MADGE gel of digest in 92 samples with 4 
blank controls
4 
Controls
No
samples
For UCP2 -866
GG    AA     GA
For UCP3 -55
CC    TT    CT
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2.2b Taqman® genotyping 
 
The principle behind the Taqman® reaction is described in Fig. 2.4. The method 
involves the inclusion of two fluorescent, dye-labelled probes for each allele of a 
specific variant.  The allele specific probes each contain a short sequence of DNA, 
a reporter dye (Labelled VIC™ or FAM™ depending upon the allele) at the 5‟ end, 
and a non-fluorescent quencher (NFQ) dye at the 3‟ end. During the PCR process, 
forward/reverse oligonucleotides as well as the labelled probes, anneal to the DNA 
of interest (Fig. 2.4.A). Amplitaq Gold® DNA polymerase is able to replicate the 
single strand of DNA until it reaches the labelled probe. Any non-specific binding 
results in a weakened interaction of the labelled probe with the DNA and 
displacement of the intact probe (no cleavage of the dye from the quencher) 
(Fig.2.4.B). If the probe is entirely complementary (hence allele specific probes) to 
the annealed DNA sequence, the 5‟ to 3‟ exonuclease activity of the enzyme 
results in the cleavage of the 5‟ dye from the rest of the probe (Fig. 2.4.C). The 
close proximity of the dye to the quencher usually prevents any significant 
fluorescent emission. However, once the dye is cleaved, fluorescence increases 
with each round of DNA replication (Fig.2.4.D). A 7900HT Sequence Detection 
machine (Applied Biosystems, California USA) is then able to determine the 
relative levels of either the VIC or FAM dyes, thereby determining the specific 
genotype. 
 
Preparing the DNA 
 
In contrast to traditional PCR and MADGE based technology, the Taqman® 
system enables high throughput genotyping in a 384 well format. In order to use 
this system, DNA was first standardised to an optimal concentration of 1.25ng/µL 
using the same methodology described in section 2.2. A Biomek 2000 robot 
(Beckman-Coulter, High Wycombe UK) was used to aliquot 4µL of standardised 
DNA from a 96 well stock array into a 384 well plate (5ng total) with 16 wells left 
blank to act as negative controls. A data sheet was also compiled in order to 
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identify each well to patient ID number. The plates were dried out overnight at 
room temperature in sterile paper bags and stored until use.  
 
 
Fig. 2.3: Schematic of the Taqman® assay system. A. represents the annealing of the 
fluorescent probes and oligonucleotides. B. If the fluorescent probe is not identical to the 
DNA sequence, the probe is displaced by the Taq. C. Successful annealing leads to 5‟-3‟ 
exonuclease of the probe. D. The VIC™ and FAM™ labels fluoresce and are picked up by 
the Taqman® machine.  
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Taqman master mix  
 
Forward/reverse oligonucleotides and labelled probes were ordered using the 
„Assay by demand‟ service available on the Applied Biosystems website 
(www.appliedbiosystems.com).  Section 2.2c lists all the assays successfully 
designed by Applied Biosystems for this thesis.  For each 384 well plate, a master 
mix was made of the ABgene QPCR Rox mix, the individual assay mix, and 
distilled sigma water.  4µL of mix was then applied to each well of the 384 plate 
using a manual Eppendorf 300, 8 channel multi-dispensing pipette and centrifuged 
(Sigma 4-15) at 200g for thirty seconds. A clear plastic lid (ABgene, Surrey UK) 
was applied to seal the plate. 
 
Fig. 2.4: Screen shot of a typical allelic discrimination plot. The three different coloured dots 
represent each individual genotype: Blue and red represent homozygotes with the green 
dots representing heterozygotes. Light blue crosses show the negative controls. Those 
dots which were not tightly clustered (circled in the figure) to a particular group were re-
genotyped. 
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Reading and entering of genotypes 
 
A standard two step heat cycle program on a Thermohybaid (Basingstoke, UK) 384 
well, heated block was used to initiate the PCR reaction (95°C for ten minutes, 
followed by 40 cycles of 95°C for 15s and 60°C for 1min), and all plates were then 
read on a 7900HT Sequence Detection machine (Applied Biosystems). The 
7900HT Taqman® machine uses SDS software 2.1 (Applied Biosystems) in order 
to differentiate the different genotypes (Fig. 2.6). SDS 2.1 produces an allelic 
discrimination plot as well as assigning genotypes automatically to an excel file 
containing patient ID numbers according to array position. To ensure no incorrect 
inputting of data, a second researcher validated all the genotypes before the data 
was finally entered into the analysis database.  
 
 
2.2c Specific Gene variants 
 
UCP2 -866G>A; rs659366 and UCP3 -55C>T; rs1800849 
 
 
These variants were genotyped in NPHSII using the RFLP method with the help of 
Dr Jeff Stephens and by using Taqman® genotyping in HIFMECH and JAM with 
the help of Kah Wah Li.  Dr Jeff Stephens kindly provided the RFLP conditions.  
The details of the Oligonucleotides and PCR and digest conditions can be found in 
table 2.1a and 2.1b repectively.  The Taqman oligonucleotides and probes can be 
found in table 2.1c. 
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Table 2.1a PCR conditions for genotyping by RFLP 
Variant  Oligonulceotides 
DNA ( l) 
POLMIX 
BSA 
MG(mmol) 
Conditions 
(OC) 
Fragment 
Length 
(bp) 
UCP2 -866 
CACGCTGCTTCTGCCAGGAC 
AGGCGTCAGGAGATGGACCG 
1.5 
NH4 
YES 
1.5 
4 MINS @ 95 
45s @ 90 
30s @ 60  
60s @ 72 
(30 CYCLES) 
5 MINS @ 72 
360 
UCP3 -55 
GGATAAGGTTTCAGGTCAGGC 
AAGGGATGAGGGAGGAGAAA 
1.5 
NH4 
YES 
1.5 
4 MINS „ 95 
40s @ 95 
55s @ 30 
60s @ 72 
(30 CYCLES) 
5 MINS @ 72 
194 
 
 
 
Table 2.1b The digest conditions for genotyping by RFLP 
 
Variant  Allele Enzyme  
Buffer 
BSA 
Incubation 
(OC)  
Fragment 
Length (bp) 
UCP2 
G 
A 
Mlu1 
NEB Buffer 2 
NO 
37 
290 + 70 
360 
UCP3 
C 
T 
HaeII 
NEB Buffer 2 
NO 
37 
110 + 64 + 20 
110 + 84  
All enzymes and buffers were supplied by New England Biolabs. 
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Table 2.2 Taqman assays design for all variants  
 
Variant 
 
Primers 
 
Probes 
 
 
UCP 2 
 
GCCAGAGGGCCCAATTGTT 
GGGCCTGGTTCGCTTTAATT 
 
 
VIC-CACGCGTCAGTTAC-NFQ 
FAM-TTCACGCATCAGTTAC-NFQ 
 
UCP3 
 
GCTGTCAACCAACTTCTCTAGGATA 
ACTGTTGTCTCTGCTGCTTCTG 
 
VIC-TCTTATACACACGGGCTGA-NFQ 
FAM-TCTTATACACACAGGCTGA-NFQ 
 
 
 
2.3 Biochemical assays 
For all biochemical assays blood was collected in EDTA-containing tubes and 
centrifuged immediately (unless specified).   The plasma was aliquoted into 
microtubes and placed into dry ice.  The samples were stored at -800C until use.  
All assays were performed on plasma not previously thawed.  All the assays were 
performed by myself with the help of Jasmin Matin in the JAM study.  The Plasma 
F2-isoprostanes were measured by myself in the laboratories of Professor Kevin 
Moore in the Centre for Hepatology at the Royal Free campus of UCL. 
2.3a Total Antioxidant Status (in House) (TAOS) 
Plasma TAOS was measured by a photometric microassay previously described 
by Sampson et al (Sampson MJ,2002). The TAOS of plasma was determined by 
its capacity to inhibit the peroxidase-mediated formation of the 2,2-azino-bis-3-
ethylbensthiazoline-6-sulfonic acid (ABTS+) radical. In the assay, the relative 
inhibition of ABTS+ formation in the presence of plasma is proportional to the 
antioxidant capacity of the sample.  There are two arms to the assay (Figure 2.5), 
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the test arm and a control arm with phosphate buffered saline (PBS) instead of 
plasma.   Plasma TAOS is therefore inversely proportional to the degree of 
oxidative stress in the sample.  
 
Fig 2.5 Measurement of plasma TAOS 
ABTS
ABTS+
Fluorescence at 405nm
H2O2
+ve
ABTS
ABTS+
H2O2
Fluorescence at 405nm
Plasma
+ve-ve
PBS
% Inhibition of  reaction (TAOS) = Control Abs-Test Abs x 100%
Control Abs
Control Arm Test Arm
 
Method 
 
Plasma (2.5 l) was placed in duplicate into 90 wells of a 96 well Nunc Immuno 
Maxisorp 96 well-plate.  2.5 l of PBS was added to 2 wells, an internal control 
sample to 2 wells and 2 wells were also left empty (as blank controls). The 
following solutions were subsequently added to each well:- 
 
-20 l of ABTS (20mmol/l). 
-20 l of HRP (30mU/ml). 
-40 l PBS (pH 7.4). 
 
The reaction was then initiated by the addition of 20 l of H2O2 (final concentration 
0.1 mmol/l). At the end of ten minutes the absorbance due to the accumulation of 
ABTS+ in the test sample was read, along with the control (containing 2.5 l of PBS 
instead of plasma).  This was performed using a Tecan GENios plate reader 
(TGPR) utilising the Magellan 3 software package. The difference in absorbance 
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(control absorbance minus test absorbance) divided by the control absorbance 
(expressed as a percentage) was used to represent the percentage inhibition of the 
reaction.  
 
2.2b Total Antioxidant Status (Randox, Ireland) (TAS) 
 
Plasma TAS is based on a similar principle to TOAS, in that the sample anti-
oxidant capacity is derived from the ability of the sample to inhibit the peroxidase-
mediated formation of the ABTS+radical.  The TAS kit uses the peroxidase 
metmyoglobin rather than horseradish peroxidase which gives a radical cation that 
is measured by the measurement of absorbance at 600nm (Fig 2.6).   The assay is 
calibrated using a 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 
standard (Randox Ireland) and a PBS blank.  Quality control is possible by the 
inclusion of a control human serum sample of known TAS.   
 
 
 
Fig 2.6 The creation of the ABTS radical in the Plasma TAS kit  
HX-Fe+++  + H2O2 X-[Fe++++ =0] +  H2O
ABTS® + X-[Fe++++ =0] ABTS®+  + HX-Fe+++
HX + Fe +++  = Metmyoglobin
X-[Fe++++ =0] = Ferrylmyoglobin
ABTS® = 2,2‟-Azino-di-[3-ethylbenzthiazoline sulphonate]
ABTS® is a registered trademark of Boehringer Mannheim
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Method. 
 
1. Cuvette method 
 
20 l of sample, standard or control is added to the cuvette followed by 1ml of 
“chromagen”.  The absorbance is read at 600nm (A1) and 200 l of “substrate” was 
added and incubated at 370C for 3 minutes.  Absorbance was read a second time 
(A2). All experiments were completed in duplicate. 
 
2. Microplate Method  
 
2.0 l of sample standard or control was placed in duplicate into 90 wells of a 96 
well Nunc Immuno Maxisorp 96 well-plate.  Using an automatic Biohit repeating 
dispenser, 100 l of “chromagen was added to each well.  The TGPR was used to 
read absorbance (A1) and then 20 l of “substrate” was added and the plate 
maintained at 370C for 3 minutes within the TGPR.  After 3 minutes the 
absorbance was read again (A2). 
 
The results were exported to an Excel spreadsheet.  Sample Absorbance (ΔA) was 
calculated A2-A1.  For each set of solutions a factor was derived from which the 
TAS could be calculated (Fig 2.7) 
 
 
Fig 2.7 The calculation of TAS 
Total Antioxidant Status:
Factor =       conc of standard   
[ΔA blank – ΔA Standard]
mmol/l = Factor x [ΔA blank – ΔA Sample]
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2.3c Bioxytech® AOP-490TM (Oxis International Inc, USA) 
 
The AOP-490TM assay measures the combined antioxidant action of the sample by 
assaying its ability to reduce the Cu++ to Cu+.  The chromogenic reagent (2,9-
dimethyl-4,7-diphenyl-1,10-phenanthroline) forms a 2:1 complex with Cu+ which 
has a maximum absorbance at 490nm.   The assay is calibrated using a standard 
curve derived from 5 uric acid standards and a deionized water control. 
 
Method 
 
The standard was prepared by adding 1.5ml of water to the “standard vial” and 
then performing four further dilutions of 500 l of standard to 500 l of water.  The 
samples or standard were diluted by adding 15 l to 585 l “R1” which contained the 
chromagen.  200 l of this solution was then added, in duplicate, to a well in the 
provided microplate.  The absorbance was measured at 490nm in the TGPR (A1) 
and 50 l of “R2” (containing the copper ions) was added to each well using an 
automatic Biohit repeating dispenser.  The plate was incubated at room 
temperature for 3 minutes and the 50 l of stop solution was added to each well 
and repeat absorbance measured (A2).  The absorbance of the sample was 
calculated as A2-A1.  The absorbance of a sample was derived from a standard 
curve and the calculation of a linear regression equation (SPSS 12.0) and the anti-
oxidant action reported as mM uric acid equivalents (Fig 2.8). 
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Fig 2.8 A typical standard curve for the AOP-490
 TM assay 
 
Determine the Uric acid equivalents for each sample from the curve and sample net absorbance by 
solving for “x”. 
[Example provide in technical specifications AOP-490
 TM 
] 
 
2.3d Glutathione/ Reduced Glutathione Ratio (Calbiochem,UK) 
 
Reduced glutathione (GSH) is a major antioxidant in human tissues, becoming 
oxidized (GSSG) during the conversion of hydrogen peroxide or lipid 
hydroperoxides to water and the respective alcohol.  When exposed to oxidative 
stress the ratio of GSH/GSSG will decrease as a consequence of GSSG 
accumulation, which makes this a useful indicator of oxidative stress.  Accurate 
measurement of GSSG requires the prevention of further oxidation of GSH.  This is 
achieved by the addition to the sample, before storage, of 1-methyl-2-vinylpyridium 
trifluoromethane-sulfonate (M2VP), a thiol scavenger reagent that leaves only 
GSSG.  A second sample is stored  without M2VP to assay GSH + GSSG.  The 
detectable product is derived from the reaction of Ellman‟s reagent (5,5‟-dithiobis-
2-nitrobenzoic acid [DTNB]) with GSH (Fig 2.9).  The GSSG in the sample is 
converted to GSH by the action of Nicotinamide adenine dinucleotide phosphate 
(NADPH) catalyzed by Glutathione reductase (GR). 
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Fig 2.9 The measurement of GSH/GSSG (see text for explanation of abbreviations) 
A) GSSG     B) Total GSH 
 
Each GSSG molecule is equivalent to 2 GSH molecules. 
 
Method  
 
The samples and reagents were prepared as follows 
 
1. Blood for GSH - 50 l of whole blood collected in an EDTA containing tube 
was placed in a microtube in dry ice and then stored at -800C until use. 
2. Blood for GSSG - 100 l of whole blood collected in an EDTA containing 
tube was placed in a microtube containing 10 l of provided M2VP and 
frozen in dry ice and then stored at -800C until use. 
3. GSH buffer – The provided vial was reconstituted in 650mls of deionized 
water. 
4. NADPH – The provided vial was reconstituted in 7.5mls of assay buffer on 
the day of use and discarded after 24 hours 
5. 5% Metaphosphoric acid (MPA) was prepared daily. 
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1. GSSG assay 
 
The sample was prepared by mixing the thawed sample with 290 l of ice cold MPA 
followed by centrifuge at 1000x g for 10 minutes.  The extract was diluted in the 
GSSG assay buffer provided (50 l extract + 700 l buffer) and stored on ice until 
use.  The low concentration standards were used for GSSG measurement 
(0,0.1,0.25,0.50 M GSH). 
 
2. GSH assay 
 
The sample was prepared by mixing the thawed sample with 350 l of ice cold MPA 
followed by centrifuge at 1000x g for 10 minutes.  The extract was diluted in the 
GSH assay buffer as above (50 l extract + 3ml buffer) and stored on ice until use.  
The high concentration standards were used for GSH measurement (0,0, 1.5,3.0 
M GSH). 
 
The reagents were then added, in duplicate, to the Nunc Immuno Maxisorp 96 
well-plate in an identical method for both the GSH and the GSSG assay. 
 
1. 50 l of sample, standard or blank 
2. 50 l of chromagen (Ellaman‟s reagent) 
3. 50 l of Enzyme (GR) 
4. Mix and incubate at room temperature for 5 minutes 
5. 50 l of NADPH 
6. Record the change of absorbance at 412nm for 3 mins 
 
Calculation 
 
The TGPR automatically calculated the gradient of the accumulation of chromagen 
based on 5 absorbance readings over the 3 minutes.   Standard curves were 
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generated for the standards based on these reaction rates in a similar way to the 
AOP-490TM kit (Fig 2.8).  The actual concentrations were calculated allowing for 
dilution by multiplying the total GSH by a dilution factor of 488 and the GSSG by a 
factor of 30.  Once the calculations of the concentration of total GSH and GSSG 
are made the ratio can be calculated.  GSH is calculated by total GSH – GSSG(x2) 
and the ratio GSH/GSSG can then be calculated. 
 
2.3e  Plasma F2-isoprostanes 
 
Measurement of isoprostane was performed by Gas Chromatography Mass 
Spectroscopy (GC-MS) after extraction, purification and derivitisation.  The ability 
of the sample to withstand oxidative stress was also assessed by the 
measurement of isoprostanes in a 200 l sample of plasma incubated with 3-
Morpolinosyndomimime chloride (SIN-1) at 370C for six hours (Ferraro B,2003).  
SIN-1 is a peroxynitrate releasing compound generating superoxide and nitric 
oxide.     The final concentration of SIN-1 was 11mmol (100 l of 2.2mg/ml added). 
 
Extraction  
 
Prior to extraction the phospholipids underwent alkaline hydrolysis.  To either 800 l 
of sample or the 200 l SIN-1 sample 10 l of 10mg BHT in 1ml methanol and 40 l  
of 8.8mg Trolox in 1 ml methanol was added.  An equal volume of 25% Potassium 
hydroxide was then added with D4-PGF2   standard.  This was then incubated at 
370C for 45 minutes.  The sample was adjusted to pH 3 using 1M HCL. 
 
Initial extraction of the prostaglandin-like compound was performed using tC18 
columns. Solid phase cartridges were used to remove water soluble and 
uncharged organic components, taking advantage of the lipid nature of the 
molecule combined with the polar –OH and –COOH groups.  These samples were 
prepared by washing with 6ml methanol, followed by 6ml of pH 3.0 water. The 
sample was then loaded onto the column using a pastette and washed with 6ml of 
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pH 3.0 water to remove water soluble compounds. At this pH, isoprostanes remain 
relatively uncharged and are bound to the solid phase. The column was then 
washed with 6ml of heptane to elute completely hydrophobic lipids. Isoprostane 
was then eluted into polypropylene tubes with 6ml of heptane, ethyl acetate and 
methanol (40:50:10), and dried under nitrogen. 
 
Derivatization- Step 1. Preparation of pentaflourbenzyl ester  
 
The pentafourobenzyl ester was prepared by the addition of 20 l 10% DIPEA (N,N-
di-isopropylethylamine in acetonitile (AcN) and 40 l 10% PFBR 
(pentaflourobenzylbromide) in AcN to each sample in the fume hood. This was left 
at room temperature for thirty minutes and dried under nitrogen. 
 
Purification 
 
The samples then underwent an additional purification with thin layer 
chromatography (TLC). TLC plates (Whatman 60A, Linear K6D, 5x20cm, 250 m 
thick) were pre-run in 100ml methanol for sixty minutes and subsequently dried. A 
TLC tank was prepared with 100ml of chloroform and ethanol (93ml: 7ml) and 
allowed to equilibrate for sixty minutes. Samples were resuspended in 40 l of 
methanol and chloroform (1:2), loaded onto the plates and run along with a 
separate plate loaded with 5ng of the methyl ester of PGF2 , which was run as a 
standard. The solvent front was run to 13cm above the application zone. The 
plates were then dried and the position of the standard visualised with 2% 
phosphomolybolic acid. The sample plates were then scraped 1.5cm above and 
1.2cm below the solvent front of the standard, and the PFBR esters extracted in 
1ml of ethyl acetate and methanol (1:1). The samples were then vortexed for two 
minutes and centrifuged for two minutes. The supernatant was then removed and 
dried under nitrogen.  
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Derivatization-Step 2. trimethylsilyl derivative 
 
Final esterification was achieved by adding 10 l of anhydrous DMF 
(dimethylformamide) and 20 l BSTFA (bis-siylyltrimethylfluoroacetamide) for thirty 
minutes. Samples were dried under nitrogen and subsequently resuspended in 
20 l of undecane, transferred to a conical autosampler vial using a Hamilton 
syringe and sealed. 
 
 Gas Chromatography-Mass Spectroscopy 
 
Four microlitres of each sample was then delivered to the GC-MS apparatus 
(Fissons GC 8000 series coupled to a Fissons Trio 1000 MS). After injection the 
isomers were separated by gas chromatography with the 8-iso-PGF2  appearing 
first. 
 
Negative ion chemical ionization with ammonia was used to determine the mass 
spectrum. Selective ion monitoring at 569m/z and 573m/z was performed, as these 
were the masses of the predominant fragments of the undeuterated and 
deuterated forms of the isomers respectively. The concentration of F2-isoprostane 
in the sample was then calculated by dividing the measure from the unknown 
sample by the standard and multiplying by concentration of the standard. Plasma 
F2-isoprostane results were expressed as pg/ml. The inter assay CV is 7% 
(Personal Communication, Dr Ali Reza, Department of Hepatology, UCL). 
 
2.3f  Plasma Non-Esterified Fatty Acids 
 
Plasma Non-esterified fatty acids (NEFA) were measured by an in vitro enzymatic 
colormetric assay (Wako Chemicals GmBH, Neuss, Germany).   The test utilizes 
three steps.  Firstly, the generation of Acyl-Coa from NEFA using the enzymre 
Acyl-CoA Synthase.  Secondly the generation of Hydrogen peroxide by the 
addition of Acyl-CoA oxidase.  Thirdly, the generation of colour from the reaction 
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between 4-aminophanazone and the hydrogen peroxide.  Oleic acid (282mol/L) 
was used as the standard and distilled water as negative control. 
 
Method 
 
The assay was performed, in duplicate, in a Nunc Immuno Maxisorp 96 well-plate 
as follows. 
 
1. 5µl sample, standard or control 
2. 100µl Reagent A (dissolved in solvent A) 
3. Mix well and leave for 10 minutes @ 37oC 
4. 200µl Reagent B (dissolved in solvent B) 
5. Mix well and leave for 10 minutes @ 37oC 
6. Read in the Tecan Plate reader @ 550nm. 
 
The result is calculated as follows 
 
         Concentration of  
         standard (mg/dL)* 
Free fatty acids (mg/dL*) = Absorbance of sample x --------------------------------------
         Absorbance of  
         Standard 
*concersion factor: mg/dL x0.035=mmol/L 
 
 
2.4 Clinical Protocols 
 
The clinical protocols were all recruited and performed by myself.   All the studies 
have been approved by committee alpha, Combined UCL/UCLH local ethics 
committee and for the fatty meal a site-specific assessment was also approved for 
the Institute of Child Health, UCL.   Healthy subjects were recruited from laboratory 
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and clinic staff while subjects with diabetes were recruited from the UDACS study. 
Excluded were those with clinically manifest CVD, smokers, those with connective 
tissue or other inflammatory disease and those with malignancy or other terminal 
illness.  Those on anti-inflammatory medications such as steroids or NSAID‟s were 
also excluded. Medication was omitted on the day of the study but patients were 
encouraged to take any medication after the study was completed. Written consent 
was obtained and all subjects were  given an information leaflet regarding the 
study.  A letter was sent to the General Practitioner of each consenting patient to 
inform them of the patient‟s participation in the study.  A small snack was provided 
for all patients before they left. 
 
2.4a Oral Glucose tolerance test 
 
The subjects attended after an overnight fast.  Blood was drawn from a cannula 
placed in the left ante-cubital vein and collected at ten minute intervals in relation to 
the ingestion of a standard 75g oral glucose load (394ml Original Lucozade, 
Glaxosmithkline (GlaxoSmithKline,2005)). Glucose was collected in oxalate tubes 
(grey top) and assayed on a YSI 2000 glucose analyzer (CV 0.9%).   Blood was 
also collected into EDTA-containing tubes and prepared for the measurement of 
TAOS.  
 
2.5b Meal rich in used cooking oil  
 
The subjects attended after an overnight fast.  Blood was drawn from a cannula 
placed in the left ante-cubital vein for assessment of lipid profile, renal function and 
glycated haemoglobin, and analysed using routine methods by Chemical 
Pathology Department, Middlesex Hospital.  Blood was also taken for glucose and 
oxidative stress markers as above. The subject was then given a prepared meal 
rich in used cooking oil.  Blood was taken for glucose and oxidative stress markers 
every hour for four hours. 
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Used cooking oil meal 
The meal consisted of 100g of vanilla ice cream (Tesco value soft serve), 200ml of 
skimmed milk, 50ml evaporated milk, 10g Yoghurt (Onken Natural), 50g of tinned 
apricots (no syrup), one egg and 46g of used cooking oil obtained from a local 
commercial restaurant (Potion Bar and Restaurant). The cooking oil was always 
obtained at the same time every week, on a Friday afternoon.  The oil was 
changed by the restaurant on Saturday morning so had been used for one week. 
The fat was stored at -200C and protected from light until use. The meal was 
blended and presented as a milkshake with chocolate syrup added as flavour if 
required.  This provided 64.4g of fat of which 30g was saturated.  The meal also 
contained 62.5g of carbohydrate and 20.5 g of protein (Williams MJA,1999).  The 
subjects were requested to drink the meal over a period of 15 minutes and the 
meal was well tolerated. 
2.5 Statistical Analysis 
Statistical analysis was performed using SPSS (version 12.1, SPSS Inc., Chicago) 
or  „Intercooled STATA‟ package (version 7.0, STATA Corporation, Texas).  The 
analysis was performed by Jackie Cooper, Fotios Drenios and myself.  For gene 
association analysis, data are reported for those individuals amongst whom high-
throughput genotyping was successful. 
Deviations from Hardy-Weinberg equilibrium were considered using chi-squared 
tests. Hardy-Weinberg equilibrium gives the expected genotype distribution based 
on the observed frequency of the rare allele (q) and common allele (p) as 
p2+2pq+q2, where p2 is the predicted frequency for homozygosity of the common 
allele, q2 is the predicted frequency for homozygosity of the rare allele and 2pq, the 
heterozygotes. These frequencies are expected provided the sample is drawn from 
a population with random mating and no strong selection. 
Specific details are include in the relevant section but in general, allele frequencies 
are shown with the 95% confidence interval.  Analysis of variance (ANOVA) was 
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used to assess the association between genotypes and baseline characteristics on 
normally distributed data, or on other data after appropriate transformation.  Chi-
squared tests were used to compare differences in categorical variables by 
genotype. 
No adjustment was made for multiplicity of testing.  However, analysis always 
followed an a-priori hypothesis or design.  In all cases a P value of less than 0.05 
was considered statistically significant.   
 
In NPHSII, survival analysis with respect to the prospective risk of cardiovascular 
disease or type 2 diabetes was carried out using Cox proportional hazards model, 
„failure‟ being the first CHD event or diagnosis of type 2 diabetes.  Results are 
presented as hazard ratios (HR) with their corresponding 95% confidence interval 
(CI).  To allow for differences in baseline data according to age and practice, age 
was included as a covariate in the model and data stratified by practice.   
 
2.6  Reagents and commonly used stock solutions and equipment 
 
Reagents 
 
Plasma Total antioxidant status: 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid 
(ABTS),  Horseradish Peroxidase (HRP) and Hydrogen Peroxide (H2O2). All supplied by 
Sigma (Poole, UK).  
 
Plasma F2-isoprostane: D4-PGF2  standards supplied by Cayman Chemical (MI, USA). 
tC18 (-Si-C18-H37: tc18 Sep-Pak) columns (Waters, MA, USA). N,N-di-isopropylethylamine 
Pentaflourobenzylbromide, dimethylformamide (DMF) and bis-
siylyltrimethylfluoroacetamide (BSFTA) and TLC plates (Whatman 60A, Linear K6D, 
5x20cm, 250 m thick). All other reagents were supplied by Sigma-Aldrich (Poole, UK).  
 
DNA Extraction: All reagents were supplied by Sigma (Poole, UK).  
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Polymerase chain reaction (PCR): PCR oligonucleotides and Taq polymerase were 
supplied by Invitrogen Ltd (Paisley, UK). 50mM MgCl2 supplied by Bioline (London, UK). 
All necessary restriction enzymes were supplied by New England Biolabs Inc 
(Hertfordshire, UK) or Roche Diagnostics (Lewes, UK). dNTPs were supplied by 
Pharmacia Biosystems Ltd (Milton Keynes, UK). 96 well PCR plates were obtained from 
Corning Inc. (Hemel Hempstead, UK). All other reagents supplied by Sigma-Aldrich Ltd. 
(Poole, UK).  
 
Gels: 19:1 30% acrylamide:N,N‟-methylenebenebisacrylamide was supplied by Protogel, 
National Diagnostics (Hull, UK). TEMED (NNN‟,N‟-tertramethylethylethylenediamine and 
Ammonium persulphate (APS) were supplied by BDH (Leicestershire, UK). Agarose was 
supplied by Helena Biosciences (Sunderland, UK) and 10× Tris Borate EDTA (TBE) was 
supplied by Severn Biotech Ltd (Worcestershire, UK). 1kb ladder was supplied by 
Invitrogen Ltd (Paisley, UK). 
 
Taqman assays: All Taqman assays were obtained from Applied Biosystems (California, 
USA). Taqman Absolute QPCR Rox mix and 384 well plates were supplied by ABgene 
(Surrey, UK).  
 
 
Commonly used stock solutions 
 
Ammonium persulphate solution (APS): 0.25g APS dissolved in 1ml distilled water.  
MADGE Loading Dye: 0.0015% bromophenol blue; 0.015% xylene cyanol; 10% glycerol; 
10mM EDTA 
 
NH4 polmix buffer: 16mM [NH4]2 SO4; 67mM Tris-HCL pH8.4; 0.01% Tween 20; 2mM 
dATP; 2mM dTTP; 2mM dGTP; 2mM dCTP 
 
Sticky Silane: 0.5% v/v glacial acetic acid; 0.5% v/v γ methacryloxy-propyl-trimethoxy-
silane 
 
TBE buffer: 0.04M Tris-borate; 1mM EDTA pH7.4 
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Reagent A (sucrose lysis buffer): 0.32M sucrose; 5mM MgCl2; 10mM Tris-HCl ph7.5; 1% 
Triton-X-100 
 
Reagent B (nuclei lysis buffer): 10mM Tris-HCl pH8.2; 0.4M NaCl; 2mM Na2EDTA pH 8.0 
TE Buffer: 10mM Tris-HCl; 1mM EDTA pH 7.6 
 
Equipment 
 
Automatic pipettes 
 
Manual Eppendorf 300, 8 channel pipette (Eppendorf, Hamburg, Germany). 
Eppendorf multipette Pro repeating dispenser (Eppendorf, Hamburg, Germany). 
Finnipipette multichannel dispenser (Life Sciences, Basingstoke, Hants, UK). 
Automatic Biohit repeating dispenser (Alpha Laboratories, UK) 
 
Plate Reader 
Tecan GENios (Tecan Group Ltd, Switzerland) 
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2.7 Declaration of activity 
 
Chapter 3 NPHSII 
 
Standardised DNA was available to me.  Genotyping was performed by a mixture 
of RFLP and Taqman.  I performed this with the help of Dr J. Stephens, Miss J. 
Matin and Ka-Wah Li.  Statistical analysis was directed by me with the help of Ms 
J. Cooper. 
 
Chapter 4 HIFMECH 
 
Standardised DNA was available to me.   I performed genotyping by Taqman with 
the help of Miss Ka-Wah Li.  Statistical analysis was directed by me with the help 
of Ms J Cooper and Ms E. Dawe. 
 
 
Chapter 5 
 
Markers of Oxidative stress in JAM 
 
I performed the selection and assessment of different assays to measure plasma 
markers of oxidative stress.  I performed the assays on the samples from the JAM 
study with the help of Miss J. Matin.  I directed the statistical analysis with the help 
of Dr Brendan Pearce (University of Washington). 
  
JAM 
 
Standardised DNA was available to me.  I performed genotyping using Taqman 
with the help of Miss Ka-Wah Li.  Statistical analysis was directed by me with the 
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help of Dr Brendan Pearce (University of Washington) who performed the 
hereditability calculations. 
 
Chapter 7 Clinical Studies 
 
The patients and normal volunteers were recruited by me.  I prepared and 
administered the glucose drink and test meal.  Venous sampling, plasma glucose 
assay, oxidative stress marker and NEFA assays were performed by me.  I 
measured plasma F2-isoprostanes in the Department of Hepatology, UCL 
[Professor K. Moore] with the help of Dr Ali Reza.  Statistical analysis was 
performed by me with the help of Dr F. Drenos. 
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CHAPTER THREE 
 
PROSPECTIVE RISK OF TYPE 2 DIABETES IN THE NORTHWICK PARK 
HEART STUDY II. 
Association of risk with the UCP2-866G>A and UCP3-55C>T Variants 
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3.1 Prospective Risk of Type 2 Diabetes in NPHSII 
 
3.1.1 Introduction 
 
As described in chapter 1, the rate of mitochondrial oxidative metabolism appears 
to be important in the development of T2DM.  UCP2 and UCP3, as part of the 
mitochondrial carrier protein superfamily are, therefore, good candidates for having 
a role in the pathogenesis of T2DM.  The UCP2 and UCP3 genes are located in a 
cluster within 8kb of each other on chromosome 11q13.  A variant associated with 
altered mRNA levels has been identified in both these genes (UCP2-866G>A; 
UCP3-55C>T).   
 
As seen in chapter 1, these variants have been associated with both obesity and 
T2DM traits which suggest that they are important in their pathogenesis (Table 
1.4c and 1.6).  The UCP2-866A is associated with higher mRNA levels and was 
associated with reduced insulin secretion or T2DM in Austrian (Krempler F,2002), 
Italian (D'Adamom M,2004) and Japanese samples (Sasahara M,2004), however, 
the -866A allele was also associated with lower subcutaneous adipose tissue 
mRNA, but not with T2DM in a mixed race sample from the USA (Wang MY,1999).   
Although 50% lower UCP3 protein has been described in subjects with T2DM 
(Schrauwen P,2001a), the UCP3-55C>T variant, which is associated with altered 
UCP3 mRNA levels (Schrauwen P,1999), has not consistently been associated 
with T2DM.  The UCP3-55T allele was associated with reduced risk of T2DM 
(Meirhaeghe A,2000), but this was not replicated in other studies (Cassell 
PG,2000; Halsall DJ,2001) . 
  
3.1.2 Aims 
 
The purpose of this research was to clarify the inconsistencies identified in cross- 
sectional gene association studies, and to further elucidate the role of identified 
genetic variation in the UCP2-UCP3 gene cluster in the development of T2DM. 
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3.1.3 Methods 
 
The Second Northwick Park Heart Study is a prospective study of over three 
thousand men who have now been followed for 15 years.  The men were healthy 
at recruitment, based on a definition that excluded men with cardiovascular 
disease, malignancy or taking regular medication.   Therefore, men with diet 
controlled T2DM, were not excluded from the study.  Analysis excludes these men 
unless stated otherwise.  New cases were identified by practice note search for 
physician diagnosed and treated T2DM according to current national guidelines.   
Obesity was defined as BMI over 30kg/m2.  Population attributable fraction (PAF) 
represents the impact of the variant on the sample in question, and is a composite 
of the exposure to the risk and the magnitude of the risk and is estimated as pd * 
(Hazard ratio -1/ Hazard ratio), where pd is the proportion of cases exposed to the 
risk factor (Greenland S,1993). 
 
3.2. Baseline Characteristics Predicting the Development of Type 2 
Diabetes 
 
The NPHSII contains a total of 3012 eligible men.  There were a total of 76 (2.5%) 
of men with T2DM at baseline.  At 10 years 86 (2.9%) new cases had been 
recorded and at 15 years 169 (5.6%) new cases were recorded.  The total 
incidence at ten years was 5.4% and 8.1% at 15 years. 
 
The baseline characteristics associated with the development of T2DM are shown 
in table 3.1a including baseline subjects with diabetes, and in table 3.1b excluding 
baseline subjects with diabetes.  The factors associated with diabetes are similar in 
both analyses [blood pressure, lipid parameters and CRP], with age being only 
significantly associated with diabetes if baseline subjects with T2DM are included. 
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Table 3.1a Baseline characteristics and their association with the development of 
T2DM over 15 years-including baseline subjects with T2DM 
 
 
 
 
No diabetes 
N=2767 
With 
diabetes  
N=245 
HR* (95% CI) P value 
Age (years) 56.0 (3.5) 56.7 (3.4) 1.31 (1.08-1.58) .005 
SBP†(mmHG) 136.3 (18.7) 142.3 (18.8) 1.32 (1.16-1.51) <0.0001 
DBP(mmHG) 84.4 (11.4) 85.6 (11.1) 1.08 (0.94-1.23) 0.26 
BMI†(kg/m2) 26.0 (3.3) 28.5 (4.0) 1.95 (1.71 – 2.22) <0.0001 
Smoking 791 (28.6%) 68 (27.8%) 0.96 (0.72-1.29) 0.80 
Cholesterol(mmol/L) 5.72 (1.01) 5.85 (1.09) 1.15 (1.01-1.31) 0.04 
Triglyceride†(mmol/L) 1.75 (0.92) 2.31 (1.2) 1.69 (1.48-1.93) <0.0001 
Fibrinogen†(g/l) 2.71 (0.52) 2.76 (0.51) 1.06 (0.93-1.21) 0.37 
CRP†(mg/l) 2.92 (3.44) 3.96 (4.32) 1.27 (1.10-1.46) 0.001 
See Table 3.1b for key 
 
Table 3.1b Baseline characteristics and their association with the development of 
T2DM-excluding baseline subjects with T2DM 
 
 No diabetes 
N=2767 
With 
diabetes  
N=169 
HR* (95% CI) P value 
Age (years) 56.0 (3.5) 56.3 (3.0) 1.16 (0.93-1.46) 0.19 
SBP†(mmHG) 136.3 (18.7) 141.3 (19.3) 1.30 (1.11-1.52) 0.001 
DBP(mmHG) 84.4 (11.4) 86.2 (11.3) 1.14 (0.98-1.34) 0.09 
BMI†(kg/m2) 26.0 (3.3) 28.6 (3.7) 1.86 (1.65 – 2.10) <0.0001 
Smoking 791 (28.6%) 54 (32.0%) 1.29 (0.93-1.79) 0.13 
Cholesterol(mmol/L) 5.72 (1.01) 5.90 (0.98) 1.20 (1.03-1.39) 0.03 
Triglyceride†(mmol/L) 1.75 (0.92) 2.27 (1.7) 1.55 (1.34-1.80) <0.0001 
Fibrinogen†(g/l) 2.71 (0.52) 2.78 (0.53) 1.17 (1.00-1.36) 0.11 
CRP†(mg/l) 2.92 (3.44) 4.05 (4.36) 1.37 (1.16-1.61) <0.001 
†geometric mean (approx sd) 
CRP measurements made after diabetes was recorded are excluded from the analysis (n=2) 
 +age and practice adjusted hazard ratio for 1 sd increase in all variables except smoking 
(current:non), obesity (>30:<30)  and age (5 year increase). 
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Excluding the subjects with T2DM at baseline, BMI, C-reactive protein (CRP), 
triglyceride, cholesterol and blood pressure were all associated with increased risk 
of development of T2DM, with BMI conferring the highest risk (HR 1.86 [1.65-
2.10:p=<0.0001 per increase of 1 SD]. A stepwise model was used to determine 
which of these variables were independently associated with T2DM (table 3.2) 
Cholesterol and blood pressure were no longer associated with T2DM, and BMI 
remained the most significant predictor.  
 
Table 3.2 Baseline Characteristics with an independent association with the risk of 
development of type 2 diabetes (stepwise model) 
  
 
HR+ (95% CI) P value 
BMI (kg/m2) 1.72 (1.49-1.99) <0.0001 
Triglycerides(mmol/L) 1.27 (1.08-1.49) 0.004 
CRP (mg/l) 1.21 (1.01-1.46) 0.04 
+age and practice adjusted hazard ratio for 1 sd increase. 
 
 When the men were divided between those whose BMI at baseline was high 
enough to warrant a diagnosis of obesity (>30kg/m2), the rates of T2DM were 
much higher than in the non-obese men (Fig. 3.1).  Obese men were 3.96 [2.87-
5.47] times more likely to go on to develop T2DM (p<0.0001) than non-obese men. 
 
Fig.3.1: Kaplan-Meier plot for the development of type 2 diabetes by the presence 
or absence of obesity.  
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3.3 UCP2-866G>A and prospective risk of Type 2 Diabetes 
 
3.3.1 Genotype Characteristics 
 
DNA was available for 2775 [92%] of men, and genotype was obtained in 2695 
[97%] of men and the frequencies were in Hardy Weinberg Equilibrium (p=0.85).  
The allele frequency for the -866A allele were 0.365 (0.35-0.38).   There was no 
difference in BMI, Systolic blood pressure, triglycerides or CRP between genotypes 
(Table 3.3). 
 
Table 3.3. Baseline characteristics by UCP2 -866 genotype 
 
  UCP2 Genotype  
 GG 
N=1088 
GA 
N=1245 
AA 
N=362 
P value 
BMI (kg/m2) 26.3 (3.4) 26.2 (3.4) 26.5 (3.5) 0.26 
Blood Pressure 
(mmHg) 
 
137.2 (18.9) 136.8 (18.5) 138.2 (19.8) 0.45 
Cholesterol (mmol/L) 5.71 (1.02) 5.73 (1.00) 5.78 (1.01) 0.59 
Triglycerides (mmol/L) 1.78 (0.94) 1.78 (0.93) 1.88 (1.03) 0.20 
CRP (mg/L) 3.04 (3.56) 2.91 (3.42) 3.31 (3.82) 0.20 
All Geometric means (approximate sds) except Cholesterol. 
  
3.3.2 Risk of Type 2 Diabetes 
 
The genotype frequency did not differ significantly between those who developed 
diabetes and those who did not (no diabetes v diabetes [GG/GA/AA%]: 40/47/13 v 
42/40/18:p=0.16) but a trend to a higher frequency of the AA genotype was seen 
when the baseline subjects with T2DM were included (40/47/13 v 42/40/18: 
p=0.06).  The Kaplan-Meier plot (Fig. 3.2) indicates that the UCP-2 AA genotype 
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only appears to be associated with the development of diabetes about 5-10 years 
earlier but there is a “catch up” in incidence in the GG+GA men by 15 years. 
   
Fig 3.2: Kaplan-Meier plot for the development of T2DM by UCP2-866G>A 
genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When 15 year risk of T2DM was examined using this recessive model the AA 
genotype was associated with an increased risk of 1.47 (0.97-2.23:p=0.07) 
excluding baseline cases, and 1.49 (1.03-2.14:p=0.03) including baseline cases, 
compared to the GG+GA men adjusted for age and recruitment site.  This risk 
effect was maintained after adjustment for BMI, blood pressure, cholesterol, 
triglycerides and CRP, with an increased 15 year risk of T2DM of 1.59 times (1.03-
2.45:p=0.04) in AA homozygotes.  The acceleration of onset of T2DM associated 
was also seen in this recessive model (Fig 3.3).  This was confirmed by examining 
the risk of diabetes at 10 years. The genotype difference for risk of diabetes at 10 
years was highly significant (HR [AA v GG/GA] 1.94[1.18-3.19]: p=0.009).   
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Fig.3.3: Kaplan-Meier plot for the development T2DM by UCP2AA genotype based 
on a recessive model 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 Interaction with Obesity 
 
As obesity was such a significant risk factor for T2DM the influence of obesity on 
the UCP2-866G>A variant was examined.  The risk of diabetes at 15 years 
associated with the AA genotype increased from 1.35 [0.79-2.32; p=0.34] to 5.55 
[2.95-10.45; p=<0.0001] in obese AA men (Fig. 4.4).  There was no evidence of 
interaction, with the effect being purely additive (p=0.85).  This remained the case 
if BMI tertiles were used instead of obesity (p=0.80) or as a continuous variable  
(p=0.26).  There was no difference in absolute (GG+GA v AA Median [IQR]: 0.20[-
0.34 to 0.72] v 0.20 [-0.3 to 0.88]: p=0.60) or percentage change in weight by 
genotype (0.25 [-0.42 to 0.91] v 0.23 [-0.38 to 1.09]:p=0.63) [Fig 3.7]. 
 
 
 
 
 
 
 
 
 
 143 
Fig 3.4:  The Hazard ratio for the development of type 2 diabetes by UCP2-866 
genotype stratified by the presence or absence of obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 UCP3-55C>T and prospective risk of Type 2 Diabetes 
 
3.4.1 Genotype Characteristics 
 
Genotype was available as for UCP2.  The genotype frequencies were also in 
Hardy Weinberg equilibrium (p=0.16) with the frequency of the rare UCP3-55T 
allele being 0.23 [0.21-0.24].   The baseline characteristics by genotype are shown 
in table 3.3 with no significant difference for any variable. 
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Table 3.4: Baseline characteristics by UCP3 -55 genotype 
 
 UCP3 Genotype  
 CC 
N=1634 
CT 
N=905  
TT 
N=155 
P value 
BMI (kg/m2) 26.3 (3.4) 26.2 (3.4) 25.9 (3.3) 0.38 
Blood Pressure 
(sys) (mmHg) 
137.1 (18.8) 136.9 (18.8) 138.0 (19.0) 0.78 
Cholesterol (mmol/L) 5.70 (1.0) 5.77 (1.0) 5.79 (1.0) 0.22 
Triglycerides (mmol/L) 1.79 (0.95) 1.81 (0.94) 1.77 (0.96) 0.90 
CRP (mg/L) 3.02 (3.56) 3.09 (3.60) 2.67 (2.80) 0.37 
All Geometric means (approximate sds) except Cholesterol 
 
 
 
 
3.4.2. Risk of Type 2 Diabetes 
 
There was no difference in genotype frequencies between those with and those 
without type 2 diabetes at 15 years (% with genotype CC/CT/TT without diabetes v 
diabetes; 60.5/33.9/3.6 v 63.0/28.6/8.4:p=0.16), with no difference if the subjects 
with diabetes at baseline were included (60.6/33.9/5.5 v 61.8/27.0/11.2:p=0.19).  
However, the Kaplan-Meier plots for development of diabetes by genotype (Fig 
4.5) and  using a recessive model (Fig 3.6) indicate that UCP3 genotype also 
appears to accelerate date of onset of diabetes.   As seen for UCP2, the TT 
genotype was associated with a significant hazard ratio [95%CI] for the 
development of type 2 diabetes at 10 years (HR[95%CI]; 2.06 [1.06-3.99]: p=0.03) 
but not at 15 years (1.50 [0.85-2.66], p=0.16). 
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Fig 3.5: Kaplan-Meier plot for the development of T2DM by UCP3-55C>T 
genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.6: Kaplan-Meier plot for the development T2DM by UCP3TT genotype based 
on a recessive model 
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3.4.3.Interaction with Obesity 
 
Risk of T2DM was again exacerbated by obesity, with the risk associated with 
UCP3TT genotype increasing to 5.65 ([2.07-15.46]: p<0.001) at 15 years in the 
obese men (Fig.3.8).  The differences were again purely additive, with no evidence 
of interaction if this was considered as BMI tertile, obesity present or not, or BMI as 
a continuous variable (p=0.91, 0.38 and 0.76 respectively).  The increase in risk of 
diabetes could again not be explained by weight gain with no difference between 
genotypes in absolute (CC+CT v TT Median [IQR]: 0.20[-0.34 to 0.74] v 0.13 [-0.32 
to 0.80]: p=0.38) or percentage weight change (0.25[-0.42 to 0.91] v 0.16[-0.42 to 
0.80]: p=0.45)[Fig. 3.7]. 
 
Fig.3.7 The absolute and percentage change in weight by UCP2 and UCP3  
genotype in the NPHSII study at five years. 
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Fig 3.8:  The Hazard ratio for the development of type 2 diabetes by UCP3-55C>T 
genotype stratified by the presence or absence of obesity. 
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3.5 Combined Genotypes and Risk of type 2 Diabetes 
 
 
3.5.1. UCP2-UCP3 Haplotypes 
 
The two variants showed weak but significant positive linkage disequilibrium 
(D‟=0.28, p<0.001). As shown in Table 3.5 all four haplotypes were present in this 
sample. As would be predicted by the single SNP analysis, only the -866A/-55T 
combination was associated with increased risk of diabetes at 10 years (AT v GC 
1.63[1.12-2.36]: p=0.01), and this effect was no longer statistically significant at 15 
years (1.27[0.93-1.73]: p=0.13).   The relatively low frequency of this haplotype 
(9%), and the recessive nature of their effect precluded a robust estimate of the 
additive effect with obesity. 
 
Table 3.5:  UCP2/UCP3 haplotypes and risk of type 2 diabetes at 10 and 15 years 
 
Haplotype Frequency in 
those without 
diabetes 
Frequency in 
those with 
diabetes 
Hazard Ratio 
[95%CI] 
P value 
10 YEARS     
GC 0.50 0.47 1.00  
GT 0.14 0.10 0.74 [0.47-1.17] 0.19 
AC 0.28 0.28 1.09 [0.76-1.55] 0.64 
AT 0.09 0.15 1.63 [1.12-2.36] 0.01 
15 YEARS     
GC 0.51 0.53 1.00  
GT 0.13 0.10 0.73 [0.50-1.05] 0.09 
AC 0.27 0.25 0.94 [0.72-1.22] 0.64 
AT 0.10 0.13 1.27 [0.93-1.73] 0.13 
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3.5.2 UCP2-UCP3 combined genotypes and Type 2 Diabetes Risk 
 
The percentage of men developing T2DM by combined UCP2-UCP3 genotype is 
shown in Table 3.6.   After adjustment for age and place of recruitment, men 
homozygous for both rare alleles (the  AA-TT genotype) were the only group 
showing a significant increased risk of T2DM at ten years (HR 4.20[1.70-
10.37]:p=0.002) or at 15 years (2.37[1.07-5.2]:p=0.03 
 
Table 3.6: Combined UCP2-UCP3 genotypes and risk of type 2 diabetes at 10 and 
15 years 
 
UCP2 UCP3 10 YEARS 15 YEARS 
% with 
diabetes 
(number) 
HR(95% CI)* % with 
diabetes 
(number) 
HR(95% CI)* 
GG CC 3.2 (24/741) 1.00 6.8% (50/741) 1.00 
CT 2.3 (6/265) 0.59 (0.24-1.44) 4.5% (12/265) 0.54 (0.28-1.03) 
TT 9.4 (3/32) 3.00 (0.89-10.04) 9.4% (3/32) 1.36 (0.42-4.37) 
GA CC 3.8 (25/663) 1.09 (0.62-1.91) 5.4% (36/663) 0.77 (0.50-1.18) 
CT 2.2 (10/461) 0.63 (0.30-1.31) 5.0% (23/461) 0.69 (0.42-1.14) 
TT 1.4 (1/71) 0.38 (0.05-2.81) 4.2% (3/71) 0.56 (0.17-1.81) 
AA CC 3.7 (6/161) 1.14 (0.46-2.79) 6.8% (11/161) 1.05 (0.54-2.02) 
CT 5.7 (8/141) 1.64 (0.73-3.67) 6.4% (9/141) 0.93 (0.45-1.89) 
TT 13.6 (6/44) 4.20 (1.70-10.37) 15.9% (7/44) 2.37 (1.07-5.25) 
*age and practice adjusted 
 
In order to obtain a more robust estimate of the effect of the combined genotypes, 
the subjects were combined into four groups on the basis of homozygosity for the 
variant alleles (UCP2-UCP3:1= GG+CC, 2= GG+GA-TT, 3= AA-CC+CT, 4= AA-
TT).  Risk of T2DM increased across the groups with increasing numbers of rare 
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alleles, progressing from no variant homozygotes to 2 variant homozygotes (1.5% 
of men) at 10 years (p=0.002) and 15 years (p=0.04)(Fig.3.9). 
 
Fig 3.9: Hazard ratios for the development of type 2 diabetes by combined UCP2-
UCP3 group genotype at A) 10 years and B) 15 years of follow up. 
 
 
A) 10 years     B) 15 years 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 3.5.3. Interaction with Obesity 
 
When the effect of the combined UCP2-UCP3 genotype was combined with 
obesity, non-obese AA-TT men showed an increased risk of T2DM of 2.50(0.91-
6.86: p=0.08) (Figure 3.10) while obese AA-TT men had an increased risk of 19.23 
(5.83-63.39: p<0.001). The effects of the individual genotypes were additive with 
no evidence of an interaction between the effect of UCP2 and UCP3 genotype (p= 
0.15).  There was also no significant evidence of interaction between the effect of 
combined genotype group and obesity (p=0.83) or with BMI as a continuous 
variable (p=0.54).  A Cox regression model with the two genotypes and BMI (as 
tertiles) showed hazard ratios [95%CI] of approximately similar magnitude for the 
two genotypes although the UCP3 risk estimate just crossed one (UCP2 1.74[1.05-
2.88]:p=0.03; UCP3 1.92[0.98-3.76]: p=0.06).  These are slightly lower than the 
single genotype unadjusted hazard ratios and are lower than the risk of developing 
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type 2 diabetes associated with the middle or upper tertile of BMI (4.13[1.70-10.05] 
and 9.61[4.14-22.32] respectively: p<0.0001 for both).   
 
Fig.3.10: The hazard ratio for the development of type 2 diabetes at 15 years of 
follow  up by combined UCP2-UCP3 genotype in those above with and without 
obesity. 
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3.5.4   Population attributable Fraction 
 
To determine the impact of genotype on the population using the Population 
attributable fraction (PAF) was calculated.  The PAF [95% CI] after 15 years of 
follow up for variation in the UCP2-UCP3 gene cluster was 5.3% [-1.1 to 11.4].    
When obesity was added to this model the PAF was similar at 4.7% [-1.6 to 10.7].  
Obesity had a much larger influence, with a PAF of 21.2% [14 to 57].  The 
influence of variation in the gene cluster as a whole was examined using the 
individual genes (Fig. 3.11A).   Variation in UCP2 genotype explained 6 (PAF 3.8% 
[-2 to 9]) cases, variation in UCP3 3 and 8 (1.9% [-1 to 5]) if adjusted for BMI which 
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is much lower than the 36 (21 [14 to 28]) cases of type 2 diabetes that would be 
explained by obesity. 
 
If PAF is examined at 10 years, then as expected, the influence of genotype is 
higher (11.6% [0 to 21.7]).  The influence of obesity is similar (25.6% [13 to 36]).  
However, as there are fewer cases of new onset Type 2 Diabetes at this time the 
number of cases due to obesity is lower [22].  The extra cases present due to 
genotype was 8 and 4 for UCP2 variation and UCP3 variation respectively (PAF 
8.5% [-2 to 18] and 5.5%[-1 to 12] respectively [Fig: 3.11]). 
 
 
 
Fig.3.11: Population attributable risk for UCP2-866G>A, UCP3-55C>T and obesity 
at  A) 15 years B) 10 years.  
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3.6 Discussion 
 
This 15 year study of the prospective risk of T2DM in healthy middle aged 
Caucasian men confirmed the significance of obesity as a major risk factor for 
diabetes, and also found a significant impact on risk of developing T2DM 
associated with variants in the genes for UCP2 (-866A) and UCP3 (-55T).  
Subjects who developed T2DM also had higher blood pressure, triglycerides, 
cholesterol and C-reactive protein (CRP) at baseline, although only BMI, 
triglycerides and CRP were associated independently with increased risk.   The 
association with CRP and triglycerides may have arisen because subjects going on 
to develop T2DM were already more insulin resistant at baseline (Duncan 
BB,2003) but this could not be confirmed as other measures of insulin resistance 
such as HOMA were not collected at recruitment.  The risk associated with BMI 
was over a third higher than any other metabolic parameter and the size of the risk 
associated with obesity, defined here as BMI>30kg/m2, was approximately four 
times that associated with the genetic variants.  In effect, after 10 years of follow 
up,1 out of 4 cases of T2DM would have been prevented if there were no obesity, 
BMI being the best marker of adiposity in the group as waist circumference was not 
collected at baseline, present in the sample, while 1 out of 10 cases would be 
prevented if there were no genetic variation at UCP2-866 or UCP3-55.  The 
additive effect of the combination of obesity and the presence of the gene variants 
increased the risk to extremely high levels, although such subjects were rare in the 
sample.  In obese subjects homozygous for either variant the risk of T2DM 
increased to over 5 times that of non-obese subjects, non-homozygous for either 
variant.   Homozygotes for both variant alleles had a risk of diabetes from 2.5 times 
higher in the non-obese, to nearly 20 times higher in obese subjects.   
 
 
The UCP2-866A allele has consistently been associated with risk of T2DM in 
cross-sectional studies in European subjects, and the mechanism of this appears 
likely to be due to increased UCP2 expression in the pancreas.  The location of the 
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-866G>A variant, within a multifunctional cis regulatory site involving putative 
binding sites for pancreatic and hypoxia-induced transcription factors, suggests 
that it is likely to be functional (Esterbauer H,2003).  Consistent with this, a 
promoter construct of the -866A allele  was associated with 1.2 fold higher 
expression vs. -866G in INSE-1 cells, derived from rat β-cells (Krempler F,2002).   
Putative mechanisms are examined in later chapters but it is likely that UCP2 
expression uncouples ATP production from glucose metabolism, reducing ATP 
production, and since insulin secretion depends on the ATP/ADP ratio as a marker 
of glucose metabolism in the pancreatic β-cell (Erecinska M,1992), secretion is 
reduced as a result.  The higher risk of developing T2DM associated with variation 
in the UCP2 gene is thus likely to be due to a pancreatic effect on insulin secretion.  
Risk is exacerbated by obesity, as obese subjects are already likely to be insulin 
resistant and will require higher insulin secretion to maintain normal glucose 
homeostasis.   
 
A different mechanism appears likely for the UCP3 risk effect.  As discussed in 
chapter 1 although UCP3 expression has been associated with higher uncoupling 
in vitro (Jaburek M,1999),  UCP3 expression is increased both by fasting and by an 
iso-caloric high fat diet, neither of which increases metabolic rate nor uncoupling.  
Also, an increase in expression does not change mitochondrial membrane 
potential.  These findings suggest that UCP3  does not have a conventional 
uncoupling function in man (Schrauwen P,2004).  Overexpression of UCP3 in mice 
which protects them from diabetes, with a 68% increase in mitochondrial palmitate 
oxidation.  This effect is specific to UCP3, as there is no increase in glucose 
oxidation, change in oxygen consumption or mitochondrial membrane potential, 
which is seen with increased uncoupling per se (MacLellan JD,2005).  UCP3 
expression will thus protect the mitochondria, by exporting the fatty acid anions and 
peroxides from the mitochondrial matrix, protecting mitochondrial function and 
preventing the development of T2DM (Schrauwen P,2003). 
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Since the UCP3-55T variant is associated with risk of diabetes in the men studied 
here, a decrease in function would be predicted for the T allele.  The variant was 
originally mapped near a TATA box (6bp) (Schrauwen P,1999) where it may affect 
transcription, but a recent report (Acin A,1999) places the variant in the „5UTR near 
a PPAR responsive element (4bp) which also suggests it could modify regulation of 
UCP3 expression.  A reduction in UCP3 function in -55T carriers has been seen in 
some but not all previous cross sectional studies.  UCP3 mRNA expression was 
higher in CT/TT male non-diabetic Pima Indians, but this study included only 24 
subjects and was based on only seven copies of the T variant from 48 alleles 
(Schrauwen P,1999).  The T allele was associated with higher BMI or WHI ratio, 
consistent with decreased function, in French and German Caucasians, South 
Asian Indian parent-offspring trios, South Asian Indians and the British Diabetic 
Association Warren 2 trios collection (Cassell PG,2000; Halsall DJ,2001; Herrmann 
SM,2003; Otabe S,2000).  However, one study showed a lower BMI in TT subjects 
in a United Kingdom sample (Halsall DJ,2001) and increased function is also 
suggested with the association of protection from diabetic neuropathy (Rudofsky 
G,2006).  In these studies, association with T2DM was examined only once and a 
relationship not found.  The variant allele was found to be protective against T2DM 
in two French cohorts although also associated with an atherogenic lipid profile 
(Meirhaeghe A,2000).  The reason for this difference is not clear; the French 
sample does not appear to be very different to the NPHSII sample although the 
NPHSII sample is nearly three times larger, which may be important when the 
impact of an individual variant is small. 
 
The overall prevalence of T2DM in this sample is 2.5% at baseline and 8.1% after 
15 years of follow up.  This is lower than that reported by the Joint Health Surveys 
Unit (Health Survey for England 2003,2004), however, the increase in prevalence 
of both diagnosed and undiagnosed diabetes between the age range 55-64 years 
and 65-74 years is similar, from 10.4%, to 18.8%.  The lower prevalence is in part 
due to the exclusion of those with diabetes on treatment at the beginning of the 
study.   Although a small number of subjects with diabetes managed by dietary 
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modification alone were included in the study the findings were consistent if they 
were included in the analysis. The method of identification of the men with T2DM, 
by the medical record search, is unlikely to include any false positive diagnosis, but 
in the absence of a full recall for fasting glucose testing some affected subjects 
may be missed. This would then result in a small underestimate of the 15 year 
incidence of T2DM, but would not confound the genetic association observed.  This 
is the first prospective study to look at risk of T2DM and, overall prospective gene-
association studies are more powerful than the case-control design (Humphries 
SE,2003) but further replication is required to resolve these apparent 
discrepancies.  
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CHAPTER FOUR 
 
THE UCP2-866G>A AND UCP3-55C>T VARIANTS IN THE 
HYPERCOAGULABILITY AND IMPAIRED FIBRINOLYTIC FUNCTION 
MECHANISMS STUDY (HIFMECH) 
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4.1 Hypercoagulability and Impaired Fibrinolytic Function Mechanisms Study 
(HIFMECH) 
 
4.1.1 Introduction 
 
The previous chapter demonstrated the association of variants in the uncoupling 
proteins 2 and 3 with prospective risk of type 2 diabetes.  The study, however, did 
not address the potential mechanisms that underlie this association.  The 
HIFMECH study is described in detail in chapter 2.  The measurement of a number 
of metabolic markers gives the opportunity to investigate the mechanism by which 
these gene variants influence risk of type 2 diabetes.  Chapter 1 describes how 
there may be an overlap in the underlying pathophysiology driving cardiovascular 
disease and type 2 diabetes.  The case-control nature of this study allows for the 
association of these variants with myocardial infarction to be studied, determining if 
the pathway of increased risk of type 2 diabetes is likely to be shared with 
cardiovascular disease, or is independent of it.     
 
4.1.2 Aims 
 
To examine the UCP2-866G>A and UCP3-55C>T  variants in the HIFMECH study 
to determine if the increase in prospective risk of type 2 diabetes is due to an 
association with adverse metabolic markers. 
 
To estimate the effect of the UCP2-866G>A and UCP3-55C>T variants on risk of 
myocardial infarction. 
 
4.1.3 Methods 
 
The HIFMECH study was designed to study genetic and environmental 
mechanisms contributing to the higher cardiovascular risk in Northern compared to 
Southern Europe (Juhan-Vague I,2002).  The study sample of Caucasian male first 
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myocardial infarction survivors below 60 years of age were recruited from four 
European centres (Northern European-Stockholm, London; Southern European-
Marseille, San Giovani Rotondo) (n=598).  A selection of randomly-selected age 
matched healthy controls was also recruited from each catchment area (n=653).   
To reduce the risk of error due to multiple testing statistical analysis followed the a-
priori design, to study the association of risk factors associated with cardiovascular 
risk in relation to the North and South of Europe, combining data from the two 
North and two Southern centres for a more statistically robust comparison.  There 
was no difference between common allele homozygotes and heterozygotes for 
prospective risk of type 2 diabetes so a recessive model was used for both 
genotypes.  The metabolic markers were studied in controls, as they are most 
similar to the participants of NPHSII.  In keeping with the original design, risk of 
myocardial infarction associated with genotype was also estimated.  Associations 
were estimated in cases only for the purpose of assessing confounding of any 
differences detected in cardiovascular risk associated with genotype.   
 
 
 
4.2. Baseline Characteristics  
 
The baseline characteristics of the HIFMECH study are shown in table 1.  There 
are significant differences between both cases and controls and between subjects 
in the North and South of Europe.  Those in the South had a better lipid profile but 
were more likely to smoke.  There was no difference between BMI between the 
North and South but waist:Hip ratio (WHR) was higher in the North than in the 
South (Controls 1 v 0.95,p<0.001; Cases 0.98 v 0.93, p<0.001). As expected, 
cases had higher rates of smoking and type 2 diabetes, whilst although 
triglycerides were higher in cases there was no clear difference in blood pressure 
and lipids. This is likely to be due to post-infarct treatments.   The frequencies of 
the UCP2-866 and UCP3-55 genotype were as expected from Hardy-Weinburg 
proportions in both the North and South sample (UCP2-866: North p=0.72, South 
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p=0.96. UCP3-55: North p=0.49, South p=0.45).  The frequency of the rare UCP2-
866A was 0.34[0.32-0.37], with no difference between the North and South 
(p=0.95).  By contrast, there was a difference between the frequency of the rare 
UCP3-55T between the North (0.28[0.25-0.31]) and the South (0.18[0.15-
0.20];p=0.001).   
 
 
Table 4.1. The baseline characteristics of the subjects determined by case/control 
and North/South status.   
 
 
NORTH SOUTH North 
V 
Cases 
V 
 
 
Cases Controls Cases Controls South Controls 
Mean SD Mean SD Mean SD Mean SD 
Age 
(yrs) 
53.0 5.1 52.7 5.1 51.0 5.6 50.5 5.6 <0.01 0.17 
BMI 
(Kg/m2) 
27.2 3.4 
 
25.8 3.1 
 
27.0 3.3 
 
26.4 3.3 0.20 <0.01 
Blood 
Pressure 
(mmHg) 
- Systolic 
 
- Diastolic 
 
 
129.3 
 
82.3 
 
 
17.7 
 
9.8 
 
 
130.4 
 
84.0 
 
 
15.8 
 
8.5 
 
 
126.9 
 
81.5 
 
 
16.2 
 
10.6 
 
 
126.4 
 
84.4 
 
 
13.3 
 
8.7 
 
 
<0.01 
 
0.82 
 
 
0.87 
 
<0.01 
 
Smoking- 
Current/Ex 
(%) 
 
 
76.8 
 
 
2.0 
 
 
61.9 
 
 
2.3 
 
 
86.9 
 
 
1.4 
 
 
61.2 
 
 
2.0 
 
 
<0.01 
 
 
<0.01 
Diabetes- 
Type 2 (%) 
 
11.6 
 
1.5 
 
0 
 
- 
 
11.5 
 
1.4 
 
0 
 
 
- 
 
0.67 
 
<0.01 
Cholesterol 
(mmol/L) 
5.65 1.22 5.68 
 
0.96 5.18 1.11 
 
5.39 0.93 <0.01 0.06 
Triglyceride 
(mmol/L) 
 
1.99 0.83 1.52 0.58 1.79 0.72 1.39 
 
0.60 <0.01 <0.01 
The blood pressure and lipid parameters include those on anti-hypertensive and lipid 
lowering agents respectively 
 
There was no difference in the characteristics of those with and without genotype in any of 
the four groups (data not shown). 
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4.3 UCP2-866G>A  
 
4.3.1 Metabolic Markers by Genotype in controls 
 
There was no difference between genotype (Analysis followed recessive effect 
identified in NPHS; AA v GX) for any of the lipid parameters (cholesterol, 
triglycerides, or apoB) (Table 4.2) in either the North, the South or with both 
samples combined.   
 
Table 4.2: The differences between lipid profiles in healthy subjects for the UCP2-
866G>A variant in the HIFMECH study. 
*adjusted for centre 
1
log transformed 
2
square root transformed 
 
Although BMI (Kg/m2) was lower in AA subjects in the North (GX v AA 26.0 [3.1] v 
24.9 [3.2]; p=0.06) there was no difference in the South (26.4[3.2] v 27.0[3.0]; 
p=0.25).  However, as shown in Fig 4.1a, WHR was lower in AA homozygotes 
compared to G carriers in both the North, South and all controls combined (North: 
1.00[0.06] v 0.98[0.07]; p=0.03: South 0.95 [0.05] v 0.93 [0.07]; p=0.04: combined 
1.00[0.06] v 0.98[0.07]; p=0.003).  There were also significant differences in fasting 
insulin between genotypes with the previously identified genotype for prospective 
risk of type 2 diabetes (UCP2-866AA) associated with significantly lower insulin 
levels (pmol/l) in the North and in all controls combined but not significant in the 
South although the same trend was seen (North: 40.4[26.5] v 30.2[13.8]; p=0.02: 
South 37.4[23.5] v 32.9[23.0]; p=0.37: combined 40.3[24.6] v 32.3[18.6]; 
p=0.02)(Fig 4.1b).  This difference was no longer significant in the North or South 
 UCP2-866 North South Combined* 
Cholesterol 
(mmol/l) 
GG/GA 
AA 
P value 
5.67 (0.98) 182 
5.69 (0.85) 31 
0.93 
5.40 (0.92) 265 
5.34 (1.00) 36 
0.70 
5.70 (0.95) 447 
5.67 (0.93) 67 
0.81 
Triglycerides 
(mmol/l) 
GG/GA 
AA 
P value 
1.53 (0.58) 182 
1.49 (0.63) 31 
0.74 
1.38 (0.59) 265 
1.41 (0.67) 36 
0.76 
1.52 (0.62) 447 
1.52 (0.68) 67 
0.97 
apoB 
(mmol/l) 
GG/GA 
AA 
P value 
97.8 (23.2) 182 
92.8 (20.0) 31 
0.25 
94.1 (20.2) 265 
93.1 (20.3) 36 
0.79 
98.1 (21.7) 447 
95.2 (20.4) 67 
0.30 
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once adjusted for BMI, but remained so in all the controls combined (North: 
42.6[25.6] v 36.1[13.8]; p=0.15: South 39.1[21.7] v 32.2[22.1]; p=0.14: combined 
42.6[24.6] v 35.6[18.6]; p=0.03)(Fig 4.1b). 
 
 
Fig 4.1:  The association of the UCP-886AA genotype with a) lower waist hip ratio 
b) lower insulin secretion (unadjusted) and lower insulin secretion  adjusted for BMI 
 
4.3.2. Risk of cardiovascular disease and genotype association in cases 
 
The odds of being a case by UCP2-8AA, compared to GG+GA, using a conditional 
logistic regression model were a modestly higher odds ratio for Myocardial 
Infarction in the North of 1.30 [95%CI 0.76-2.23] but not in the South 1.00 [0.60-
1.68].   The risk for North and South combined was 1.19 [0.81-1.75]; p=0.38(Fig 
4.2).   In cases, the AA genotype was associated with significantly lower than  
cholesterol in the South [p=0.04] and higher in the North [p=0.05] but in the 
combined group no significant difference was seen.  Triglycerides were lower in AA 
subjects in both North and South and in the combined group the difference was 
statistically significant [p=0.05]. These differences may have occurred by chance 
but would be likely to weaken any association between the AA genotype and 
cardiovascular disease.  There were no other statistically significant associations in 
cases between metabolic markers and genotype [p=0.17-0.78]. (Table 4.3) 
a) Waist Hip Ratio
0.94
0.96
0.98
1
1.02
1.04
1.06
1.08
GG +GA AA
UCP2 -866 Genotype
b) Fastin insulin before and after 
adjustment for BMI
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GG +GA AA
UCP2 -866 Genotype
F
a
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n
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unadjusted Adjusted
p=0.02  p=0.03 
p=0.003 
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Fig 4.2:  The Odds ratio for Myocardial Infarction associated with the UCP2-
886G>A genotype in HIFMECH 
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Table 4.3: The association of the UCP2-866G>A genotype and metabolic markers 
in cases in the HIFMECH study. 
*adjusted for centre,
1
log transformed,
2
square root transformed 
 
 UCP2 North South Combined* 
BMI1  
(Kg/m2) 
GG/GA 
AA 
P value 
27.3 (3.4) 182 
26.8 (3.0) 39 
0.36 
27.1 (3.4) 249 
26.5 (3.0) 33 
0.31 
27.3 (3.4) 431 
26.8 (3.0) 72 
0.17 
WHR GG/GA 
AA 
P value 
0.98 (0.06) 182 
0.99 (0.05) 39 
0.19 
0.95 (0.06) 232 
0.95 (0.07) 31 
0.87 
0.98 (0.06) 414 
0.98 (0.06) 70 
0.40 
Cholesterol 
(mmol/L) 
GG/GA 
AA 
P value 
5.58 (1.21) 170 
6.00 (1.24) 37 
0.05 
5.23 (1.12) 237 
4.81 (0.91) 32 
0.04 
5.65 (1.16) 407 
5.67 (1.15) 69 
0.90 
(N/S Interaction 
p=0.005) 
Triglycerides1 
(mmol/L) 
GG/GA 
AA 
P value 
2.02 (0.83) 170 
1.87 (0.86) 37 
0.31 
1.82 (0.72) 237 
1.59 (0.70) 32 
0.08 
2.02 (0.81) 407 
1.82 (0.81) 69 
0.05 
apoB2 
(mmol/L) 
GG/GA 
AA 
P value 
106.3 (28.9) 
170 
111.8 (25.0) 37 
0.29 
97.3 (22.3) 237 
90.1 (20.9) 32 
0.08 
107.6 (25.9) 407 
106.7 (24.1) 69 
0.78 
Insulin1 
(pmol/L) 
GG/GA 
AA 
P value 
45.8 (30.7) 169 
38.1 (25.2) 36 
0.14 
57.8 (40.6) 145 
56.3 (45.9) 17 
0.88 
45.9 (31.4) 314 
40.1 (28.5) 53 
0.19 
Insulin1 (BMI 
adjusted) 
GG/GA 
AA 
P value 
42.0 (23.8) 166 
37.2 (21.0) 36 
0.24 
56.6 (37.7) 145 
57.7 (45.7) 17 
0.91 
42.0 (25.8) 311 
38.9 (25.0) 53 
0.41 
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4.4 UCP3-55C>T 
 
4.4.1  Metabolic Markers by Genotype in controls 
 
UCP3-55C>T genotype was not associated with differences in waist hip ratio, BMI 
or insulin.   The lipid parameters were unremarkable except the TT genotype was 
associated with higher apoB in the South (Table 4.4). 
 
 
Table 4.4: The association of the UCP3-55C>T genotype and metabolic markers in 
controls in the HIFMECH study.  
 
 UCP3 North South Combined* 
BMI1  
(Kg/m2) 
CC/CT 
TT 
P value 
25.8 (3.1) 221 
25.4 (3.5) 22 
P=0.51 
26.4 (3.2) 309 
26.2 (2.3) 11 
P=0.81 
25.8 (3.1) 530 
25.4 (3.1) 33 
P=0.49 
WHR CC/CT 
TT 
P value 
1.00 (0.06) 220 
1.01 (0.06) 21 
P=0.54 
0.95 (0.06) 200 
0.94 (0.09) 6 
P=0.65 
1.00 (0.06) 420  
1.00 (0.06) 27 
P=0.71 
Cholesterol 
(mmol/L) 
CC/CT 
TT 
P value 
5.74 (0.99) 204 
5.44 (0.96) 20 
P=0.19 
5.37 (0.93) 308 
5.84 (1.01) 11 
P=0.10 
5.71 (0.95) 512 
5.70 (1.03) 31 
P=0.92 
Triglycerides1 
(mmol/L) 
CC/CT 
TT 
P value 
1.51 (0.58) 204 
1.63 (0.78) 20 
P=0.40 
1.39 (0.62) 308 
1.42 (0.51) 11 
P=0.85 
1.52 (0.64) 512 
1.61 (0.70) 31 
P=0.46 
apoB2 
(mmol/L) 
CC/CT 
TT 
P value 
98.3 (23.1) 204 
95.8 (21.5) 20 
P=0.51 
93.9 (20.1) 308 
102.8 (23.6) 11 
P=0.03 
98.1 (21.6) 512 
99.8 (22.7) 31 
P=0.68 
Insulin1 
(pmol/L) 
CC/CT 
TT 
P value 
39.9 (25.5) 205 
37.3 (26.5) 20 
P=0.65 
36.1 (22.6) 202 
42.4 (27.3) 9 
P=0.45 
39.3 (24.9) 407 
39.7 (27.2) 29 
P=0.94 
Insulin1 (BMI 
adjusted) 
CC/CT 
TT 
P value 
43.0 (24.6) 205 
41.2 (21.8) 20 
P=0.75 
37.6 (21.2) 202 
45.3 (27.1) 9 
P=0.33 
42.0 (23.8) 407 
43.4 (24.0) 29 
P=0.76 
*adjusted for centre,
1
log transformed,
2
square root transformed 
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5.4.2  Risk of Cardiovascular disease and genotype association in cases 
 
There was a lower odds ratio for myocardial infarction associated with TT 
homozygotes of borderline significance in the North (OR[95%CI] 0.45[0.2-1.05]: 
p=0.06) but not so in the South (0.51[0.18-1.48]: p=0.22).  The odds ratio for 
myocardial infarction in the study combined was lower in those with the TT 
genotype (0.47[0.25-0.92]: p=0.03 
 
Fig 4.3:  The Odds ratio for cardiovascular disease associated with the UCP3-
55C>T  genotype in the HIFMECH study. 
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The UCP3-55TT homozygotes had lower mean cholesterol in the North and South, 
although the result was of borderline significance in the North (Cholesterol 
(mmol/L) CC +CT v TT: North 5.7[1.2] v 5.1[0.9], p=0.09; South 5.2[1.1] v 4.2[1.1], 
p=0.04; combined 5.7[1.2] v 4.9[1.0], p=0.01).  A similar association was seen with 
apoB but in the North the differences were not significant (p=0.22) (Table 4.5). 
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Table 4.5  The association of the UCP3-55C>T  genotype with metabolic markers 
in cases in the HIFMECH study. 
 
 UCP3 North South Combined* 
BMI1  
(Kg/m2) 
CC/CT 
TT 
P value 
27.2 (3.2) 209 
27.7 (5.0) 13 
P=0.57 
27.0 (3.3) 292 
25.3 (3.4) 5 
P=0.24 
27.2 (3.2) 501 
27.1 (4.6) 18 
P=0.87 
WHR CC/CT 
TT 
P value 
0.98 (0.06) 210 
0.98 (0.07) 12 
P=0.82 
0.95 (0.06) 272 
0.95 (0.08) 5 
P=0.95 
0.98 (0.06) 482 
0.98 (0.07) 17 
P=0.82 
Cholesterol 
(mmol/L) 
CC/CT 
TT 
P value 
5.70 (1.23) 198 
5.08 (0.90) 12 
P=0.09 
5.20 (1.11) 279 
4.15 (1.08) 5 
P=0.04 
5.68 (1.16) 477 
4.94 (0.95) 17 
P=0.01 
Triglycerides1 
(mmol/L) 
CC/CT 
TT 
P value 
1.99 (0.85) 198 
2.17 (0.64) 12 
P=0.49 
1.79 (0.72) 279 
1.61 (0.45) 5 
P=0.56 
1.99 (0.82) 477 
2.05 (0.60) 17 
P=0.76 
apoB2 
(mmol/L) 
CC/CT 
TT 
P value 
108.1 (28.5) 198 
98.0 (24.4) 12 
P=0.22 
96.8 (22.2) 279 
76.3 (20.3) 5 
P=0.03 
108.0 (25.6) 477 
94.4 (23.5) 17 
P=0.03 
Insulin1 
(pmol/L) 
CC/CT 
TT 
P value 
44.1 (29.6) 198 
50.3 (33.7) 11 
P=0.52 
56.0 (38.8) 170 
73.8 (66.1) 3 
P=0.50 
44.3 (30.1) 368 
52.0 (35.7) 14 
P=0.39 
Insulin1 (BMI 
adjusted) 
CC/CT 
TT 
P value 
41.5 (23.7) 194 
42.1 (22.2) 11 
P=0.93 
55.3 (36.8) 170 
76.9 (36.4) 3 
P=0.40 
41.3 (25.5) 364 
44.8 (23.1) 14 
P=0.63 
*adjusted for centre,
1
log transformed,
2
square root transformed 
 
.  
 
4.5 Discussion 
 
Analysis of the UCP2-866 variant in the HIFMECH study provides two important 
observations.  Firstly, these data confirm the previous studies in Europe [see table 
1.4c] showing that AA subjects are leaner [2% lower WHR] in both the North and 
the South, and secondly that AA subjects have lower fasting plasma insulin levels.   
In the healthy subjects the difference in fasting insulin levels persisted when 
adjusted for body mass index.  There was no other relationship between genotype 
and any of the adverse metabolic markers, suggesting that the effect of genotype 
variation is not through conventional risk factors for type 2 diabetes.   This 
association with β-cell dysfunction could have been replicated if the variant was 
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also associated with pro-insulin or insulin split products which are associated with 
early β-cell dysfunction but these were not available for this study sample. 
 
This study was underpowered to detect an association between genotype and 
cardiovascular risk.  The UCP2-866AA was associated with a modestly higher 
odds ratio for myocardial infarction in the North but not in the South.  This is in 
keeping with other data suggesting that the A allele is associated with risk of 
cardiovascular disease in healthy men (Dhamrait SS,2004) and carotid 
atherosclerosis in women (Oberkofler H,2005).  The A allele is also associated with 
higher markers of oxidative stress in men with type 2 diabetes (Dhamrait SS,2004).  
Why this association is seen more strongly in the North is not clear.   The mean 
WHR [%] was higher in the North [Controls 100 v 95 p<0.001; Cases 98 v 93, 
p,0.001] and this and other environmental factors such as diet could alter oxidative 
stress load.  The UCP2 gene promoter is induced by oxidative stress through both 
hypoxic and toxic pathways, and differences in oxidative stress load could alter the 
influence of UCP-2 promoter variants on transcription function (Krempler F,2002; 
Oberkofler H,2005). 
 
The association of the A allele with higher oxidative stress suggests that this allele 
is associated with lower “uncoupling”.  This is in contrast to the obesity and insulin 
data where the A allele is “protective” and associated with higher uncoupling.  This 
could be explained if the different alleles behave in different ways at baseline and 
under oxidative stress loads, such as that from cardiovascular risk factors. This is 
supported by the findings that THP-1 (macrophages)  and HUVEC (endothelium) 
cells (Oberkofler H,2005), compared to INSE-1 (Krempler F,2002) and Paz-6 cells 
(Esterbauer H,2001) show differences in transcription factor binding.     Different 
effects in different disease processes could also be explained by differential 
regulation of UCP2 in different tissues.  Indeed, in pancreatic cells [INSE-1] the 
effect of the UCP2A promoter construct is enhanced transcription under PAX6 
stimulation [which would be associated with diabetes], but  lower transcription in 
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COS-7 cells, which would be associated with higher oxidative stress [see Fig 7.2, 
page 210].   
 
The association of the UCP3TT genotype with type 2 diabetes does not seem to be 
explained by differences in conventional risk factors for type 2 diabetes or by 
markers of insulin resistance.  In healthy controls the only association of an 
adverse metabolic marker with UCP3 genotype was an association with higher 
ApoB in the South. The significance of this finding is uncertain given the number of 
comparisons performed.  The association of the UCP3 TT genotype with type 2 
diabetes must be explained through a mechanism not measured in the HIFMECH 
study.   
 
The association of the TT genotype with protection from myocardial infarction is a 
novel finding.  How the genotype associated with type 2 diabetes is also 
associated with cardiovascular disease is unclear and the association could be a 
chance finding.  The putative role of UCP3 in mitochondrial metabolism, protection 
from oxidative stress from over-nutrition, would also be expected to protect from 
cardiovascular disease.  This genotype was associated with increased prospective 
risk of diabetes in NPHSII (see chapter 4) The HIFMECH study is cross sectional 
in nature, this design is more susceptible to confounding than prospective studies.  
The association may have occurred as a result of a confounding factor, such as the 
association of lower cholesterol of 0.75mmol/l with the TT genotype in cases.  This 
association was seen both in the North and the South although was based on only 
17 TT homozygotes and was not seen in the NPHSII study.  The reduction of 
cholesterol from 5.68 to 4.94mmol/l (assuming a HDL of 1.0mmol/l) in a 65 year old 
normotensive, non-smoker reduces the 10 year risk of cardiovascular disease by 
13% (http://cvrisk.mvm.ed.ac.uk/calculator/framingham.htm) which would explain, 
at least in part, some of the lower risk observed.   The expression of UCP3 may 
also be stimuli or organ specific, as is the case with UCP2.  There is currently little 
information on the effect of UCP3 variants on UCP3 transcription and is based on 
small numbers (Schrauwen P,1999) or very rare variants (Chung WK,1999) and do 
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not provide much evidence of control of UCP3 expression.  If the association of the 
-55UCP3TT variant with risk of type 2 diabetes and protection from cardiovascular 
disease is replicated, then further work will be required to understand the 
mechanisms underlying these data. 
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5.1 Assays of Plasma Markers of Oxidative Stress in The Japanese 
American Family Study 
 
5.1  Introduction 
 
The association of risk of type 2 Diabetes associated with variation in UCP2 and 
UCP3 has been examined in chapters 3 and 4.  The UCP2  variant is 
associated with lower insulin secretion but the mechanism for this, and the 
mechanism for the risk associated with UCP3-55TT is as yet unclear.  It is 
possible that these genetic variants are associated with differences in non-
classical risk factors for type 2 Diabetes, more specifically the modification of 
oxidative stress.  
 
As described in chapter 1, living organisms have developed a wide range of 
complex anti-oxidant systems to counteract the damaging effects of reactive 
oxygen species.  The oxidative stress balance within an organism can be 
determined by several different methods.  A component of one of the anti-
oxidant systems can be measured directly or a component of the cell damaged 
by reactive oxygen species can be assayed.  Other methods rely on the 
concept of anti-oxidant capacity, which is estimated as the capacity of the 
sample to scavenge free radicals in a test solution, and represents the sum of 
the anti-oxidant systems. There are two main methods to determine anti-oxidant 
capacity, based on the ability of the sample to inhibit an oxidizing reaction or to 
drive a reducing reaction. 
 
The Japanese American Family (JAM) study is a family study to investigate risk 
factors for coronary heart disease and type 2 diabetes.  The Principal 
investigator of the study is Prof. Melissa Austin and the subjects were recruited 
in the United States of America, from in or around Washington, and were of 
Japanese descent (Austin MA,2004a).  The subjects are well characterised, and 
stored unthawed frozen plasma samples were available. The plasma markers of 
oxidative stress give an indication of the amount of free radical mediated 
damage present, and enable the examination of the factors that determine 
oxidative stress burden in this population.   The genetic component of type 2 
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Diabetes may in part be through modification of the body’s ability to generate or 
protect itself from oxidative stress. 
 
5.2 Aims 
 
1. To compare different methods of measuring anti-oxidant capacity with the 
aim of developing a method of measuring oxidative stress markers that was 
accurate and capable of handling a large number of samples.  
 
2. To measure markers of oxidative stress in plasma samples of subjects from 
the Japanese American Family Study. 
i) Examine the factors that predict levels of plasma markers of 
oxidative stress.  
ii) Determine the genetic contribution to plasma markers of oxidative 
stress by calculating heritability. 
iii) Examine if genetic variation in the UCP2-UCP3 gene cluster is 
associated with variation in levels of oxidative stress markers. 
 
 
5.3 The assessment of different methods to measure plasma markers 
of oxidative stress burden 
 
5.3.1 Methods 
 
Once the different types of method had been identified, a kit was selected for 
each method on the basis of practicality, cost and technical specifications.  
Products were compared from the major suppliers to this laboratory. 1) A 
glutathione/ reduced glutathione (Calbiochem;354103) assay was chosen as an 
assay of a single component of the anti-oxidant systems; 2) Total anti-oxidant  
Status (TAS- Randox; NX2332) as an oxidation reaction based on ABTS, 
Metmyoglobin and Hydrogen peroxide and 3) AOP-490® (Oxis; 21052) as a 
reducing reaction based on copper ions.  Detailed methods for each kit are 
illustrated in chapter 2.  These methods were also compared to the Total Anti-
oxidant Status (TOAS) method, based on ABTS, Horseradish peroxidase and 
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hydrogen peroxide, which was developed within this group from the method of 
Sampson et al.  
 
The plasma used for these studies was provided by members of the group.  
Blood was collected into EDTA-containing tubes and centrifuged at 3500g for 8 
minutes.  The plasma was separated and stored at -800C in microtubes until 
use.  The samples were stored by sample number only, no record was kept that 
would enable later identification of the sample. The inter-assay coefficient of 
variation (CV) was calculated by dividing the standard deviation by the mean 
and is expressed as a percentage.  Inter-assay variability was calculated on the 
basis of one of these samples repeated in the plate up to 40 times.  The 
correlation between the assays was calculated by assaying the same ten 
samples with each kit.  A different aliquot was used for each kit and the assays 
were performed on the same day. 
 
5.3.2 Results 
 
5.3.2a Calculation of inter-assay variation. 
 
The methods were all performed in accordance with the manufacturers 
instructions.  However, for the TAS kit this required samples to be run 
individually in 1ml cuvettes.  The method was modified to enable the use of the 
kit in a 96 well plate format by reducing the volume of reagents by 100.  This 
method uses similar volumes to the TOAS assay.  The dilution was tested by 
comparing the values obtained for the TAS control serum by both methods.  
There was no difference between the two samples (Fig 5.1).  The expected 
value was 1.55 [1.16-1.94] mmol/L .The cuvette method assayed this sample as 
1.44 [1.23-1.97], whilst the 96 well plate dilution method assayed this sample as 
1.31 [1.25-1.37].  There was no significant difference between the two methods 
(p=0.86). 
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Fig 5.1: Comparison of the 96 well plate modified method (n=20) of using the 
TAS reagents with the manufacturers recommended cuvette method 
(n=8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The inter-assay variation for the different methods is shown in Table 5.1.  The 
TAS CV was measured in plasma and for the control serum provided.   The 
Randox kit is supplied with more than one set of reagents.  Measurement of 
TAS for the control serum supplied was repeated alongside the measurement of 
TAS in the plasma sample.  The CV of the assay was lower when the second 
set of reagents was used (21% v 9%).  The time taken to assay 40 samples 
was also estimated (ie samples in duplicate in a 96 well plate, including 
controls, blanks, etc).  The CV for the TOAS was lower (4.1%) but the 
glutathione assay had the lowest (1.0%).  However, this method required the 
longest time and the samples needed pipetting and preparation at collection.   
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Table 5.1: The interassay CV for the oxidative stress assays. 
 
Assay Sample N Mean 
Std 
Deviation 
CV(%) 
Time for 
40 
samples 
TAS (mmol/l)  
Control 
1 
20 1.31 0.28 21.2 15 mins 
 
Control 
2 
20 1.77 0.16 9.0  
 Plasma 14 1.04 0.09 9.5  
TOAS(%) Plasma 14 53.3 2.20 4.1 25 mins 
AOP-490 
(mmol/L) 
Plasma 8 0.16 0.03 21.1 35 mins 
Glutathione 
Ratio 
EDTA 
Blood 
20 21.25 0.22 1.0 60 mins 
 
 
5.3.2b Relationship between different methods 
 
A total of 10 volunteers had plasma taken on the same day and stored in 
separate aliquots for assay with each method.  The samples were defrosted at 
the same time and run on the same plate.  Linear regression was used to 
determine the relationship of the methods.  There was no significant correlation 
between any of the methods (Table 5.2) with the highest value seen being 
between TAOS and the GSH/GSSG method (r=0.32, p=0.37).   
 
Table 5.2: The relationship between different methods of measuring plasma 
markers of oxidative stress in 10 volunteers. (Pearson correlation)  
 
 AOP-490 [p] TAOS [p] TAS [p] GSH:GSSG 
GSH:GSSG 0.12 [0.7] -0.32 [0.4] 0.11 [0.8] 1 
TAS 0.25 [0.5] -0.79 [0.8] 1   
TAOS 0.16 [0.7] 1     
AOP-490 1       
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5.3.3 Discussion 
 
The assays available for the determination of oxidative stress vary in their cost 
and ease of use.  The difference in oxidative stress levels between subjects 
with different genotypes is likely to be small, and therefore the chosen method 
needs to be simple enough to perform on a large number of samples.  The ‘in-
house’ TOAS assay showed the least variability, but is the most familiar, and 
the effect of familiarity is likely to explain the significant improvement in TAS 
variability between the initial assay and the repeat assay of the provided control 
serum performed with the assay of the plasma sample. The glutathione assay 
requires pre-preparation of samples at the sampling site and this makes it 
unsuitable for large scale studies.  The lack of variability may also reflect the 
fact that oxidized GSH in healthy volunteers is found at the lower level of 
detection for the kit, and this may reflect lack of ability to discriminate between 
samples rather than laboratory precision. The AOP-490® test would also be 
suitable, as the CV is likely to improve with increased familiarity.  However, the 
much higher cost of nearly £1.65 per sample, compared with 22p for TAS and 
5p for TOAS, made this impractical to perform in large scale genetic association 
studies.                  
 
 
 The use of any combination of these methods would be desirable as they are 
detecting different spectrums of anti-oxidant activity, as indicated by the low 
correlation between them.    Therefore, the combination of TOAS and TAS was 
chosen, even though the only difference in the two tests is the catalytic enzyme.  
The correlation of value in 10 healthy subjects was essentially negligeable (-
0.08)  and the spectrum of the anti-oxidant system that each is measuring 
appears likely to be  sufficiently different for them to independently validate 
findings.    
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5.4 Plasma Oxidative stress markers in the Japanese American Family 
Study 
 
5.4.1 Methods 
 
A previously unthawed plasma sample was used for the plasma markers of 
oxidative stress.  The assays were selected on the basis of the previous work in 
this chapter.  Variables were transformed to normal where appropriate.  
Heritability was calculated using The Statistical Analysis for Genetic 
Epidemiology (SAGE) program and was carried out by Brendan Pierce in 
Washington, using an analytical strategy suggested by myself.  Genotype was 
determined using Taqman© Technology as previously described in chapter 2.   
 
 
5.4.2 Results 
 
Serum was available for 490 subjects.  TOAS was successfully measured in 
476 subjects and TAS in 490, the discrepancy arises mainly due to the rejection 
of samples with significant haemolysis which TAS can correct for but TOAS 
cannot.   The analysis was limited to the Nissei and Sansei generations due to 
the very small numbers in other generations; in total this excluded only four 
subjects. The characteristics of the subjects are shown in table 5.3.  The Nissei 
generation was nearly thirty years older and as a result had higher blood 
pressure, lipids and rates of type 2 diabetes.  The heritability calculation was 
based on these subjects recruited from 68 separate Japanese-American 
families as defined on page 100.      
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Table 5.3: Baseline characteristics of the Japanese American Family Study 
 
 Total Nissei Sansei 
 
N= 490 215 275 
Gender  
[M/F] 
215/275 [43.8%] 95/130 [42.2%] 120/141 [46%] 
Age  
[years] 
54.5       [16.5] 69.7     [8.8] 41.6       [7.9] 
LDL  
[mg/l] 
116.9     [31.2] 120.6   [32.8] 113.75   [29.6] 
HDL  
[mg/l] 
54.0       [14.9] 54.5     [15.5] 53.6       [14.6] 
Triglycerides 
[mg/l] 
136.4     [90.2] 151.0   [82.9] 123.6     [94.8] 
Systolic BP 
[mmHg] 
122.0     [19.1] 131.1   [20.7] 113.9     [12.9] 
Diastolic BP 
[mmHg] 
76.1       [10.2] 77.5     [9.9] 74.9      [10.3] 
BMI 
[kg/m
2
] 
24.5       [3.7] 24.7     [3.6] 24.3      [3.9] 
Smokers – 
Never/Ex 
Current 
 
276/153 
40 [8.5%] 
 
103/97 
14  [6.5%] 
 
170/56 
25 [9.9%] 
Diabetes Y/N 49/441[11%] 42/183 [18%] 7/254 [2.68%] 
Mean [SD] 
 
5.4.2a  Relationship between TAS and TOAS 
 
Mean TOAS [SD] was 53.34% [8.5] and mean TAS was 1.36mmol/L [0.22]. 
TOAS was transformed to the square to normalize the distribution. There was a 
weak but significant positive correlation between the two measures (r=0.076, 
p<0.001). Therefore, only 7.6% of the variability in either marker can be 
explained by a relationship with the other (Fig 5.2).  
 
 
 
 
 
 181 
Fig 5.2: The relationship between plasma TAS and TOAS in the Japanese 
American Family Study  
 
 
sqtoasr= √ Plasma TOAS 
plasma randox = plasma TAS 
 
5.4.2b Oxidative stress markers and biochemical characteristics 
 
The mean TOAS (mean[SD] 54.6[30.8] v 53.3[28.2]: p=0.009) and TAS (1.41 
[0.2] v 1.31[0.2]:p= 0.0001) were both lower in women than in men  (Fig 5.3) 
and TAS but not TAOS was lower in the Sansei generation (6%).  There were 
no differences for mean TAS or TOAS by Diabetes or smoking status [Table 
5.4].   
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Fig 5.3:  The mean of two markers of oxidative stress by gender in the 
Japanese American Family Study. (Mean [SE]) 
TOAS TAS
P=0.009 P=0.0001
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Table 5.4:  The comparison of mean TOAS and TAS by baseline characteristics in the 
Japanese American Family Study. 
 
 TOAS [%] TAS [mmol/L] 
Diabetes Y  
                (n=49) 
               N  
                (n=441) 
52.81[29.96] 
 
54.15[32.61] 
0.35 1.37[.223] 
 
1.36[.217] 
0.70 
Generation: Nissei 
                    (n=215) 
                   Sansei       
                   (n=275 ) 
54.22[30.17] 
 
53.82[18.43] 
0.50 1.40[.211] 
 
1.32[.218] 
0.0013 
Smokers  Current 
                 (n=40 ) 
                 Ex 
                 (n=153 ) 
                 Never  
                 (n= 276) 
53.79[27.55] 
 
54.21[30.28] 
 
53.95[29.10] 
0.92 1.33[.235] 
 
1.38[.222] 
 
1.34[.214] 
0.29 
Mean [SD] 
 
 
Simple linear regression showed a statistically significant correlation between 
TAS and triglycerides [ln], HDL cholesterol [Square], LDL cholesterol [Square 
root], age, Systolic Blood pressure (SBP[reciprocal]) and BMI.  A significant 
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correlation with TOAS was only seen with triglycerides and systolic blood 
pressure.  The relationship in all cases was weak, with the largest R2 of 4% 
[Table 5.5].  Where a correlation was described with both TAS and TOAS, i.e. 
for triglycerides and SBP, this was in opposite directions, however, the 
correlation was weak in both cases and the line of best fit was close to 
horizontal.  
 
Table 5.5: Correlation between oxidative stress markers and metabolic markers in the 
Japanese American Family Study. 
 
 TOAS TAS TAS V 
TOAS 
 Β R2 p Β R2 p  
Triglycerides -0.11 0.03 0.0001 0.502 0.03 <0.00001 <0.00001 
HDL  0.007 0.001 0.16 -0.857 0.03 <0.00001 <0.00001 
LDL  0.13 0.004 0.08 0.45 0.002 0.005 0.11 
AGE 0.078 0.0004 0.37 14.81 0.04 <0.00001 0.0001 
SYS BP -0.010 0.007 0.04 0.274 0.003 0.005 0.01 
BMI 0.13 0.001 0.53 3.32 0.04 <0.00001 0.001 
 
 
The ability of the two assays to measure the same signal was examined by 
comparing the distribution of the residuals.  In all cases these were significantly 
different.  In total 10 variables were examined and the two markers of plasma 
oxidative stress gave the same answer in 3 only.  However, using best subsets 
regression [Minitab V14] to identify the best multiple regression model the same 
independent predictors were identified for both TAS and TAOS. The amount of 
variability in oxidative markers due to the five identified predictors [age, sex, 
Triglycerides, BMI and systolic blood pressure] was R2 =7.0% for TOAS and 
11.9% for TAS [Table 5.6]. 
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Table 5.6:   The best multiple regression model for both TOAS and TAS as identified 
by best subsets regression [Minitab v14] in the Japanese American Family Study 
 
 
 
5.4.2c Heritability 
 
The familial correlation coefficients for both measures of total anti-oxidant status 
are shown in table 5.7.  There was a significant correlation between parent-
offspring and sibling pairs, indicating that there is likely to be some genetic 
determinant of plasma markers of oxidative stress.  However, the highest 
correlations were between spouses [TAS 0.60 (0.39-0.81); TOAS 0.50 (0.25-
0.50)].     
 
Table 5.7:  Familial correlations for two plasma markers of oxidative stress in the 
Japanese American Family Study. 
 
 TAS (RANDOX) TOAS (In-house) 
Pairs Correlation Coefficient 
(95% CI) 
Pairs Correlation Coefficient  
(95% CI) 
Unadjusted Adjusted Unadjusted Adjusted 
Spouse 
pairs 
41 0.60 
(0.39, 81) 
0.58 
(0.37,0.79) 
38 0.50 
(0.25,0.75) 
0.50 
(0.25,0.75) 
Parent : 
offspring 
287 0.28 
(0.11,0.45) 
0.29 
(0.13,0.45) 
266 0.26 
(0.09,0.43) 
0.27 
(0.10,0.44) 
Sibling 374 0.36 
(0.20, 52) 
0.32 
(0.16,0.48) 
337 0.30 
(0.14,0.46) 
0.29 
(0.13,0.45) 
 
The genetic variance component [SEM] for TAS was 0.03 [0.0045] and for 
TAOS was 31.41 [6.98].  After adjustment for age and gender the genetic 
variance component for TAS was 0.02 [0.004] and 33.35 [7.50] for TOAS.   The 
 TOAS TAS 
Β P Β p 
Trigs -332.8 <0.0001 0.05 0.009 
AGE 9.14 0.001 0.003 <0.0001 
SYS BP -149.4 0.008 -0.038 0.007 
BMI 21.25 0.061 0.007 0.008 
Gender -219.8 0.007 -0.091 <0.0001 
R2 =  0.0699  11.93 
P=  <0.0001  <0.0001 
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heritability estimates for the TAS kit and in-house TOAS were 0.56 [p<10-7] and 
0.48 [p<10-7] respectively.  When adjusted for age and gender these results 
were essentially unchanged [TAS= 0.54, [p<10-7] and TOAS = 0.49 [p<10-7]; Fig 
5.3].    There was also a significant variance component due to the marital 
relationship, although less than the genetic component [TAS 0.02 [0.003]; 
TOAS 27.23 [7.39] and TAS 0.02 [0.003]: TOAS 33.90 [7.76] adjusted for age 
and gender.   The lower heritability for TOAS may be in part due to estimation of 
a random variance component  for TOAS 7.25 [9.01] not seen for TAS although 
this was not significant [p>0.05] when adjusted for age and gender (0.18[9.44]). 
 
Fig 5.4:   The heritability of two plasma markers of oxidative stress in the 
Japanese American Family Study. 
0.44
0.46
0.48
0.5
0.52
0.54
0.56
0.58
TAS TOAS
  Unadjusted Adjusted [Age + gender]
All estimates p<10-6
 
5.4.2d UCP2-UCP3 genotype and markers of oxidative stress. 
 
UCP2-866G>A and UCP3-55C>T genotyping was restricted to these subjects in 
whom plasma was available.   Genotype was obtained in 94% and 95% of 
subjects for UCP2-866 and UCP3-55 respectively.  Genotype frequencies were 
as predicted from Hardy Weinberg proportions [Table 5.8].  There was no 
difference in genotype frequencies by generation [p>0.05].   
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Table 5.8: UCP2 -866G>A and UCP3-55C>T genotype frequencies in the Japanese 
American Family study.   
UCP2 GG GA AA Undetermined 
Total 142  224 102 12 
Ninsei 63 106 49 2 
Sansei 79 118 52 9 
UCP3 CC CT TT Undetermined 
Total 201 208 52 18 
Ninsei 93 93 26 8 
Sansei 108 115 26 9 
 
There were no significant differences in any of the baseline characteristics by 
either genotype [Table 5.9]. 
 
 
Table 5.9:  Baseline characteristics by genotype in the Japanese American Family 
Study. 
UCP2 GG GA AA  
Age  52.3  [16.2] 55.0 [16.1] 56.4 [16.7] 0.11 
Triglycerides 132.0[91.1] 142.48 [96.8] 136.0 [78.3] 0.40 
HDL 53.9 [14.6] 54.0 [15.0] 52.85 [15.6] 0.58 
LDL 113.1 [31.4] 117.3 [31.2] 121.1 [31.88] 0.07 
BMI 24.44 [3.75]  24.69 [3.87] 24.51 [3.46] 0.79 
SYS BP 120.7 [17.45] 123.6[20.2] 122.3 [19.0] 0.67 
Gender M:F 52/50 99/125 59/83 0.33 
Nissei/Sansei 49/52 106/118 63/79 0.52 
Diabetes N/Y 89/13 203/21 127/15 0.64 
SMOKING 
curr/Ex/Never 
3/39/54 25/67/123 9/44/84 0.07 
UCP3 CC CT TT  
Age  53.8  [16.1] 54.4 [16.8] 55.6 [14.8] 0.76 
Triglycerides 131.5[85.7] 142.54 [95.1] 147.1 [98.8] 0.53 
HDL 5.41 [15.2] 52.9 [15.0] 51.75 [13.6] 0.17 
LDL 115.9 [32.6] 116.8 [30.6] 121.5 [31.28] 0.56 
BMI 24.11 [3.54]  24.92 [4.01] 24.81 [3.29] 0.08 
SYS BP 122.2 [20.32] 121.2[18.1] 126.9 [17.8] 0.06 
Gender M:F 84/117 90/119 28/24 0.29 
Nissei/Sansei 93/108 93/115 26/26 0.81 
Diabetes N/Y 179/22 189/20 46/6 0.84 
SMOKING 
curr/Ex/Never 
18/53/121 15/73/110 4/21/26 0.24 
Mean [SD]: Units as in Table 5.3. 
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There was no relationship between UCP2-866 genotype and either TOAS 
[GGvGAvAA: %[SD] : 54.4[29.0] v 53.8[29.0] v 54.0 [30.6];p=0.40] or TAS 
[mmol/l [SD]: 1.35[.22] v 1.35[.21] v1.38[.22]; p=0.32].  There was also no 
relationship between UCP3-55 genotype [CCvCTvTT] and either marker of 
oxidative stress [TOAS. 54.0[29.6] v 53.8 [28.7] v 54.6 [30.5];p= 0.47: TAS 
1.35[.22] v 1.35 [0.21] v 1.40 [0.22]; p=0.24] [Fig 5.4]. 
  
Best subset regression analysis has previously identified the best predictive 
model for both the markers of oxidative stress contained the same five 
variables.  The addition of the genotype data to this model [Table 5.10] made no 
significant difference in the predictive value of the model if the genotype data 
was added separately [Model 2 = addition of UCP2 genotype; Model 3 = 
addition of UCP3 Genotype] or combined [Model 4 = Addition of both UCP2 and 
UCP3 genotype]. The largest effect seen was the inclusion of UCP2 genotype 
to the TAOS model increased the R2 from 6.99% to 7.5% (p=0.66)    There is no 
association with variants in the UCP2-UCP3 gene cluster with plasma markers 
of oxidative stress in the Japanese American Family study. 
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Table 5.10:  Multiple regression models and determinants of plasma markers of 
oxidative stress in the Japanese American Family Study.  
 
 
TOAS Model 1 Model 2 Model 3 Model 4 
Β p Β p Β P Β p 
Trigs -332.8 <0.0001 -345.4 <0.0001 -349.5 <0.0001 -380.7 <0.000
1 
AGE 9.14 0.001 9.77 0.01 9.58 0.001 9.07 0.002 
SYS BP -149.4 0.008 -148.6 0.03 -146.9 0.009 -133.4 0.021 
BMI 21.25 0.061 21.39 0.10 21.11 0.067 21.98 0.059 
Gender -219.8 0.007 -224.2 0.01 -221.4 0.008 -180.4 0.034 
UCP 2 
GA 
AA 
  
 
 
-61.9 
14.6 
 
0.54 
0.89 
   
-18.6 
106.7 
 
0.86 
0.42 
UCP 3 
CT 
TT 
    
. 
 
0.25 
119.4 
 
0.99 
0.37 
 
49.71 
178.4 
 
0.60 
0.23 
R2 = 0.0699  0.075  0.0697  0.0705  
P= <0.0001  <0.0001  <0.0001  <0.0001  
V Model 
1 
  0.66  0.64  0.67  
 
 
TAS Model 1 Model 2 Model 3 Model 4 
Β p Β p Β P Β p 
Trigs 0.05 0.009 0.46 0.19 0.05 0.011 0.45 0.023 
AGE 0.003 <0.0001 0.003 <0.0001 0.003 <0.0001 .0031 <0.000
1 
SYS BP -0.038 0.007 -0.332 0.19 -0.040 0.006 -0.368 0.012 
BMI 0.007 0.008 0.007 0.008 0.007 0.009 0.007 0.009 
Gender -0.091 <0.0001 -0.85 <0.0001 -0.081 <0.0001 -0.828 0.000 
UCP 2 
GA 
AA 
   
-0.26 
-0.003 
 
0.31 
0.89 
   
-0.02 
0.009 
 
0.45 
0.78 
UCP 3 
CT 
TT 
     
-0.0002 
0.32 
 
0.99 
0.35 
 
0.009 
0.38 
 
0.69 
0.32 
R2 = 11.93  11.12  10.79  10.59  
P= <0.0001  <0.0001  <0.0001  <0.0001  
V Model 
1 
  0.49  0.61  0.63  
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5.5  Discussion 
 
The examination of plasma markers of oxidative stress in the Japanese 
American Family study confirmed the observation in the kit comparison work 
that  the two methods show a low correlation even though they  use similar 
reactions.  This is likely to be due to differences in affinity of the components of 
the anti-oxidant system and the enzyme involved, in this case horseradish 
peroxidase and metmyloglobin peroxidase.   This difference has led some 
authors (Block G,2006: Schlesier K, 2002) to suggest that two markers should 
be reported to confirm the effect of a studied variable on plasma markers of 
oxidative stress.   
 
The use of this strategy in the Japanese American Family study was, in part, 
successful.  A high heritability was seen for both TAS and TOAS markers and 
familial correlations suggested that some of this may be in part due to similar 
diet and environment, as the highest familial correlation was seen in spouse 
pairs.  This high level of heritability is in keeping with a previous study using an 
ABTS and metmyoglobin based method (Wang XL,2001).  This study was also 
a family study with a Mexican American sample, although they had not yet 
developed cardiovascular disease.  In subjects with a higher environmental 
oxidative stress burden, a higher percentage of the unexplained variation in 
TAS was explained by genetic factors.    The slightly higher estimate of 
heritability for the Japanese American Family study may be in part due to the 
higher oxidative stress burden increasing the genetic influence.   
 
However, the comparison of correlation with metabolic parameters recorded 
was weak and not consistent between the two methods.   The failure to 
demonstrate likely associations with smoking and diabetes status may be due 
to study power or the use of therapy for primary or secondary prevention, which 
would be expected to lower oxidative stress burden.  Targets for blood pressure 
and lipid lowering therapy are more demanding in patients with type 2 diabetes, 
and a number of these drugs, including statins, aspirin and ace inhibitors have 
been shown to reduce the oxidative stress burden (Ceriello A, 2006).  The lack 
of association with oxidative stress markers and smoking is based on only forty 
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[8%] current smokers and no stratification of amount of smoking was included in 
the study or an assessment of how recently participants had become ex-
smokers.  These factors would weaken the strength of an association present 
and may explain why none was found.   There was also no stratification of 
severity of diabetes to indicate how much hyperglycaemia is present, as it is this 
that is likely to be associated with plasma markers of oxidative stress per se.  
The plasma marker of oxidative stress has been associated with diabetes 
medication but not the diagnosis of diabetes, suggesting that in this case that 
diabetes medication is acting as a surrogate for diabetes severity.   This is the 
fourth study across a variety of samples selected from Finland (Alho H,1999), 
China (Woo J, 1997) and Mexican Americans (Wang XL,2001) that describes 
lower plasma markers of oxidative stress in women despite lower risk of 
cardiovascular disease.  Lower levels of anti-oxidant capacity in women despite 
lower risks of coronary artery disease may be due to the protective effect of 
oestrogen being through anti-oxidant components of low affinity with the assays 
used, or through other mechanisms.  In men the anti-oxidant levels present may 
have been stimulated to higher levels given an increased burden of oxidative 
stress.  This paradoxical difference is worthy of further study.  
 
Multiple regression demonstrated the best model for predicting oxidative stress 
was based on the five variables of triglycerides, age, systolic blood pressure, 
BMI and female gender.  However, the variation in these factors only explained 
11.9% of the variation in TAS and 7.0 % of TAOS suggesting that other non-
measured factors are important. These are likely to be diet and exercise, 
alcohol consumption and use of medication.  
 
The addition of genotype data did not improve the model and mean TAS or 
TOAS did not differ by genotype, including with the use of a recessive model.  
There are a number of possible reasons for this.  
 
This is a family study and we have made no allowance for the fact that many of 
the subjects share a relationship with others as this would have also reduced 
the power of the study.  The UCP2 -866A variant is known to function differently 
under different conditions (Oberkofler H, 2005) and the effect on plasma 
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markers of oxidative stress is greater when there is a higher environmental load 
of oxidative stress production.  Forty three percent of the sample is from a 
younger generation with lower blood pressure and less adverse lipid profiles as 
well as low rates of diabetes.  Under this low burden the differences in function 
between the two alleles may be too small to detect.  We have used two different 
plasma markers of oxidative stress and they have correlated poorly with each 
other and with adverse metabolic markers.  These markers in effect measure 
what is left of the anti-oxidant systems in plasma as a surrogate for the 
production of ROS.  Uncoupling proteins are found in the mitochondrial 
membrane and changes in mitochondrial oxidative stress may have significant 
effects on mitochondrial function without detectable changes to other areas of 
the cell of the extracellular matrix.  This will make the differences between 
genotype undetectable using this method at early stages in the disease 
process, whilst it is possible to detect them later such as when cardiovascular 
disease has developed (Dhamrait, 2004).  The number of rare homozygotes is 
low, especially for the UCP3-55C>T variant with only 52 (10.6%) rare 
homozygotes in the study.  This current sample size gives only a 65% percent 
chance of detecting an association at 80% power [p=0.05] based on these 
means.   
There is also the possibility that these variants do not behave in the same way 
in subjects of Japanese descent.  Although, the frequency of the UCP2-866A 
allele is consistent across a number of European samples [0.30-0.40] as well as 
the Middle East [Iran (Akrami SM, 2007)], North India (Rai E, 2007) and Taiwan 
(Wang TN, 2007) the rare allele frequency in other ethnic groups including 
Korean (Yoon Y, 2007) and Japanese samples (Ji Q,2004)  has been 
consistently higher [0.45-0.50].   In these samples the -886A has not been 
associated with type 2 diabetes although it has been found in association with 
hypertension and triglycerides as well as lower weight loss on a low calorie diet.  
The frequency of the rare allele differs between the Northwick Park Heart Study 
and the Japanese American Family study [0.37 v 0.46;p<0.01].   The 
relationship between UCP2 genotype and plasma markers of oxidative stress 
was reported in a sample from the Northwick Park Heart study (Dhamrait S, 
2004) and such an association may not be present in Japanese Americans.    
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The UCP3-55T has been less widely studied in Japanese samples and there 
seems to be no difference in rare allele frequency between European and 
Korean samples.  However, the rare allele frequency in the Northwick Park 
Heart Study is lower than the Japanese American Family Study [0.22 v 0.34; 
p<0.05] suggesting that the populations are distinct at the UCP2-UCP3 gene 
cluster. Further work is required to determine which are the important variants in 
samples of Japanese ancestry are and to determine if variation at the UCP2-
UCP3 also is associated with type 2 diabetes. 
 
In summary, plasma markers of oxidative stress are highly influenced by 
genetic variation and this may explain the failure of anti-oxidant interventions in 
clinical settings.  Environmental influences on plasma markers of oxidative 
stress are poorly understood and expected factors, such as diagnosis of 
diabetes, are not always associated with changes in plasma markers of 
oxidative stress.  The finding of an association with variation in the UCP2-UCP3 
gene cluster was not replicated in a sample of Japanese descent. 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SIX 
 
FUTURE WORK – DEVELOPING A MODEL TO STUDY GENETIC INFLUENCES 
ON THE MODIFICATION OF OXIDATIVE STRESS 
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6.1 The study of genetic influences on the modification of oxidative stress 
 
6.1.1 Introduction 
 
Genes that modify oxidative stress, either through the augmentation of anti-oxidant 
defenses, or through promoting reactive species production, would be potential 
candidates for being important in the aetiology of type 2 diabetes or cardiovascular 
disease or both.  Gene association studies that identify such candidates do not 
give information on the direction of causality or on the potential mechanisms.  
Further investigation is required to demonstrate that the gene variant is associated 
with a change in gene function.  Investigation of the pathophysiological effect of 
this change in function can give insight into the mechanisms of these complex 
disorders and open up new therapeutic windows.  The evidence from previous 
chapters suggests the UCP2-866G>A and UCP3-55C>T variants are good 
examples of variants with an influence in gene function, and that both are 
associated with complex diseases and are associated with differences in markers 
of oxidative stress.  The investigation of how individuals with different variants 
handle an oxidative stress load would give us further understanding of their role in 
health and disease. 
 
6.1.2  Aims 
 
To develop an experimental model that will enable the study of the effect of genetic 
variation on oxidative stress burden.   The differences between genotype are 
expected to be small, therefore, the number of subjects required to demonstrate a 
difference between two genotypes would require a model that is easy to perform 
on a number of subjects.   
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6.2  Oral Glucose Tolerance Test 
 
6.2.1  Methods 
 
An oral challenge was thought to be the simplest and most practical way of 
inducing an oxidative stress burden.  Oxidative stress markers provide the most 
efficient way of assessing this.  A glucose load has previously been shown to 
induce an increase in markers of oxidative stress (Sampson MJ,2002).  Volunteers 
were recruited from the group and staff of the department of diabetes and 
endocrinology (UCLH).  A 75g oral glucose tolerance test was performed, with the 
glucose administered in the form of lucozade.  Plasma was sampled at 10 minute 
intervals for 3 hours to study the glucose and oxidative stress [ROS] response 
further, and identify an ideal time point for sampling when comparing genotypes. 
 
6.2.2 Results 
 
A total of 10 volunteers, age range 25-57 attended for the study.  Fasting glucose 
was 5.2 mmol/l (range 4.6-6.5mmol/l) and peaked at 20 minutes (8.4mmol/l[6.1-
12.6]) returning to baseline at 20 minutes (Fiq. 6.1).  
 
Fig 6.1: Mean glucose in healthy volunteers over 3 hours following a 75 g oral 
glucose load   
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There was no association between time and plasma TAOS (Kendalls Tau test 
p=0.82) (Figure 6.2)  
 
 
Fig. 6.2: Plasma TAOS over 3 hours after a 75g oral glucose load in healthy 
volunteers. 
       
 
25
35
45
55
65
0 20 40 60 80 10
0
12
0
14
0
16
0
18
0
Time (minutes)
P
la
sm
a 
TA
O
S 
%
 (9
5%
CI
)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine if the failure to demonstrate a change in markers of oxidative stress 
was due to the marker being used, a subgroup of subjects (n=3) were used to 
measure F2-isoprostanes by gas chromatography-mass spectrometry before and 
after in-vitro stimulation with SIN-1.  This is a peroxynitrate releasing compound 
generating superoxide and nitric oxide which stresses the anti-oxidant components 
of the plasma and will generate further F2-isoprostanes, especially if the anti-
oxidant components have already been depleted by a recent challenge  
(Ferraro B,2003).  There was no change in F2-isoprostanes over time (Fig. 6.3) in 
the first three samples and no further subjects were assayed. 
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Fig. 6.3: Plasma F2-isoprostanes at baseline and after SIN-1 exposure at 20 
minute intervals over 3 hours after 75g oral glucose load in healthy volunteers. 
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6.2.3 Discussion 
 
 
The oral glucose tolerance test did not induce a measurable change in oxidative 
markers in healthy volunteers.  This challenge would, therefore, not be useful to 
study genetic differences.   There are a number of reasons why the oral glucose 
tolerance test failed to induce a change.   The age range of the volunteers was 
wide but the majority were young (mean 34.4) and a number undertake regular 
exercise (n=5[50%]).  Although, after exercise there are higher levels of oxidative 
stress, exercise also stimulates the expression of anti-oxidant defenses, and after 
repeated bouts of exercise the anti-oxidant systems adapt, with higher de novo 
synthesis of anti-oxidant defences, so these individuals may not show increased 
oxidative stress under this stimulus (Ji LL,2002). This also means that they are 
likely to be relatively insulin sensitive, and the peak glucose, and the area under 
the curve for the glucose excursion would be low, so that the impact of the 
challenge would be less.  The oral glucose tolerance test has induced a change in 
F2-isoprostanes in subjects with type 2 diabetes but the peak glucose in this study 
was 21.1mmol/L (Sampson MJ,2002). 
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 The appearance of altered membrane components after oxidation takes about six 
hours.  The shorter time course may mean that the altered cellular anti-oxidant 
components has not yet had time to equilibrate with  plasma components and that 
this is why no difference was detected.   The use of SIN-1 to stress the plasma 
should overcome this but this still made no difference (Ferraro B,2003).   
 
 
6.3 Meal rich in used cooking oil 
 
6.3.1 Methods 
 
The failure to induce adequate oxidative stress with a glucose load led to the 
examination of a fat-based challenge.  Review of the literature led to the selection 
of a meal rich in used cooking oil, which when given to healthy volunteers induced 
endothelial dysfunction.  This was not induced when unmodified cooking oil was 
used, suggesting that used cooking oil provides the strongest challenge (Williams 
MJA,1999).  The failure to show a difference in healthy volunteers may have been 
in part due to the failure to induce significant metabolic abnormalities.  To 
overcome this, a sample of patients with type 2 diabetes was selected from the 
UDACS study.   Subjects attended fasting and were given the meal as detailed in 
chapter 2.  Blood was sampled every hour for four hours for glucose, NEFA and 
markers of oxidative stress.  To improve the characterization of changes in anti-
oxidant capacity it was decided to use more than one oxidative stress marker 
(Block G,2006). 
 
6.3.2 Results 
 
The baseline characteristics for the subjects that attended the fatty meal challenge 
are shown in table 6.1.  The subjects are older than the previous study and show a 
wide range of metabolic derangement.  They show a wide range of metabolic 
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control of both glucose and lipid parameters.  Baseline markers of oxidative stress 
also showed a wide range (TOAS 50%-70% and TAS 1.26-1.93 mmol/L). 
 
Table 6.1: Baseline characteristics of the subjects in the fatty meal pilot study 
 (n=9) 
  Mean    + Standard 
Deviation 
Range 
Age (years) 62.5 6.1 54-74 
BMI (kg/m2) 26.6 4.5 21.7-32.6 
Glucose (mmol/l) 10.3 5.3 7.2-24.1 
Hba1c (%) 8.1 1.5 6.3-11.3 
HDL cholesterol (mmol/L) 1.8 0.8 0.9-3.2 
LDL cholesterol (mmol/L) 2.1 1.0 0.3-3.8 
Triglycerides (mmol/L) 4.6 1.1 2.8-5.9 
NEFA (mmol/L) 0.46 0.26 0.07-0.99 
Creatinine (mmol/L) 100.7 60.4 61-258 
TAS (mmol/l) 1.5 0.2 1.3-1.9 
TOAS (%) 60.9 9.4 50.0-70.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The meal contained 68g of carbohydrate, and the change in plasma glucose over 
the four hours is shown in fig. 6.4.  Glucose increased from a baseline of 10.3 
mmol/l [SD 3.5] and peaked at 16.3mmol/l [5.5] at 3 hours.  The glucose was 
significantly higher than baseline throughout the study (p=0.05,0.006,0.004,0.02 at 
1,2,3 and 4 hours respectively).  The changes in NEFA are shown in fig 6.5.  NEFA 
levels were high at baseline, falling to significantly lower levels at t=60 and 
120mins, reaching a nadir at t=120, with no significant change to levels following 
this time.   
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Fig. 6.4: Mean (+ SEM) plasma glucose in subjects with type 2 diabetes after a 
meal rich in used cooking oil (N=9) 
0
5
10
15
20
25
0 60 120 180 240
Time (mins)
Pl
as
m
a 
G
lu
co
se
 
(m
m
ol
/L
) *
** **
*
*p<0.05, p<0.001
 
 
Fig 6.5: Mean (+ SEM) plasma Non-esterified fatty acids in subjects with type 2 
diabetes after a meal rich in used cooking oil 
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There was a small decrease [5.4%] in plasma TOAS (Fig. 6.6) across four hours 
from (mean [SD]) 60.6% [9.4] to 57.4% [8.4].  This was not statistically significant 
(p=0.31 at 240 mins).  TAS was also measured during the study (Fig.6.7).  There 
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was a significant reduction in plasma TAS of 13% at 2 hours (p=0.005) and 15% at 
3 hours (p=0.13) from (Mean[SD]) 1.50mmol/l[0.19]  to 1.30[0.14] and 1.27[0.15] 
respectively.  TAS had begun to recover at four hours increasing to 1.37[0.19] 
although this was just still significantly different to baseline (p= 0.054). 
 
Fig 6.6: Mean (+ SEM) TOAS in subjects with type 2 diabetes after a meal rich in 
used cooking oil. 
50
55
60
65
0 60 120 180 240
Time (mins)
TO
A
S 
(%
)
 
 
Fig 6.7: Mean (+ SEM) TAS in subjects with type 2 diabetes after a meal rich in 
used cooking oil. 
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6.3.2 Discussion  
 
The meal rich in used cooking oil did have an effect on oxidative stress markers 
when given to subjects with type 2 diabetes.   There was a small reduction in 
plasma TOAS of 5% [p=0.31] and a statistically significant fall in TAS that was 
detectable at two hours and persisted for a further hour.  This was associated with 
an increase in plasma glucose and a fall in plasma NEFA. 
 
Plasma NEFA are known to fall immediately after a meal because insulin sensitive 
lipase activity is inhibited by post –prandial insulin secretion (Frayn KN,1994).   The 
levels return to pre-meal levels after approximately three hours (Austin MA,2004b).  
The NEFA response to an oral challenge may vary with the fat content of a test 
meal (Jackson KG,2005), although the results of studies has been variable 
(Burdge GC,2006).    This may have been because the early response does not 
differ between subjects and any differences are seen in the recovery phase 
(Burdge GC,2006).      
 
This model is more promising in delivering a method that is capable of being used 
to study oxidative stress generation.  The model is simple and could be limited to 
three hours for subject convenience.  The method requires the availability of a 
source of used oil that has been exposed to similar cooking and temperature wear. 
  This model could be used to study the influence of UCP2 and UCP3 variants on 
oxidative stress by comparing the magnitude of the change in oxidative stress 
markers between wildtype and variant homozygotes.  However, the study is time 
consuming and on the basis of a difference in TAS at three hours of 1.49 mmol/L 
[SD 1.93] with a 25% difference between AA and GG homozygotes (Dhamrait 
SS,2004) a total of 385 patients per genotype would have to be recruited to give 
the study 80% power at p<0.05 to detect a difference between genotypes 
[www.stat.ubc.ca/~rollins/stats/sssize/N2.html].  This number of subjects would 
raise a number of practical difficulties.  The number of patients to screen to identify 
the required number of rare homozygotes would be large.  There would also be 
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difficulties in procuring a large volume of standardized oil.  A commercial source 
would be inconsistent and the oil would have to be prepared in-house to a standard 
use protocol, and this prepared oil would also require further study to ensure it 
replicates the results obtained with this commercial oil preparation.  The practicality 
of this study is limited by the ability to accurately measure acute change in ROS 
production.  This type of study is only likely to become more practical once the 
measurement of oxidative stress improves. 
 
 
The two methods of oxidative stress used are both based on the inhibition of an 
oxidative reaction by the plasma sample.  The TAS assay is based in a commercial 
kit whilst the TOAS is based on in house reagents and this could produce 
differences in precision but the CV for both assays are similar [9.0 v 4.2 %]. The 
assays differ only in the enzyme used [Horseradish peroxidase in TOAS and 
peroxidase metmyoglobin in TAS].  This almost certainly explains that while both 
assays changed in the same direction only TAS reached statistical significance.  
There is no current data to suggest which components of the anti-oxidant defences 
show higher affinity with these enzymes but this does suggest that the used 
cooking oil does affect some components more than others and identification of 
these specific components could lead to a more specific assay of the change in 
oxidative stress burden with the used cooking oil and improve the power of the 
model to detect differences between genotype.  
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7.1 Summary of Data 
 
The role of modification of oxidative stress by uncoupling proteins 2 and 3 in the 
aetiology of type 2 diabetes was examined using variation in Uncoupling Protein 
2 and 3 Gene cluster.  A prospective study of over 3000 men confirmed the 
association of variants within the gene cluster with type 2 diabetes.  A second 
study demonstrated that uncoupling protein 2 may play a role in insulin 
secretion.  UCP2 and UCP3 gene variants were not associated with any 
conventional risk factors for type 2 diabetes in healthy subjects.  Markers of 
oxidative stress can be used to indicate levels of oxidative stress burden, not all 
methods are suitable for large scale genetic studies.  Two internally assessed 
methods were used to study heritability of oxidative stress burden in a family 
study and robust estimates of heritability were obtained.  However, in this study 
UCP2-UCP3 gene variants were not associated with levels of oxidative stress 
markers.  Finally, a model was developed that suggests that oxidative stress 
markers could be used to measure genetic influences on ROS production. 
 
7.1.1 Chapter 3, The Northwick Park Heart Study II  
 
Subjects who developed T2DM also had higher blood pressure, triglycerides, 
cholesterol and C-reactive protein (CRP) at baseline, although only BMI, 
triglycerides and CRP were associated independently with increased risk.  This 
study confirmed the significance of obesity as a major risk factor for diabetes, 
and also found a significant impact on risk of developing T2DM associated with 
variants in the genes for UCP2 (-866A) and UCP3 (-55T).   The population 
attrtibutable faction at 10 years was 25.6% for obesity and 11.6% for genetic 
variation in the UCP2-UCP3  gene cluster. 
 
7.1.2 Chapter 4 The Hypercoagulability and Impaired Fibrinolytic Function 
Mechanisms Study  
 
Data from this study confirmed previous studies in Europe showing that UCP2-
866 AA subjects are leaner.  Secondly that AA subjects have lower fasting 
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plasma insulin levels.   In the healthy subjects the difference in fasting insulin 
levels persisted when adjusted for body mass index.  There was no other 
relationship between genotype and any of the adverse metabolic markers for 
either genotype. 
 
7.1.3 Chapter 5 The Japanese American Family Study 
 
The assays available for the determination of oxidative stress vary in their cost 
and ease of use.  Methods of measuring plasma markers of oxidative stress 
with very small differences in the assay reaction correlate poorly suggesting 
they measure different spectrums of the anti-oxidant system.  A high heritability 
was seen for both TAS and TOAS markers and familial correlations suggested 
that some of this may be in part due to similar diet and environment as the 
highest familial correlation was seen in spouse pairs. The comparison of 
correlation with metabolic parameters recorded was weak and not consistent 
between the two methods with independent associated factors explaining a low 
proportion of the variation on plasma markers of oxidative stress in both cases. 
 
7.1.4  Chapter 6 The study of genetic influences on the modification of oxidative 
stress  
 
An oral glucose tolerance test did not induce a measurable change in oxidative 
markers in healthy volunteers.  A meal rich in used cooking oil did have an 
effect on oxidative stress markers when given to subjects with type 2 diabetes.  
This was associated with an increase in plasma glucose and a fall in plasma 
NEFA. 
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7.2 Conclusions 
 
7.2.1 Uncoupling Protein 2 
 
These data suggest the association of the UCP2-866 A variant with type 2 
diabetes in Caucasian men, in keeping with data from previous European 
samples.   This variant was also associated with a leaner phenotype in a 
number of previous studies and also in data from chapter 4.  The mechanism of 
action cannot, therefore, be through conventional risk factors for type 2 diabetes 
which are dominated by obesity (chapter 3).  Investigation of the UCP2 
knockout mouse suggests that the mechanism of action may be through a direct 
effect on glucose dependant ATP production in the pancreatic β-cell itself.  A 
defect in insulin secretion is associated with the UCP2-866A (chapter 4), even 
when corrected for BMI.   This paradox has led to the description UCP2 as a 
“diabetes devil and adiposity angel” and suggests that UCP2-886A is 
associated with higher transcription, more energy use and less insulin secretion 
[Fig 7.1].   
 
Fig 7.1 Mechanism of action the UCP2-866A variant associated with higher 
transcription in the β-cell. 
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However, UCP2-886A has also been associated with higher plasma markers of 
oxidative stress and cardiovascular disease, an association also suggested in 
chapter 4.   This would be in keeping with reduced transcription or at least 
reduced “uncoupling”.  This identifies a further paradox, where in certain 
conditions or organs the UCP2-866A variant behaves differently and supports 
the differences found in transcription factor binding.  The regulation of the UCP2 
promoter is certainly tissue specific, with PAX-6 associated with higher 
transcription from the variant promoter in INSE-1 cells and lower in COS-7 cells.   
A model of UCP2  regulation is shown in Fig 7.2.    
 
The failure to find an association with oxidative stress in a Japanese-American 
Family study is not consistent with other studies.   There are a number of 
reasons for this (Chapter 5).   
 
Fig 7.2  A model of tissue specific regulation of UCP2  
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In summary, these data suggest that UCP2-866AA gene variant is accelerating 
the onset of type 2 diabetes by a direct effect on reducing insulin secretion in 
the β-cell of the pancreas.  
  
7.2.2 Uncoupling Protein 3 
 
Overexpression of UCP3 in mice protects them from diabetes, with a 68% 
increase in mitochondrial palmitate oxidation.  Since, the UCP3-55T variant is 
associated with risk of diabetes in the men studied here (chapter 3) a decrease 
in function would be predicted for the T allele.  There is little data examining 
UCP3 mRNA expression from different alleles.  The only study in 24 subjects 
suggested higher levels in CT/TT male non-diabetic Pima Indians, but this was 
based on only seven copies of the T variant from the total 48 alleles.  Clinical 
studies have been more consistent, with the association of the -55T variant with 
higher BMI in most but not all previous studies.   The association with type 2 
diabetes of the UCP3-55TT has not previously been described although the 
variant has been described to be protective from type 2 diabetes in two French 
cohorts.  This could be because of sample size or timing.  The Kaplan-Meier 
plot suggests that the presence of the variant accelerated the onset of type 2 
diabetes rather than being associated with new cases of type 2 diabetes.  This 
observation is important as it would be necessary to include this information in 
any model that used this variant to predict onset of type 2 diabetes.  It would 
also explain why genetic prediction is as yet yielding only small improvements 
above conventional risk factors (Humphries SE. 2007).  
 
The association of the UCP3 TT genotype with type 2 diabetes must be 
explained through a mechanism not measured in the HIFMECH study (Chapter 
4).    This includes most conventional risk factors including BMI, lipids and 
insulin secretion.   The physiological role of UCP3 is poorly understood but 
these findings are consistent with our current understanding of pathophysiology 
of type 2 diabetes with lower fat oxidation and reduced UCP3 protein found in 
subjects in type 2 diabetes.  Variation in UCP3 was not found to be associated 
with two different plasma markers of oxidative stress (Chapter 5).  They are also 
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consistent with the UCP3-55T allele as the variant associated with reduced 
function. 
 
In summary,  these data suggest that the UCP3-55C>T variant accelerates the 
onset of type 2 diabetes by an as yet unidentified pathway that does not appear 
to affect other traditional risk factors for the development of type 2 diabetes.  
This is consistent with our current understanding of the role of UCP3 [Fig 7.2]. 
 
Fig 7.3 Suggested mechanism of action the UCP3-55T variant associated with 
lower transcription . 
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7.2.3 Oxidative Stress 
 
Measuring plasma markers of oxidative stress offers the promise of helping to 
understand the pathophysiology of a number of human diseases including type 
2 diabetes.  However, as demonstrated (Chapter 5) there is a significant 
difference in methods even when the difference in the assay reaction is small.   
The heritability of two plasma markers of oxidative stress was high but as 
correlation between spouses was the highest the conclusion that there is a 
significant genetic influence on oxidative stress burden cannot be made with 
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confidence.   The variability in oxidative stress burden does not, however, 
appear to be explained by variation in conventional adverse metabolic 
indicators, suggesting that the major determinants are either hereditary or 
environmental factors not measured such as diet. 
 
When using plasma markers of oxidative stress to study disease the difference 
between samples needs to be large to detect a difference as demonstrated by 
the failure to detect a difference in a small sample (chapter 5) or a weak 
stimulus (chapter 6).  Once, the stimulus is increased to an extent that 
significant metabolic excursions are seen then plasma markers of oxidative 
stress could be useful in identifying small genetic differences (Chapter 6).  
 
 
7.3 Limitations of Study      
 
The aims of this thesis were to use a genetic strategy to study the role of 
uncoupling proteins 2 and 3 in the pathogenesis of type 2 diabetes.  The 
demonstration of increased prospective risk of type 2 diabetes in association 
with the UCP2-UCP3 gene cluster variants studied was performed in Caucasian 
men recruited from nine General Practices throughout the UK.  A prospective 
study is a strong study design but the definition of type 2 diabetes has changed 
over time and the use of medical records to find cases may reduce the number 
of men identified but this is only likely to weaken the association found.  
   
The data from the HIFMECH study was collected from across Europe and the 
Japanese American family study from the United States.  The study of gene and 
gene-environment interactions is unlikely to be consistent across all these 
groups,  and even within the two distinct North and South Europe groups there 
were differences in the impact of the genotype on traits and possibly on 
cardiovascular heart disease risk.   The conclusions of the study are also based 
on the assumption that type 2 diabetes is a homogeneous disorder and that 
genetic causes across these populations are similar. 
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The baseline characteristics in each study were also different and not measured 
at a central laboratory.  The normal ranges in each study are likely to be slightly 
different.  The HIFMECH study had more information on metabolic markers but 
the population was less homogeneous.  The cross sectional nature means that 
it is not possible to draw causative conclusions about associations.  The 
Japanese American Family study was useful for investigating the heritability of 
plasma oxidative stress markers but had little environmental information on 
which to examine further the results identified.    This study was not designed to 
examine genotype association with baseline characteristics and is 
underpowered.  The power of the study is further weakened by the presence of 
related individuals.  
 
Plasma markers of oxidative stress still offer a very poor reflection of the 
underlying redox state of the cell, and probably more importantly the 
mitochondria.  The replication of findings using two different markers is a useful 
technique but also exposes the inadequacy of current assays.  These data all 
use a manual method to determine plasma markers of oxidative stress and, 
although the intra-assay CV did improve with time, it was still significantly higher 
than that quoted in the product literature using automated techniques. 
 
The UCP2-UCP3  gene cluster has not yet been identified as associated with 
type 2 diabetes in any of the Genome wide scans yet performed. The failure to 
replicate these findings could suggest that the standard of statistical proof 
applied is not sufficient for the association to be regarded as proven.  The 
association of the UCP2-886G>A variant with oxidative stress has recently been 
shown to exhibit a significant gene environment interaction [Stephens JW, 
2007].  These variants may not be acting across a whole population but only in 
sub groups such as smokers and these studies would then not have the power 
to detect the increased risk.  The failure to replicate these findings could also be 
based on population selection, as the UCP2-UCP3 gene variants accelerated 
onset of type 2 diabetes, so an appropriate time frame is required to identify the 
effect.   
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7.4 Future Work 
 
The structure and function of the UCP2-UCP3   gene cluster is still not well 
understood.  There are a number of paradoxes related to the function of UCP2 
and the rates of transcription of both mRNA in different organs and under 
different stimuli needs to be better understood.   UCP2 transcription should be 
studied at baseline and under oxidative stress in different cell types and under 
different transcription factors.  The possibility of such organ and transcription 
factor specific modification of UCP3 transcription should also be investigated.   
This will enable a better understanding of the function of these genes and add 
to the understanding of the role of mitochondrial dysfunction in type 2 diabetes. 
 
The gene variants could currently be used in a genetic testing model based on 
healthy middle aged white men. If genetic testing using these variants is to have 
a wider application, the role in women and in different ethnic groups also 
warrants further study to determine if is the same as healthy Caucasian men.   
The ability to predict development of type 2 diabetes at different ages, coupled 
with other variants also requires further study.   Genetic tests to predict type 2 
diabetes can only be useful if they give value above conventional risk factors.  
There is evidence that this can be the case for cardiovascular disease, another 
complex polygenic disease, although this required the use of 6 candidate genes 
(Humphries SE, 2007).  The use of genetic testing for prediction of type 2 
diabetes using three variants did improve prediction slightly [ROC 0.58] in a 
British Caucasian sample (Weedon MN, 2006).  The value of the addition of 
UCP2-UCP3 gene cluster variants to this group warrants further study. 
 
The rate of oxidative damage is likely to be as a result of interaction between 
genes and the environment.  The methods to assess oxidative stress burden 
such as plasma markers of oxidative stress require further study before being 
accepted as useful surrogate markers of risk of type 2 diabetes, including 
prospective predictive power.   A study which collects data on lifestyle is also 
required to see what in the environment predicts plasma markers of oxidative 
stress. 
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The model developed offers a promising method of investigating not only the 
role of uncoupling protein genes in modification of oxidative stress burden but 
also a number of other genes and also possible interventions. 
 
This study also raises the possibility that mild pharmacological uncoupling or  
potentiation  of UCP3 function  could act as drug targets for the prevention and 
development of type 2 diabetes. 
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